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Illicit opioid use takes thousands of Americans’ lives each year, reduces the quality of 
life for affected individuals, and results in sizable socioeconomic costs. Existing research 
has supported medication-assisted treatment (MAT) for this condition; however, MAT 
participants often continue to experience opioid craving and using behaviors. 
Mindfulness based relapse prevention (MBRP) uses mindfulness meditation and 
cognitive behavioral therapy to reduce likelihood of substance use relapse. This study 
used a combination of physical dependence theory, positive incentive theory, and 
classical conditioning theory to evaluate the impact of MBRP on illicit opioid use and 
cravings in a quantitative randomized, controlled experimental design. Volunteer 
participants (n=52) from a California Bay Area MAT program site were randomly 
assigned to experimental and control groups. Illicit opioid use, opioid cravings, and 
mindfulness data outcomes were evaluated at pretest, midtest, and posttest intervals for 
the experimental group receiving MBRP and treatment as usual and a treatment as usual 
control group. Multiple feasibility confounds including participant dropout interfered 
with study implementation, resulting in insufficient statistical power for analysis. The 
findings indicated the importance of anticipating feasibility problems in future similar 
study designs; however, on an individual level MBRP participants did report positive 
reactions to treatment. Empirically determining MBRP effectiveness in reducing illicit 
opioid use and cravings for MAT program participant may foster positive social change 
by reducing public health, behavioral, social, and legal problems, as well as human 
suffering associated with illicit opioid use. 
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Chapter 1: Introduction to the Study 
Introduction 
This pilot study involved evaluating the effectiveness of Mindfulness-Based 
Relapse Prevention (MBRP; Bowen, Chawla, & Marlatt, 2011) manualized treatment in 
reducing illicit opioid use for individuals with opioid use disorder. MBRP was planned 
for implementation at a medication assisted treatment (MAT) program site located in the 
California Bay Area, where patients with opioid use disorder receive comprehensive 
treatment services for their condition. Despite MAT service provision efforts, opioid use 
relapse remains a serious concern for MAT program participants. Relapse involving illicit 
opioid use has strong and negative impacts on the physical, psychological, and social 
wellbeing of MAT program patients. Prior to implementation of this study, the 
effectiveness of MBRP as a treatment adjunct was not yet evaluated in MAT program 
settings. This study is an attempt to address this research gap. 
This study was intended to foster beneficial social change through increasing 
awareness within medical, psychological, and treatment fields regarding indications and 
effectiveness of MBRP applications in the context of MAT programs. Further, if found 
effective, use of MBRP in the MAT program setting would likely reduce MAT program 
patient relapse frequency, thus improving the quality of life and MAT program 
effectiveness for patient participants. In addition, reduced relapse rates arising through 





costs associated with relapse, as well as related demands and costs in terms of healthcare, 
law enforcement, legal, and social services systems.  
This chapter includes a description of the background for the study, summary of 
relevant research, gaps in research this study attempted to fill, and need for the study. 
Chapter 1 continues with the problem statement, relevance and significance to the field, 
and the identified critical research gap. The study purpose is delineated, including core 
methodological approaches, intent, and identified variables and potential mediating 
variables. Next, study research questions and hypotheses are included along with a 
description of measurement methods. Following this, I describe relevant theoretical and 
conceptual frameworks and how they relate to the phenomena being evaluated, research 
questions and hypotheses, and how they inform the study’s methodological design. The 
nature of the study is then discussed including its design rationale, variables and potential 
mediating variables, and methodology. All known variables and key terms are 
operationally defined. Assumptions underlying the study are critically examined. The 
scope and delimitations of the study are discussed, including an examination of internal 
and external validity. Following this, limitations of the study are described, including 
relevant internal and external validity threats, potential biases, and measures to address 
these concerns. The significance of the study for the field is then addressed and social 
change implications are discussed. Chapter 1 concludes with a summary of the chapter  







Opioid use disorder has emerged as a growing societal problem over the past 
several decades. The National Institute on Drug Abuse (NIDA, 2020) reported that in 
2017, opioid overdose was implicated in the deaths of more than 47,000 Americans. 
There was a 430% increase in U.S. hospitalizations associated with illicit opioid use 
between 1999 and 2009 (Substance Abuse & Mental Health Administration (SAMHSA; 
2011). The NIDA (2020) reported that as of the end of 2018, opioid overdose was the 
primary cause of 128 deaths each day in the U.S. The Centers for Disease Control (CDC, 
2021) reported that drug overdose deaths have increased by 400% since 1999, including a 
6% increase in opioid-related deaths overall and a 15% increase in synthetic opioid 
associated deaths during 2019. The Office of National Drug Control Policy (ONDCP, 
2011) said there was an increase of 402% in prescription opioid use among Americans 
from 1997 to 2007. The NIDA (2011) reported that of the 7 million individuals in the 
U.S. in 2010 who used prescription drugs nonmedically, 5.1 million abused opioids. The 
SAMHSA (2020a) said between 2018 and 2019, there were 10.1 million individuals who 
misused opioids, and two-thirds of drug overdose deaths were opioid related. Taken 
together, these reports suggest an increasing frequency of opioid misuse and opioid 
associated deaths over the past 2 decades.   
MAT has been established as a highly effective treatment for opioid use disorder 
(Batki et al., 2005; Kosten & George, 2002; Parrino et al., 1993; SAMHSA, 2020b, 





relapse among MAT program participants remains a significant liability (Kreek, 2007). 
Relapse rates while enrolled in MAT tend to reduce over time, with an average rate of 
19.7% measured over a 36-month treatment episode (Clark et al., 2014). Moreover, 
discontinuance of MAT is associated with a relapse rate of almost 100% (Calsyn et al., 
2006), suggesting that whereas relapse while enrolled in MAT is a concern, it is a much 
greater concern where treatment is discontinued. This suggests the need for effective 
treatment adjuncts that are likely to reduce this propensity toward relapse within the 
context of MAT program settings. MBRP, a manualized treatment approach for 
substance use integrating mindfulness practices with cognitive behavioral therapy 
techniques, has been found to be highly effective as a treatment for substance use 
disorders (Bowen et al., 2009; Bowen et al., 2011; Bowen & Enkema, 2014; Bowen & 
Kurz, 2012; Witkiewitz & Bowen, 2010; Witkiewitz et al., 2013a; 2013b). MBSR has not 
yet been evaluated as a treatment adjunct for individuals participating in MAT programs.  
This pilot study addressed a gap in research by evaluating MBRP for 
effectiveness as an adjunctive treatment for individuals enrolled in a MAT program. This 
study will lead to beneficial social change through increased researcher and clinican 
awareness of effectiveness of MBRP applications in the context of MAT programs. 
Further, if found effective, use of MBRP in the MAT program setting would likely 
reduce MAT program patient relapse frequency, thus improving the quality of life and 
MAT program effectiveness for patient participants. In addition, reduced relapse rates 





risks and costs associated with relapse, as well as related use demands and costs in 
healthcare, law enforcement, legal, and social services systems. 
Problem Statement 
Opioid use disorder is a current and pervasive problem in the U.S. Over 3.7 
million individuals in the U.S. have used heroin (NIDA, 2005a). In 2004, approximately 
314,000 individuals used heroin (NIDA, 2005a). This increased by over 47% to 669,000 
heroin abusers in 2012 and 745,000 persons in 2019 (NIDA, 2014b). The NIDA (2014a) 
said 5.1 million individuals used opioid medication illicitly in 2012. The SAMHSA 
(2020a) said that 10.1 individuals abused opioids in 2019, an increase of almost 50% 
from 2012. Chronic pain affects 33% of Americans and is a factor strongly implicated in 
opioid use disorder (Johannes et al., 2010; NIDA, 2014a). The SAMHSA (2020a) said in 
2019, 9.7 million individuals abused prescription opioids. Drug Awareness Warning 
Network (DAWN) data indicated a 183% increase in ER visits associated with illicit 
opioid use during the period from 2004 to 2011 (SAMHSA, 2013a). The SAMHSA 
(2020a) reported a 30% increase for the period from July 2016 to September 2017. These 
data trends strongly suggest that illicit opioid use is continuing to increase at a concerning 
rate. 
Opioid use disorder is characterized as a chronic relapsing condition where post-
remission relapse is highly likely (California Society of Addiction Medicine, 2008; 
Dennis & Scott, 2007; Leshner, 1989; 2001; SAMHSA, 2020b, Volkow, 2007a; 2007b). 





are likely to benefit from adjunctive treatment interventions (Logan & Marlatt, 2010; 
Parrino et al., 1993). Relapse into illicit opioid use is strongly associated with increased 
risk of disease contraction, including hepatitis C (HCV) and human immunodeficiency 
virus (HIV) and adverse medical complications, and is further associated with elevated 
risk of oversedation, coma, and death due to central nervous system suppression 
(California Society of Addiction Medicine, 2008; Parrino et al., 1993; Volkow, 2007a; 
2007b). Further associated risks include secondary general medical conditions, 
symptomatic exacerbation of concomitant psychiatric disorders, criminal behavior in 
order to sustain illicit opioid use, and social dysfunction leading to marginalization by 
and alienation from familial and other potential supportive resources (California Society 
of Addiction Medicine, 2008; Parrino et al., 1993; Volkow, 2007a; 2007b). Any 
therapeutic adjunct associated with reduced relapse risk is likely to benefit the health and 
wellbeing of MAT program participants. 
Mindfulness-based practices are effective in treatment of several general medical 
conditions including fibromyalgia, cancer, multiple sclerosis, eating disorders, and 
impaired immune system response (Chang et al., 2004; Jain et al., 2007; Kabat-Zinn, 
2002; 2009; Zeidan et al., 2011). Mindfulness-based practices have been found to be 
effective as treatments for anxiety, depression, posttraumatic stress disorders, and 
substance use disorders (Brantley, 2007; Brewer et al., 2010; Davidson, 2010; Farb et al., 
2012; Marlatt, 2006; Modinos et al., 2010). A research gap exists in that MBRP has not 





individuals being treated at MAT programs. This pilot study was used to address this 
research gap by examining the effectiveness of MBRP in reducing illicit opioid use for 
participants currently enrolled in a MAT program in California. 
 
Purpose of the Study 
Study Intent 
The purpose of this quantitative pilot study design was to evaluate the 
effectiveness of MBRP as a therapeutic adjunct to MAT program participation. I 
examined the relationship between mindfulness of MAT program participants and 
frequency of illicit opioid using and craving behaviors.  
Study Variables 
I used a concurrent mixed methods design, including quantitative, randomized, 
and controlled experimental single-site pilot designs using repeated measures. 
Multivariate analysis of covariance (MANCOVA) was used to evaluate relationships 
between the dependent and independent variables over time.  
The dependent variables (DVs) in the study were based on the outcomes of two 
standardized measures broadly used in substance abuse treatment and research. The first 
was the Addiction Severity Index (ASI; McLellan et al., 1985). The ASI is used to 
evaluate for examinee functioning across multiple domains, asking lifetime problem 
frequency for a total number of years, where the problem was evidenced at least once 
during any year, and problem frequency within past 30 days, where the problem was 





severity and need for treatment. The ASI Alcohol/Drugs subscale data was used in this 
study. This ASI subscale is scored through weighted summing of individual item results 
within each subscale. Index composite score ranges from no problem severity (0.00) to 
very high problem severity (1.00) The ASI Alcohol/Drugs subscale data outcomes were 
used in this study to measure severity of participant opioid use at three specified testing 
intervals. 
The Opioid Craving Scale (OCS; McHugh et al., 2014) is used to measure 
severity of cravings for illicit opioids. It consists of three visual analogue scale items 
measured in 0 (no desire for opioids) to 10 (strong desire for opioids) for item one, and in 
severity from 0 (no severity) to 10 (extremely strong severity) for the remaining two 
items. The first scale measures the strength of desire to use opioids during the past 24 
hours. The second scale measure how strong desire to use opioids has been during the 
past week when exposed to an environmental cue associated with opioid use. The third 
scale requires recollection of the most recent environment and time of day where the 
examinee used opioids and rates the likelihood of opioid use if the examinee were in that 
environment at that time today (McHugh et al.). The OCS was used in this study to 
measure participant opioid craving severity at three specified testing intervals.  
The independent variable (IV) levels in the study were the MBRP manualized  
treatment intervention administered for a proscribed 8-week period as an adjunct to 





TAU in the control group of MAT program participants during a concurrent 8-week 
period. 
 A potential mediating variable (MV) in the study was the effect of MBRP 
manualized treatment on participant states of mindfulness. This was evaluated by 
observing variance between pretest, midtest, and posttest outcome scores measured by 
the Toronto Mindfulness Scale (TMS; Lau et al., 2006). The TMS measures two factors 
of mindfulness: curiosity and decentering. It consists of 13 questions associated with each 
factor. The examinee indicates level of agreement with test item statements using a Likert 
scale response from zero (no agreement) to four (very much agreement). Higher scores 
indicate increased clinical evidence of mindfulness effects in the test subject. 
Statistical covariance data outcomes of TMS scores would likely reveal any 
significant mediating associations between changes in participant mindfulness and DV 
outcomes. The MV outcomes were used only for observational purposes, and were not 
included in the study research questions and hypotheses. 
Research Questions and Hypotheses 
RQ1: Is exposure to MBRP manualized treatment associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H01: Exposure to MBRP manualized treatment is not associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 





Ha1: Exposure to MBRP manualized treatment is associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program. 
RQ2: Is exposure to MBRP manualized treatment associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H02: Exposure to MBRP manualized treatment is not associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Ha2: Exposure to MBRP manualized treatment is associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Dependent Variables 
The DVs were frequency of illicit opioid use as measured by ASI Alcohol/Drugs 
subscale outcomes and severity of participant opioid cravings as measured by Opioid 
Craving Scale outcomes. 
Independent Variable 
The IV for this study consisted of treatment with two distinct levels: the 
experimental group level wherein the MBRP manualized treatment intervention was 





program, and the control group level wherein the participants received only TAU at the 
MAT program. 
Groups were randomly assigned using a random number table. Each experimental 
group participant was exposed to MBRP manualized treatment. Participants not attending 
a minimum of six out of eight possible MBRP group sessions while participating in TAU 
at the MAT program were classified as study dropouts. The control group level 
experienced TAU as it was practiced within the context of the MAT program and did not 
receive the MBRP manualized treatment. For the control group condition, participants 
discontinuing TAU at the MAT program during the eight-week study period were 
classified as study dropouts. The only between groups variable was administration of the 
MBRP manualized treatment. This variable was measured by participant completion of 
the eight weeks required in the MBRP treatment protocol.    
Theoretical and Conceptual Framework for the Study 
Theoretical Foundation 
Mindfulness practices have been found to be effective in terms of treating 
multiple conditions including stress associated conditions, impaired immune system 
response, cancer, chronic pain, and substance use disorders (Chang et al., 2004; Jain et 
al., 2007; Kabat-Zinn, 2002; 2009; Shapiro & Schwartz, 2000; Witkiewitz et al., 2005; 
Zeidan et al., 2011). Their effectiveness is associated with improved treatment outcomes 
for multiple psychiatric disorders, including substance use conditions (Brewer et al., 





Modinos et al., 2010). The area of the brain known as the prefrontal cortex (PFC) 
regulates behavior to minimize risk of physical harm and assure optimal chances for 
survival. The mesolimbic dopaminergic system regulates behaviors associated with 
rewarding activities such as eating, drinking, sexual activity, and mood-altering substance 
use.  Cognitive deficits in PFC mediation of signals from the mesolimbic dopaminergic 
system increase the opioid-dependent individual’s vulnerability to relapse, and reduce 
capability to regulate drug craving, seeking, and using behaviors (Childress et al., 2008; 
Dennis & Scott, 2007; Kosten & George, 2002). States of mindfulness reflect calm, fully 
aware, and optimally balanced cognitive functioning arising from ongoing practice of 
nonjudgmental, nonreactive acceptance of experiential phenomena. These mindful states 
have been associated with more adaptive PFC regulation of limbic system signaling than 
is consistently found in individuals that do not practice mindfulness (Brewer et al., 2010; 
Farb et al., 2012; Ostafin & Marlatt, 2008; Modinos et al., 2010). This suggests that 
increased attentional control over illicit opioid craving, seeking, and using behaviors 
achieved through mindfulness practice may reduce illicit opioid use. Research suggests 
opioid use disorder signs and symptoms associated with relapse might be effectively 
mediated through clinical applications of mindfulness such as MBRP. 
Conceptual Framework 
Ostafin and Marlatt (2008) observed that implicit processes regulated in the 
limbic system of the brain are strongly associated with substance use disorders. These 





and seeking behaviors, thereby reducing illicit opioid use and resultant health risk 
behaviors and offering symptomatic relief and improved quality of life for participants. 
Wenk-Sormaz (2005) noted that meditation facilitated cognitive and affective 
responsivity. This suggests that engagement in mindfulness-based practices may increase 
individual capability for regulating emergence of autonomic substance use cravings via 
enhanced PFC functioning.  
Continued mindful experiencing of substance use cravings deconditions 
associations between substance use behavior and cravings, thereby decreasing 
vulnerability to relapse (Marlatt & Chawla, 2007; Ostafin & Marlatt, 2008). Marlatt and 
Chawla (2007) said this therapy ultimately reduces substance cravings and counteracts 
substance addiction through facilitating awareness and acceptance of present moment 
experiences, thereby reducing individual propensities toward using substances to cope 
with aversive existential realities. 
Mindfulness-based treatment interventions have been found effective in terms of 
treating substance use disorders and associated craving, seeking, and using behaviors 
(Bowen et al,, 2011; Bowen et al., 2005; Bowen et al., 2006; Bowen et al., 2009; 
Witkiewitz et al., 2005). Whereas MBRP has been found effective in reducing illicit 
opioid, stimulant, and alcohol relapse frequency in several distinct populations, it has not 
been conclusively evaluated for its effectiveness as a treatment adjunct for individuals 





opioid use and the chronic relapsing nature of  OUD for MAT program participants 
suggests a need to evaluate the effectiveness of MBRP as a treatment adjunct.  
This study was an attempt to fill identified research gaps through determining the 
efficacy of the MBRP protocol as a treatment adjunct for use by MAT programs, 
clinicians, and patients. If established as effective in terms of reducing MAT patients’ 
risk of relapse, MBRP protocol would thus represent an inexpensive, efficient, and cost-
effective means of reducing potential harms posed to MAT program participants due to 
illicit opioid use relapse. 
Mindfulness-based treatment interventions that are effective in terms of regulating 
illicit opioid use, craving, seeking, and using behaviors in MAT participants merit further 
empirical investigation. MAT program treatment effectiveness and quality of life for 
MAT participants would likely be enhanced through integration of mindfulness-based 
interventions that support them in reducing illicit opioid cravings and use. Aversive 
effects involving cooccurring psychiatric conditions, crime, health care overuse and 
costs, social alienation, and stigma would be reduced through implementation of 
treatment adjuncts that reduce illicit opioid relapse frequency, duration, and severity. 
MBRP is a group treatment model, thus reducing staff/patient ratios and associated costs 
while still offering enhanced treatment effectiveness. Enhanced MAT outcomes and 
reducing associated costs likely would improve public perception of MAT effectiveness 
and the need for enhanced treatments for opioid dependence, thereby reducing social 





use disorders, further facilitating support for and increased participant enrollment in 
MAT programs. A more in-depth review follows in Chapter 2.  
Nature of the Study 
Design Rationale 
This study was intended to determine if participant exposure to MBRP 
manualized treatment is associated with reductions in frequency of illicit opioid use and 
opioid use cravings for individuals concurrently participating in MAT programs for their 
opioid use disorder. I addressed the research questions through measurements of DV 
frequency outcomes associated with reported opioid use and cravings throughout the 8-
week study period. A gap in the research addressed by this study is that no research 
evaluated the effects of MBRP manualized treatment on illicit opioid use of MAT 
program participants.  
Key Variables 
The two DVs in this study were frequency of participant illicit opioid use as 
measured by ASI Alcohol/Drugs subscale (McLellan et al., 1985) and severity of 
participant opioid cravings as measured by the Opioid Craving Scale (McHugh et al., 
2014). 
The IV for this study consisted of two levels: the experimental group exposed to 
MBRP manualized treatment in addition to TAU at the MAT program, and the TAU-only 
control group. This IV was considered valid if participants assigned to the experimental 





participants remain in TAU for the concurrent eight-week period of their experimental 
group counterparts.  
Potential MVs included observed changes in participant mindfulness as measured 
by participant TMS outcome scores. Attempts were made to identify mediating variables 
and describe their potential effects on the study outcomes.   
Methodology 
The research design was a quantitative randomized controlled single-site pilot 
study design using repeated measures. This is a mixed within-between subjects design 
with time as the within-subjects factor and groups as the between-subjects factor. 
MANCOVA was used to statistically evaluate relationships between dependent, 
independent, and any identified MVs over time.. 
The study duration was 8 weeks, consistent with established requirements of 
MBRP manualized treatment. Data collection occurred during MBRP manualized 
treatment administration.  
Definitions 
Cue Reactivity: A condition where nonvolitional neurobiological responses to 
environmental conditions serve as stimuli for opioid craving, seeking, and using 
behaviors (Childress et al., 2008; Dennis & Scott, 2007). 
Medication Assisted Treatment (MAT) Program: A comprehensive treatment 





pharmacotherapy, counseling and medical and social support services (Parrino et al., 
1993). 
Meditation:  The contemplative state wherein the individual reflects on 
experiential phenomena as they arise into conscious awareness (APA, 2007). 
Methadone: A synthetic opioid analgesic medication used to treat opioid 
dependence and chronic pain (Parrino et al., 1993). 
Mindfulness: A condition wherein an individual’s awareness is focused on 
unfolding experience (APA, 2007).  
Mindfulness-Based Relapse Prevention: A therapeutic approach to treatment of 
substance use disorders involving mindfulness meditation and cognitive behavioral 
therapy interventions (Marlatt & Chawla, 2007). 
Mindfulness-Based Stress Reduction: A therapeutic approach involving 
mindfulness practices to reduce maladaptive stress reactivity and improve quality of life 
(Kabat-Zinn, 1982, 2002). 
Mindfulness Meditation: A specific contemplative approach in which thoughts, 
feelings, and sensations are intentionally and nonjudgmentally experienced as they arise 
into conscious awareness (APA, 2007). 
Opioids: Drugs with pain relieving and euphoric effects (APA, 2007). 
Opioid Dependence: The condition where continued exposure to opioid drugs 





Opioid Relapse: The phenomenon where an individual returns to illicit opioid use 
after a sustained period of abstinence (Parrino et al., 1993). 
Opioid Tolerance: Condition where increasing amounts of opioids are needed to 
experience drug effects (APA, 2013). 
Opioid Use Disorder: A persistent maladaptive pattern of illicit opioid use despite 
attempts to reduce or eliminate such use, continuing over a sustained period of time, and 
presenting with  adverse symptoms. 
Opioid Withdrawal: The condition where, once dependence has occurred, 
discontinuance of the exogenous opioid results in the onset of multiple adverse physical 
symptoms (APA, 2013). 
Vipassana: A mindfulness meditation practice where intentional focus on 
breathing is used to regulate attention and enhance experiential awareness (Fenner, 
2002). 
Assumptions 
DVs for this study were frequency of participant-reported illicit opioid use and 
opioid craving. Illicit opioid use was measured using the ASI Alcohol/Drugs subscale 
(McLellan et al., 1985), and opioid craving was measured through the OCS (McHugh et 
al., 2014). These scales were assumed to be reliable and accurate means of evaluating 
frequency of participant illicit opioid use and craving. 
This DV was assumed to have normal distribution and homogeneity of variance 





randomly assigned from the larger MAT program patient population where the study was 
conducted. 
It was also assumed that statistical covariance analysis would reveal any 
significant mediating associations between changes in participant mindfulness and DV 
outcomes. 
Scope and Delimitations 
Internal Validity 
This pilot study involved examining the effects of MBRP group participation on 
illicit opioid use and opioid cravings experienced by opioid-dependent individuals 
enrolled in MAT programs. Whereas mindfulness practices have been evaluated for their 
effectiveness in terms of reducing illicit substance use of participants in multiple program 
settings, including substance use treatment facilities, no research has specifically 
addressed the use of MBRP manualized treatment in a MAT program setting. By 
targeting MBRP in MAT programs, I isolated a narrow segment of individuals with 
substance use disorders who were MAT program participants, and further narrowed the 
evaluative focus through limiting the approach to MBRP.  
External Validity 
This study only included participants who were concurrently enrolled in a MAT 
program. Thus, individuals experiencing opioid use disorder who were not participating 
in the MAT program selected for the study were not eligible for participation. Similarly, 





participation. Since the MAT program normally does not admit individuals who are less 
than 18 years of age, such individuals were not considered eligible for study 
participation. No other study participation restrictions were planned. 
 The study was not intended to evaluate for other general medical or psychiatric 
conditions. The study was not intended to evaluate for psychological practices that 
inform psychotherapeutic interventions for MAT program patients, including therapeutic 
approaches such as active listening, motivational interviewing, cognitive behavioral 
therapy, trauma therapies such as seeking safety, or general addictions counseling 
approaches. The study was not intended to evaluate for neurobiological functioning 
associated with opioid use disorder. 
Potential Generalizability 
Generalizability of this study’s outcomes was limited in that it was a pilot study with 
a limited number of participants (n = 60). Reduced numbers of participants are associated 
with reduced statistical power, which in turn suggests reduced generalizability. Further, 
although participants were randomly assigned to either experimental or control group, the 
study depended on volunteer participants. It is possible, especially given the limited 
number of participants, that those selected did not fully represent normative 
characteristics typically present within the larger MAT program participant population. 
This study was intended to evaluate MSRP manualized treatment effectiveness in 
terms of reducing illicit opioid use within the specific population of MAT program 





generalizability could be used as a basis for development of studies with larger 
populations, greater statistical power, and greater generalizability for the general 
population of MAT program patients. 
Limitations 
A potential limitation of this study was that a sufficient number of participants did not 
complete the entire study period. Such dropout cases were noted with reasons for early 
discontinuance and addressed in my discussion of data analysis. Additional possible 
limitations may have included potential extraneous variable effects such as variance in 
participant age, gender, psychiatric status, general medical conditions, and practical 
factors limiting participation including scheduling and transportation constraints. The 
effects of these potential extraneous variables were not measured and remain unknown. A 
further potential limitation was that only one MAT program site was used for study 
purposes. It is possible that this site had unique or unknown effects on study participants 
that may have resulted in skewing data or otherwise limited generalizability. 
At the time of study implementation, I had several years of experience practicing 
mindfulness meditation, and thus could be influenced in terms of confirmation bias 
involving research outcomes that favored beneficial effects of mindfulness practices on 
MAT program patients. To guard against this, the study was structured such that MBRP 
group services were not provided at a MAT program location where I worked, and study 







While MAT programs are as a highly effective treatment model for individuals with 
opioid use disorder, the potential for relapse among MAT program participants remains 
significant. Kreek (2007) said 20% of MAT program patients may relapse at any given 
time. Given this, MAT participants, despite the known effectiveness of MAT, remain at 
risk for episodic relapse and are likely to benefit from adjunctive treatment interventions 
that reduce such risk (Logan & Marlatt, 2010; Parrino et al., 1993). 
Mindfulness-based treatment interventions have been demonstrated to be effective at 
reducing relapse rates among populations with substance use disorders, specifically in 
MAT program populations (Stotts et al., 2009). This study was built to address existing 
research gaps by evaluating the effects of MBSR as a treatment adjunct for MAT 
program patients. This application of MBSR could be broadly used in MAT programs 
throughout the U.S., thereby fostering positive social change through reducing illicit 
opioid use relapse rates and its harmful concomitants among thousands of individuals 
benefiting from MAT program participation. 
Summary 
This chapter includes the rationale for and scope of this pilot study. This 
discussion includes the study background, problem statement, purpose, research 
questions and hypotheses, theoretical and conceptual frameworks, and research methods 
along with assumptions and limitations of the study. This pilot study was intended to 





for MAT program patients and determine if MBRP is effective in terms of relapse 
prevention as evidenced by reduced frequency of illicit opioid use and reduced opioid 
craving severity among those participating in the MBRP protocol. 
A quantitative experimental design was proposed, comparing two groups: the 
experimental group exposed to weekly MBRP procedures, and the TAU group used as a 
control. Both groups were composed of randomly selected participants concurrently 
participating in a MAT program located in the Bay Area of California. This study 
involved testing the hypothesis that use of MBRP as a treatment adjunct within the 
context of a MAT program would result in changes in frequency of participant illicit 
opioid use as measured by the ASI Alcohol/Drugs subscale (McLellan et al., 1985) and 
changes in severity of participant opioid craving as measured by the OCS (McHugh et al., 
2014).   
Chapter 2 includes a literature review with information regarding historical and 
current social problems associated with opioid use disorders. It continues with 
explanations of historical and current treatment approaches used to address opioid use 
disorder, the role of MAT programs in treatment for this condition, theoretical concepts 
relevant to opioid use disorders, diagnostic formulation, evaluation, and treatment 
approaches, and examination of neurobiological substrates of opioid use disorders and 
their relevant implications. This chapter continues with an exploration of the historical 
antecedents of mindfulness practices, transitioning into contemporary clinical 





Neurobiological research evaluating substrates associated with mindfulness practices are 
explicated, as well as potential relevance to the neurobiology of opioid use disorders. 
Multiple mindfulness-based treatment approaches are discussed, and research evaluating 
their effectiveness is critically examined. This leads to an in-depth evaluation of MBSR 
and a rationale for its potential use as a treatment adjunct for MAT program patients. 
Chapter 3 includes the research design and methodology for the proposed study. Chapter 
4 includes study outcomes, including data and statistical analyses, and Chapter 5 includes 







Chapter 2: Literature Review 
Introduction 
Opioid use disorder with physiological dependence is characterized as a chronic 
relapsing condition where post-remission relapse is highly likely. MAT has been firmly 
established as a highly effective treatment for opioid use disorder. Despite comprehensive 
pharmacological, psychological, and medical information offered in MAT programs, 
participants remain at risk for episodic relapse of illicit opioid use, and are thus likely to 
benefit from adjunctive treatment interventions that reduce the likelihood of relapse 
(Logan & Marlatt, 2010; Parrino et al., 1993, SAMHSA, 2020b).  
Relapse involving illicit opioid use is strongly associated with increased risk of 
disease contraction, including HCV and HIV and adverse medical complications, and is 
further associated with elevated risk of oversedation, coma, and death due to central 
nervous system suppression (Parrino et al., 1993; Volkow, 2007a; 2007b). Further 
relapse-associated risks include onset of secondary general medical conditions, 
symptomatic exacerbation of cooccurring psychiatric disorders, criminality due to 
sustained illicit opioid use, and social dysfunction leading to marginalization by and 
alienation from familial and other potential supportive resources (Parrino et al., 1993; 
Volkow, 2007a; 2007b). Any therapeutic adjunct reducing relapse risk is likely to benefit 
the health and wellbeing of MAT program participants. 
The purpose of this pilot study was to evaluate the effectiveness of MBRP 





pilot study also considered the potential mediating effect of changes in participant 
mindfulness as measured by TMS scores associated with concurrent participation in the 
manualized MBRP treatment adjunct. In addition, correspondent changes in terms of 
participant frequency of illicit opioid use were evaluated.  
Examining the effects of MBRP on individuals participating in MAT programs 
for opioid dependence necessitates evaluation of the nature of opioid use disorder, 
including its neurobiological, psychological, and social concomitants, as well as potential 
relationships with mindfulness. This chapter involves investigating etiology, theoretical 
perspectives, and empirically-supported treatment options for substance and opioid use 
disorders in terms of physiological dependence, including how the condition is evaluated 
and treated within the context of MAT programs. The chapter continues with 
examinations of individual and social problems associated with illicit opioid use. 
Neurobiological structure and functioning of opioid use disorders are explicated. The 
chapter includes a brief description of the history and development of MAT programs, 
including a synopsis of the current MAT program philosophy and approach to opioid use 
disorder treatment.  
This chapter continues with an explanation of the historical antecedents of 
mindfulness practices. The nature of mindfulness and relevant aspects of mindfulness 
practice are discussed, as well as relationships between states of mindfulness and 
attentional processes. Neurobiological structure and functioning of the central and 





implications of these findings in terms of MBRP as an adjunctive treatment for opioid use 
disorder are explored. Relevant aspects of contemporary psychological treatment 
approaches incorporating mindfulness practices are described. 
Literature Search Strategy 
 The Walden University online library was used to access EBSCOHost in order to 
find research related to mindfulness and substance use disorder treatment applications. 
Databases used included Academic Search Premiere, PsycArticles, PsycInfo, SocINDEX, 
Thoreau, Mental Measurements Yearbook, CALDATA, National Institutes of Health, 
American Psychiatric Association, American Psychological Association, American 
Medical Association, Substance Abuse and Mental Health Services Administration, 
Centers for Substance Abuse Treatment, National Institute on Drug Abuse, Food and 
Drug Administration, PubMed, and National Library of Medicine. Google and Google 
Scholar were also used.  
Key search terms were substance use, substance use disorder, opioid use 
disorder, mindfulness, neurobiology, neurobiology of mindfulness, neurobiology of 
attention, mindfulness and attention, attentional regulation, attentional dysregulation, 
attention regulation, opioid use disorder, neurobiology of opioid use disorder, 
neurobiological substrates of opioid use disorder, neurobiological substrates of attention 
regulation, neurobiological substrates of mindfulness, mindfulness based stress 
reduction, MBSR, mindfulness based cognitive therapy, MBCT, mindfulness and rational 





behavioral therapy, CBT, cognitive therapy, CT, mindfulness based relapse prevention, 
MBRP, acceptance and commitment therapy, ACT, Buddhism, and yoga nidra. Abstracts 
were reviewed for relevance to determine applicability of each article. Articles including 
only abstracts were not used.  
Research journal articles, texts, and treatment manuals published prior to 2017 
were used where applicable to denote seminal findings in literature that provide historical 
perspectives, or to compare and contrast with more recent findings.  
Numerous seminal texts and articles were used as references to describe historical 
antecedents of mindfulness practices and psychological functioning associated with 
mindfulness practices and measures used to assess mindfulness.  
Relevant online research articles were downloaded for further study. Relevant 
home and work library journals and texts on neurobiology, theoretical bases and 
treatment approaches for substance use disorders, mindfulness theory and practice 
research, treatment manuals, and clinical applications were used. 
Illicit Opioid Use in America 
Recent Epidemiological Trends in Illicit Opioid Use  
Illicit opioid use is a severe and pervasive problem in the United States. There 
were 669,000 heroin abusers in 2012 (NIDA, 2014b), increasing to an estimated 745,000 
in 2019 (SAMHSA, 2020a). The NIDA asserted that some 5.1 million individuals used 
opioid medication illicitly in 2012 (NIDA, 2014a), a number that has increased to 10.1 





2010; NIDA, 2005b; 2014a) indicated that chronic pain affects some 33% of Americans 
and is a factor strongly implicated in opioid use disorder. The SAMHSA reported that 
Drug Awareness Warning Network (DAWN) data indicated a 183 percent increase in ER 
visits associated with illicit opioid use during the period from 2004 to 2011 (SAMHSA, 
2013a), with an overall 430% increase observed for the period from 1999 to 2009. The 
Office of National Drug Control Policy (ONDCP; 2011) reported a 402 percent increase 
in prescription opioids use by Americans from 1997-2007. The NIDA (2011) reported 
that in 2010 seven million U.S. individuals used prescription drugs nonmedically 
including 5.1 million that abused opioids. This number increased to  and the SAMHSA 
reported that . The Centers for Disease Control and Prevention (CDC; 2021) asserted that 
for the period from 1999 to 2019 close to 500,000 persons died from an opioid overdose, 
and that drug overdose deaths have increased by 400% since 1999, including a six 
percent increase in opioid-related deaths overall, and a 15% increase in synthetic opioid 
associated deaths during the year period ending in 2019.  
Opioid misuse has been increasing since 2007 (NIDA, 2011). In 2014, over 2 
million individuals experienced the condition of opioid use disorder (National Institute on 
Drug Abuse; NIDA, 2014a), a number that increased to 1.6 million in 2019 (SAMHSA, 
2029a). The NIDA asserted that in 2013 more than 207 million opioid medication 
prescriptions were written. Some 58% of Americans were prescribed opioids in 2017 
(CDC, 2019). The National Survey on Drug Use and Health for 2012 report indicated 





2013b). Subsequently,  the SAMHSA (2020a) reported that 745,000 persons used heroin 
in the year preceding 2019. The NIDA (2011; 2014b) asserted that marked increases in 
heroin use have resulted from an estimated near 50 percent of young individuals 
transitioning from prescription opioid use to heroin use. Moreover, Johannes et al. (2010) 
and NIDA (2014a) estimated that a third of Americans experience some form of chronic 
pain and this condition is strongly associated with opioid use disorder. An estimated 41 
percent of individuals with chronic pain conditions abuse opioid medication 
(Manchikanti et al., 2007).  
Of much concern is the increasing number of deaths from opioid overdoses, 
which quadrupled over the 10-year period preceding 2014 (NIDA, 2014a). The NIDA 
(2014) asserted that more individuals die from prescription opioid overdose than from all 
other drugs of abuse combined, and that as of 2019 more than two-thirds of all drug 
overdoses were opioid related. The NIDA (2020) reported that as of the end of 2018 
opioid overdose was the primary cause of 128 deaths each day in the United States. The 
CDC (2021) reported that drug overdose deaths have increased by 400% since 1999, 
including a six percent increase in opioid-related deaths overall, and a 15% increase in 
synthetic opioid associated deaths during the year period ending in 2019. The CDC 
(2020) noted that in the year period ending in May, 2020 there were more than 81,000 
drug overdose deaths, a number that included a 98% increase in opioid related deaths 
reported by several states in the western U.S., and reflected the highest number of 





strongly suggest that illicit opioid use and its harmful effects are continuing to increase at 
a very concerning rate. 
1,200 MAT programs were in existence as of the end of 2010 providing treatment 
services to an estimated 270,000 opioid dependent individuals (SAMHSA, 2011). The 
SAMHSA (2020b) reported an estimated 1.2 million individuals enrolled in MAT 
programs as of the end of 2019. In  MAT programs are a highly effective treatment for 
opioid use disorder (Kosten & George, 2002; Parrino et al., 1993; SAMHSA, 2020b; 
Volkow, 2007b). Opioid use disorder with physiological dependence is a chronic, 
relapsing condition where post-remission relapse is highly likely (APA, 2013; Dennis & 
Scott, 2007; Kosten & George, 2002; Leshner, 1989; 2001; Parrino et al., 1993; 
SAMHSA, 2020b, Volkow, 2007a; 2007b). MAT participants are at risk for episodic 
relapse of illicit opioid use and are likely to benefit from adjunctive treatment 
interventions (Logan & Marlatt, 2010; Parrino et al., 1993). 
Relapse-Associated Concerns 
The medical, psychological, and social risks associated with relapse into illicit 
opioid use are of great concern (CSAT, 2005; Chalk et al., 2013). Individuals 
experiencing relapse are at high risk for overdose, oversedation effects, and death 
(CSAT; Parrino et al., 1993; SAMHSA, 2020b). Overdose death rates associated with 
illicit opioid use have tripled since 1990 and continue to increase (Chalk et al., 2013). 
The risk of relapse for persons with opioid use disorder is strongly associated with stress 





include hepatitis C (HCV) and human immunodeficiency virus (HIV), and their adverse 
medical complications. Further associated risks include complications of secondary 
general medical conditions, symptomatic exacerbation of concomitant psychiatric 
disorders, criminality engaged in to sustain illicit opioid use, and social dysfunction 
leading to marginalization by and alienation from familial and other potential supportive 
resources (Parrino et al., 1993; SAMHSA, 2020b, Volkow, 2007a; 2007b). Research 
findings suggest that as many as 20 percent of MAT program participants experience 
relapse into illicit opioid use (Kreek, 2007). Taken together, these considerations strongly 
suggest that any therapeutic adjunct associated with reduced relapse risk is likely to 
reduce harm potential and benefit the health and well-being of the MAT program 
participant. 
Theoretical Foundation 
Potential for Mindfulness-Based Treatment Adjuncts  
Mindfulness-based treatment interventions are effective in treating substance use 
disorders and their associated craving, seeking, and using behaviors (Bowen et al., 2005; 
Bowen et al., 2009; Chiesa & Serriti, 2013; Garland et al., 2012; Witkiewitz & Bowen, 
2010; Witkiewitz et al., 2012; Witkiewitz et al., 2005; Zgierska et al., 2009). In their 
evaluation of mindfulness-based treatments for substance use in an incarcerated 
population Bowen et al. (2006) found a significant reduction in opioid and other 





found that use of mindfulness and CBT practices reduced symptomatic severity of opioid 
and other substance abuse disorders in participants. 
Mindfulness based relapse prevention (MBRP) uses mindfulness meditation and 
cognitive behavioral therapy practices to reduce substance use relapse (Bowen et al., 
2011; Bowen et al., 2006; Bowen et al., 2009; Marlatt & Chawla, 2007). Marlatt and 
Chawla and Ostafin and Marlatt (2008) found that continued mindful experiencing of 
substance use cravings deconditions the association between substance use behavior and 
the craving, thereby decreasing vulnerability to relapse. Marlatt and Chawla observed 
that this therapy ultimately reduces substance cravings and counteracts substance 
addiction through facilitating awareness and acceptance of the present moment 
experience, where such experience is in some way disturbing or uncomfortable, thereby 
reducing the individual’s propensity toward using substances to cope with aversive 
existential realities. 
A relapse liability exists in opioid dependent persons. Cognitive deficits in 
prefrontal cortex (PFC) mediation of signals from the mesolimbic dopaminergic system 
increase opioid dependent individuals’ vulnerability to environmental substance use cues 
and reduce their capability for regulation of drug craving and seeking behaviors 
(Childress et al., 2008; Dennis & Scott, 2007; Kosten & George, 2002). Wenk-Sormaz 
(2005) showed in a randomized, controlled study that meditation facilitated cognitive 
flexibility and affective responsivity and deconditioned maladaptive implicit cognitive 





may increase individual capability for regulating emergence of autonomic substance use 
cravings through upregulation of PFC functioning. 
Role of Neurobiological Research Findings 
Ostafin and Marlatt (2008) posited that addiction implies the existence of 
automatic processes that are largely nonconscious, unintentional, and difficult to control. 
Wenk-Sormaz (2005) observed that mindfulness practices, through their emphasis on 
decentered attentiveness toward phenomena and facilitation of volitional states of 
selective arousal, deautomatize habitual cognitive processing and facilitate awareness of 
cognitive processes that include intentionality, attentiveness, and awareness. Mindfulness 
facilitates reregulation of previously habituated substance use-related cognitive and 
behavioral patterns into more adaptive and beneficial processes (Ostafin & Marlatt). 
States of mindfulness have been empirically associated with stronger PFC structure and 
more adaptive regulation of limbic system signaling (Brewer et al., 2010; Ostafin & 
Marlatt). Taken together, these neurobiological research findings suggest that 
mindfulness practices may enhance control of opioid use cravings and seeking behaviors, 
thereby reducing illicit opioid use and resultant health risk behaviors and offering 
concomitants of symptomatic relief and improved quality of life for participants. 
Examining the effects of MBRP on individuals participating in MAT for opioid 
dependence necessitates evaluation of the nature of opioid use disorder, including its 
neurobiological, psychological, and social concomitants, and their potential 





state described as mindfulness. To that end, the etiology, theoretical perspectives, and 
empirically supported treatment options for opioid use disorder with physiological 
dependence are investigated, together with a description of how the condition is 
evaluated and treated within the context of a MAT environment. Neurobiological 
structure and functioning relevant to opioid use disorder are explicated. A brief 
description of the history and development of MAT programs is offered, along with a 
synopsis of the current MAT program philosophy and approach to opioid use disorder 
treatment.  
Following this, the nature of mindfulness and mindfulness practices are discussed. 
Neurobiological structure and functioning relevant to states of mindful attention are 
evaluated, and the implications of these findings for use of MBRP as an adjunctive 
treatment for opioid use disorder are explored. Finally, relevant aspects of contemporary 
psychological treatment approaches incorporating mindfulness practices are described, 
the use of treatment interventions based on these models is explicated, and the relevance 
of these theoretical constructs and interventions for treatment of opioid use disorder 
within the context of MAT programs is offered.    
Theoretical Bases for Substance Use Disorders 
Three predominant theoretical explanations for the etiology of substance use 
disorders exist. Physical dependence theory explains substance use disorders (SUDs) as 
arising from neurobiological changes associated with drug exposure and continued use 





interrelationship between hedonic drug effects and expectations about those effects held 
by the substance user (Kolb & Wishaw, 2009). Classical conditioning theory emphasizes 
the effects of drug exposure over time on unconscious cognitive functioning (Koob & 
Kreek, 2007; Koob & Moal, 1997; Nestler & Aghajanian, 1997).  
Physical Dependence Theory 
Koob and Kreek (2007) observed that physical dependence theory asserts through 
repeated drug administration the individual develops tolerance and dependence. 
Tolerance is observed when sensitivity to drug effects decreases. Alteration of the dose-
response curve results in attenuated drug effects given continued dosing at the same level, 
with resultant need to increase the drug dosage to regain desired drug effects. 
Dependence is observed when the individual maintains optimal levels of the drug within 
his or her physiological system in order to prevent the onset of withdrawal syndrome, the 
constellation of aversive symptoms uniquely characteristic to each substance when drug 
administration is discontinued or reduced.  
Koob and Moal (1997; 1998) asserted that dependence arises through hedonic 
homeostatic dysregulation, as central nervous system neurotransmitter levels adjust in 
response to exogenous drug molecule exposure, a condition referenced as allostasis 
(Koob & Moal, 1997; 1998). Thus, in response to continued administration of exogenous 
opioids natural opioid (endorphin) production is downregulated. Should the exogenous 
opioid supply be reduced, the individual experiences the characteristic aversive signs and 





nausea, and diarrhea, among others (Parrino et al., 1993). Initial treatment approaches 
suggested that through detoxification a substance dependent individual could gradually 
reduce her or his physical dependence on the substance and eventually achieve a state of 
drug abstinence without associated withdrawal discomfort (Koob & Kreek). However, as 
Koob and Kreek observed, the majority of detoxified individuals relapse into substance 
use, leading to considering treatment alternatives to detoxification. 
Positive Incentive Theory 
Positive-incentive theory attempts explanation of substance use disorders through 
suggesting that the euphoria associated with substance use is the primary motivator for 
continued substance use, rather than abstinence syndrome avoidance (Kolb & Wishaw, 
2009). This theory is based on the hedonic hypothesis (Kolb & Wishaw), suggesting that 
pleasure associated with substance use is the primary motivator for continued use. Moal 
and Koob (2007) noted that two interrelated functions are central to positive-incentive 
substance use theory: the positive incentive value, describing the individual’s anticipated 
pleasure of substance effects; and the hedonic value, the actual pleasurable effects of the 
drug that the individual experiences.  
Kolb and Wishaw (2009) observed that with repeated drug administration, the 
positive incentive value increases, thereby explaining the substance user’s transition 
along the substance use continuum from initial drug exposure, to regular use, to abuse, 
and thence to dependence. This suggests why some individuals do not become addicted 





substance are insufficient to motivate them to use the substance repeatedly. A related 
explanation in some cases is that positive incentive value for some substance using 
individuals does not change with repeated exposure as it does with their substance 
dependent counterparts. Moal and Koob (2007) noted that the compulsion to continue 
administrating the drug is largely driven by its perceived positive-incentive value, which 
facilitates sensitization to anticipated drug effects, whereas the individual will tend to 
become increasingly desensitized toward the hedonic effects of the substance. This 
suggests why many substance abusers and dependents continue to use, and their 
substance use cravings actually increase, despite their experiencing of decreased hedonic 
drug effects. A limitation of the positive-incentive theory is that it fails to account for 
classical conditioning effects associated with continued substance use and fails to explain 
the phenomenon of nonconscious interoceptive and exteroceptive cueing associated with 
substance craving and withdrawal states (Childress, 2008; Koob & Kreek, 2007). 
Classical Conditioning Theory 
Learning theory, as applied to substance use disorders, suggests that repeated 
instances of substance using behavior result in classical conditioning effects, thereby 
fostering interrelated psychological and neurobiological constituents of substance 
dependence (Koob & Kreek, 2007; Koob & Moal, 1997; Nestler & Aghajanian, 1997). 
Conscious and nonconscious associations motivate the individual to continue substance 
use through repeated contemporaneous pairings of substance administration with hedonic 





drug administration raises the hedonic reward threshold experienced by the user, thereby 
fostering continued increases in drug administration in order to achieve the desired drug 
effects.  
Koob and Kreek (2007) asserted that this conditioning is similar to that involved in 
other intrinsically rewarding behaviors such as eating, drinking, and sexual activity. Such 
behaviors are associated with upregulation of the neurotransmitter dopamine throughout 
various components of the mesocorticolimbic pathway of the mesotelencephalic 
dopamine system of the brain (Koob & Moal, 1997; Kosten & George, 2002). 
Neurotransmissions from the ventral tegmental area to the nucleus accumbens are 
implicated in dopamine upregulation associated with addictive behavioral conditioning 
(Kosten & George). Moal and Koob (2007) posited that addiction develops through 
changes in striatal regulation mechanisms; specifically, through increased dorsal striatum 
activity along with activation of hypothalamic stress circuits, along with concurrent 
reduction in prefrontal cortex mediation of these centers. Koob and Kreek observed that 
the prefrontal cortex mediates relapse associated with drug-priming effects, the amygdala 
is implicated in cue-activated relapse, and the hypothalamus mediates relapse associated 
with stressors.      
Moal and Koob (2007) described contingent drug tolerance as that associated with 
drug effects experienced by the substance user. The individual tends to experience these 
effects within the situational context associated with original conditioning to the drug 





Situational stimuli become predictive of drug effects, such that normative levels of 
substance tolerance may not exist in novel situations, thus exacerbating the risk of 
overdose, even with previously administered amounts of the same substance the 
individual is dependent on. Both interoceptive and exteroceptive situational stimuli are 
conditioned with continued substance administration and tend to increase drug 
sensitization effects. Situational compensatory conditioning effects likely factor in the 
phenomenon experienced by many individuals with opioid use disorder histories, who, 
despite years of abstinence and recovery, may experience the onset of opioid withdrawal 
symptoms when exposed to an environmental cue associated with prior drug use 
experience (Parrino et al., 1993). Situational compensatory conditioning effects suggest 
why some individuals with considerable substance use experience situational specific 
opioid overdose. 
Substance Use Pathology   
Substance use occurs along a continuum, ranging from: (a) non-pathological, 
experimental or casual use; to (b) escalating drug abuse with resultant harmful effects; 
and thence to (c) pathological, compulsive use associated with physical dependence on 
the substance (APA, 2013; Moal & Koob, 2007). Dyscontrol of substance use is 
evidenced despite adverse consequences (APA; Moal & Koob, 2007). This symptomatic 
constellation includes several additional neurobiological and behavioral effects. There is 
a marked propensity for relapse despite even years of abstinence. Affective dysregulation 





substance use as coping) is frequently evidenced. Also observed is compromised 
executive functioning that reduces the individual’s capacity for regulating behavior 
appropriately and effectively, leading to dysfunctional behaviors at home, in the 
workplace, and in larger social settings. Increased compulsion and preoccupation with 
substance craving, seeking, and using is frequently found. Secondary illnesses associated 
with substance toxicity effects may occur. Co-occurring medical and psychiatric 
conditions that are secondary to, or exacerbated by, continued substance use are also 
frequently observed (Moal & Koob, 2007; Leshner, 2001). Leshner (1999; 2000) asserted 
that the psychological, social, and physical functional impairments associated with 
substance use disorder are highly unlikely to resolve without treatment.  
Historically, substance use disorders have been viewed as personal and social 
failure. Social perspectives on persons with substance use problems have insistently 
regarded such individuals as immoral and amotivated (Volkow, 2007a). These negatively 
biased public perceptions continue to persist (Livingston et al., 2012). Substance use 
disorders pose a societal challenge to overcome these longstanding negative assumptions 
and biases misrepresenting substance use disorders as characterological problems 
(Volkow). 
Nature of Opioid Use Disorder 
This study’s predominant focus is on evaluating the effectiveness of a specific 
mindfulness-based manualized treatment for individuals participating in MAT for opioid 





Understanding the neurobiological substrates of opioid use disorder provides a context 
within which the effects of mindfulness practice on neurobiological systems implicated in 
the opioid use disorder condition are more clearly apprehended and evaluated. This 
discussion now focuses on neurobiological structures and functions associated with 
substance use conditions.  
Mechanism of Action 
Opioid drugs are classified according to their mechanism of action in the CNS. 
Agonists, such as heroin, oxycodone, and methadone increase brain cell activity at 
specific CNS receptor sites. Antagonists, such as naltrexone, decrease brain cell activity 
at specific CNS receptor sites. Partial agonists, such as buprenorphine, both increase and 
decrease brain cell activity at specific CNS receptor sites (Koob & Moal, 2007; Parrino et 
al., 1993, SAMHSA, 2020). 
Agonist Drug Effects 
Agonist drugs increase synaptic activity (Stanford, 1988). Synapse references the 
microscopic space lying between adjacent neurons, where a predominant number of 
receptor sites are located for the purpose of neurotransmission (Koob & Moal, 2006). 
Direct acting drug molecules attach to receptor sites; and indirect acting drug molecules 
target other synaptic functions, such as neurotransmitter reuptake (Koob & Moal, 2007). 
Examples of direct acting drugs include heroin, morphine, methadone, and other opioids 
(Koob & Kreek, 2007). Examples of indirect acting drugs are amphetamine, 





reason humans may be especially vulnerable to opioid dependence is due to the structural 
similarities between endogenous opioid neurotransmitters such as µ-opioids (Zubieta et 
al., 2005), and exogenous opioid molecules, such as codeine, oxycodone, heroin, and 
morphine. 
Homeostasis, Tolerance, and Dependence 
Homeostasis references the innate tendency for physiological systems to function 
toward balance (Koob & Moal, 1997). The central nervous system (CNS, e.g., brain and 
spinal cord) operates on this principle. Use of exogenous drugs disrupts homeostasis, 
resulting in CNS attempts to regain neurobiological equilibrium (Koob & Moal). Koob 
and Moal asserted that where illicit substance use continues for extended periods, 
neurobiological homeostasis is impaired, resulting in a state of disequilibrium that leads 
to a state of hedonic homeostatic dysregulation, wherein natural neurotransmitter 
functioning re-regulates to maintain the new, artificial neurobiological homeostasis 
partially dependent upon the exogenous drug supply. 
Koob and Moal (1997) posited that this hedonic homeostatic dysregulation state 
results in emotional distress that is frequently associated with further substance use. 
Continued disruption of homeostasis through substance use thus results in 
neurobiological and thence psychological dependence, the condition of allostasis (Koob 
& Moal, 1997). This state is identified in DSM5 (APA, 2013) as substance use disorder 
with physiological dependence. Given this condition, the individual is neurobiologically 





Tolerance is the process the body engages in to achieve homeostasis in response 
to exogenous substance exposure (Koob & Moal, 2006; 2007). It results in physiological 
adaptation to greater drug potency, more frequent drug use, or increased drug exposure 
through changes in method of drug administration, such as from oral use to intravenous 
use. Increased drug exposure results in increased tolerance, eventually resulting in using 
the substance to prevent the onset of abstinence syndrome rather than to obtain euphoric 
drug effects initially experienced (Koob & Moal, 2006; 2007; Parrino et al., 1993; 
Stimmel & Kreek, 2000).  
Dependence and tolerance are interrelated, in that increasing drug use is directly 
associated with increased tolerance to the drug effects and the resultant condition of 
allostasis (Moal & Koob, 2007). Once allostasis occurs, continued exogenous drug 
exposure is necessary to prevent the onset of abstinence syndrome, the constellation of 
withdrawal symptoms associated with the specific drug used (Moal & Koob; Parrino et 
al., 1993). Thus, hedonic homeostatic dysregulation (Koob et al., 1998) leads to allostasis 
and at that point, the individual is physiologically dependent on the exogenous substance. 
Koob and Moal (1997) posited that the individual is compelled to respond to 
environmental disequilibrium (insufficient substance availability) with substance seeking 
and using behaviors in order to maintain allostasis. 
Continued allostasis, or drug dependence, is fostered through exposure to hedonic 





dopamine levels (Moal & Koob, 2007), and secondarily reinforced through associated 
reductions in frequency and severity of aversive abstinence syndrome effects.   
Opioid drug molecules have an affinity for mu receptors in the nucleus 
accumbens, ventral tegmental area, and locus ceruleus brain areas; all implicated in 
opioid use disorder (Kolb & Wishaw, 2009; Kosten & George, 2002). Three CNS 
functions are implicated in opioid use disorder. The first is the initial condition of 
hedonic homeostatic dysregulation wherein the reward pathway is activated in response 
to continued exogenous opioid exposure leading to allostasis and resultant physiological 
dependence on exogenous opioids. The second is classical conditioning hedonic effects 
of exogenous opioid exposure and avoidance of aversive effects experienced in opioid 
withdrawal. The third is cognitive deficits that foster continued opioid use and 
dependence (Kosten & George, 2002; Moal & Koob, 2007). 
Reward Pathway 
The neurobiological system predominantly implicated in opioid use disorder is the 
CNS (Kolb & Wishaw, 2009). Kolb and Wishaw observed that CNS functioning 
regulates hunger, thirst, and sexual drives, reinforcing behaviors that address these core 
survival needs. These brain areas are collectively referenced as the mesolimbic 
dopaminergic reward pathway (Kosten & George, 2002; Moal & Koob, 2007). Reward 
pathway function and structure fosters conditioned behavioral responses, predominantly 
through increases in levels of the neurotransmitter dopamine that are temporally 





In this way, opioids and other drugs of abuse function as dopamine agonists by increasing 
the levels of that neurotransmitter in the brain (Koob & Moal, 1997; Koob et al., 1998).  
Through operant neuronal cellular conditioning processes, these increases in 
dopamine levels associate the cue, which can be the drug exposure itself or any 
environmental factor associated with drug use, with euphoric mood (Childress et al., 
2008; Moal & Koob, 2007). Childress et al. noted this neurobiological mechanism 
activates in response to the individual’s exposure to drug-associated environmental cues, 
resulting in onset of drug craving, and in some cases, abstinence syndrome. Koob and 
Kreek (2007) observed that for persons with opioid use disorder exposure to 
environmental stressors precipitates the onset of drug cravings and withdrawal 
symptoms. Moal and Koob observed that substance use behaviors are reinforced through 
this reward pathway functioning such that the compulsion to seek and use drugs becomes 
the affected individuals’ predominant focus. 
Opioid-Associated Reward Pathway Activation  
Given continued exogenous opioid use, mu receptors in the brain become 
occupied with the exogenous opioids. Moal and Koob (2007) observed that repeated 
ingestion of exogenous opioids activates homeostatic functioning, reducing endogenous 
endorphin production that results in the condition of hedonic homeostatic dysregulation. 
Continued exposure to exogenous opioids thence fosters the condition of neurobiological 
allostasis where the individual is dependent on the exogenous opioid supply in order to 





withdrawal symptoms (Moal & Koob, 2007). The individual is then physiologically 
dependent on exogenous opioids, thus meeting diagnostic criteria for opioid use disorder 
304.00 according to DSM-5 criteria (APA, 2013); described as either mild (305.50), 
moderate (304.00), or severe (304.00), depending on associated symptom prevalence. 
Classical conditioning effects reinforce associations between this euphoric mood 
and opioid use, fostering continued use of exogenous opioids. The ventral tegmental area 
within the brain’s reward pathway increases release of dopamine in the nucleus 
accumbens resulting in enhanced sensations of well-being and euphoria (Kosten & 
George, 2002; Sun et al., 2011). Any period of exogenous opioid abstinence results in 
onset of aversive opioid withdrawal symptoms, further reinforcing continued ingestion of 
exogenous opioids (Kosten & George). Most individuals with this condition will engage 
in continued illicit opioid use in their attempts to feel a sense of well-being and to avoid 
the discomfort of opioid withdrawal. 
Individuals with opioid use disorder frequently continue their illicit drug seeking 
and using behaviors despite severe socioeconomic consequences (Moal & Koob, 2007). 
Such behaviors are often asserted as evidence of the affected individual’s lack of 
commitment to recovery from substance use, or as evincing his or her lack of sufficient 
willpower or poor character (Volkow, 2007a).  Kosten and George (2002) suggested that 
the prefrontal cortex (PFC), an integral part of aforementioned neurobiological reward 
pathway, regulates cognitions associated with adaptive executive behaviors and thus 





individuals with opioid use disorder these sound judgment and planning capabilities are 
compromised, being overridden by bottom-up neurobiological signals from the brain’s 
limbic system that support opioid drug craving, seeking, and using despite the likelihood 
of aversive consequences. 
Moal and Koob (2007) posited that inhibitory top-down messages sent from the 
PFC advising against illicit opioid use and its inherent psychosocial, legal, health, and 
economic consequences are negated by the bottom-up signals emanating from the limbic 
system, regulated in part by contextual drug-associated memories stored in the 
hippocampus and the associated withdrawal anxiety and fear associations regulated by 
the amygdala. Koob et al. (1998) asserted the existence of a residual deficit state in the 
neurobiological reward pathway that leaves the substance dependent individual 
vulnerable to and predisposed toward relapse. Nestler and Aghajanian (1997) observed 
that chronic opioid use results in genetic adaptations that foster structural and functional 
changes in CNS neuronal and synaptic structures, thereby increasing the affected 
individual’s liabilities toward opioid use disorder. 
Opioid Receptor Sites 
The molecular structure of opioid drugs helps them attach to opiate receptor sites 
in the brain (Kosten & George, 2002). Parrino et al. (1993) noted that natural opioid 
compounds such as codeine and morphine, semisynthetic compounds such as heroin, and 
synthetic compounds including oxycodone, hydromorphone, and methadone, readily 





receptor types in the CNS, the mu receptor is predominantly implicated in the condition 
of opioid use disorder.  
Endogenous and Exogenous Opioids 
Endogenous opioids naturally occupy mu receptor sites within the CNS (Parrino 
et al., 1993). These endorphin and enkephalin opioid protein molecules are referenced as 
peptides, and under normative conditions, the CNS uses them to help regulate pain and 
mood (Parrino et al.). Homeostatic regulation processes cause these natural opiates to 
reduce or stop producing in response to exogenous opioid use. Mu opioid receptor sites 
are then occupied by exogenous opioid molecules reflecting the condition of allostasis 
(Moal & Koob, 2007; Parrino et al.). 
Persistent Receptor Disorder 
In their seminal research on opioid use disorder and its treatment using 
methadone, Dole and Nyswander (1965) observed that replacement of endogenous with 
exogenous opioids results in persistent receptor disorder, a process subsequently 
identified as hedonic homeostatic dysregulation (Koob & Moal, 1997). Where reduced 
levels of the exogenous opioid drug are not replaced by natural opioids, mu receptor sites 
are left unoccupied and the individual experiences the resultant discomfort of withdrawal 
symptoms (Moal & Koob, 2007). To avoid the aversive experience of opioid withdrawal 
individuals engage in opioid drug seeking behavior thereby explaining the chronic 






Opioid Abstinence Syndrome 
Opioid abstinence syndrome (OAS), or opioid withdrawal, occurs in individuals 
that have physiological dependence on exogenous opioids and experience abrupt 
discontinuance of the drug supply. Kosten and George (2002) asserted that in opioid 
withdrawal reduced levels of mu receptor site occupation within the locus ceruleus 
elevates noradrenaline levels resulting in a constellation of aversive signs and symptoms 
(see Table 1). OAS frequently results in opioid craving and seeking behavior because the 
affected person seeks immediate relief from the resultant physical discomfort. Simply 
ruminating on the possibility of experiencing OAS frequently results in discomfort 
anxiety (Ellis et al., 1988) that motivates the opioid dependent person to engage in drug 
seeking and using behavior regardless of potential life consequences (Kosten & George).  
Frequently used illicit opioids include those with a short half-life of about four 
hours, such as hydrocodone and heroin (Parrino et al., 1993). This brief half-life means 
that unless the drug is readministered about every four hours, mu receptor site occupation 
will decrease resulting in the onset of opioid withdrawal symptoms (Kosten & George, 
2002). Further, as opioid tolerance and dependence increase, the individual must either 
increase frequency of his or her opioid drug use or use a more potent form of the drug in 
order to stave off withdrawal symptoms (Dennis & Scott, 2007). Opioid dependent 
individuals seeking MAT program services frequently report increasing opioid use to 









Objective and Subjective Opioid Withdrawal Signs and Symptoms 
________________________________________________________________________ 
Objective       Subjective 
________________________________________________________________________ 
Runny nose (rhinorrhea)    Diarrhea 
Dilated pupils      Nausea 
Tearing eyes (lacrimation)    Insomnia 
Sweating (diaphoresis)    Chills 
Gooseflesh (piloerection)    Abdominal pain  
  
Yawning      Muscle/joint aches 
Sneezing      Anxiety 
Coughing      Crawling skin sensation 
Salivating      Irritability 
Gagging/vomiting     Jitteriness 
Restlessness      Opioid craving/seeking/using 
________________________________________________________________________ 
Note: Adapted from “State methadone treatment guidelines (Technical Assistance Publication Series # 
7),” by Parrino et al., 1993, pp. 106-113. Published in the public domain by U.S. Department of Health and 
Human Services, Substance Abuse and Mental Health Administration, Center for Substance Abuse 
Treatment. 
 
Environmental cues can trigger onset of OAS. Cue reactivity in substance use 
disorders is strongly associated with substance cravings, urges to use, and onset of 
objective and subjective substance withdrawal signs and symptoms (Childress et al., 
2008; Dennis & Scott, 2007). Childress et al. suggested that cue reactivity occurs 
nonconsciously in response to environmental triggers prior to conscious awareness of or 
volitional control over neurobiological and related physiological responses to the 





experience onset of OAS from encountering situations similar to those in which prior 
opioid use occurred. The inherently aversive nature of opioid withdrawal and the ready 
availability of its environmental precipitants suggest the need for effective cognitive 
behavioral interventions to regulate these involuntary symptoms.   
Considered together, the neurobiological functions of mesolimbic reward pathway 
activation, hedonic homeostatic dysregulation, allostasis, cognitive deficits, and opioid 
abstinence syndrome strongly suggest that the opioid dependent person, without 
treatment intervention, will tend to be increasingly preoccupied with illicit opioid 
craving, seeking, and using, regardless of potential adverse consequences (Kosten & 
George, 2002; Leshner, 2001; Moal & Koob, 2007). These considerations further suggest 
that in order to be effective, any form of treatment for the condition of opioid use 
disorder must increase the affected person’s capabilities for mediating these 
neurobiological liabilities. This proposal now examines use of methadone medication in 
the context of MAT programs, an evidence-based treatment intervention that effectively 
addresses the preceding problems and facilitates a return to normal human functioning for 
the opioid dependent person. 
Methadone Medication Use and Effects 
Introduction to Methadone Medication 
Parrino et al. (1993) observed that methadone is a synthetic opioid analgesic with 
a half-life of 24-36 hours. Medication formulations include 40 mg wafers, 10 mg tablets, 





medication is effective because of its neuropharmacological mechanisms including mu 
opioid receptor binding, neurological blockade, and steady state neurological regulation. 
Mu Opioid Receptor Binding 
When methadone metabolite molecules bind with mu opioid receptors in the brain 
the methadone metabolite molecules cross the blood brain barrier and occupy mu 
receptor sites in the brain’s ventral tegmental area and locus ceruleus, both key functional 
areas in the mesolimbic reward pathway (Dole & Nyswander, 1965; Kosten & George, 
2007). Kosten and George posited that this bonding action within the ventral tegmental 
area of the brain’s limbic system structure elevates dopamine levels in the nucleus 
accumbens, resulting in nominal feelings of contentment and wellbeing, much as the 
average non-opioid dependent individual is likely to experience when engaged in 
rewarding behavior. The mu receptor sites remain occupied by methadone metabolite 
molecules for up to 36 hours-during which the individual feels normal levels of well-
being and emotional responsiveness and does not experience OAS (opioid withdrawal 
signs and symptoms) or opioid cravings (Dole & Nyswander; Parrino et al., 1993). These 
drug effects are essential in facilitating stable mood, preventing onset of opioid 
withdrawal distress, and forestalling opioid use cravings that would otherwise precipitate 
relapse into illicit opioid use. 
Illicit Opioid Blockade Effects 
The efficacy of methadone medication is partly due to the affinity for its 





Nyswander (1965) posited that methadone molecules would bind to mu receptor sites 
even in the presence of competing alternate opioid molecules including heroin. Parrino et 
al. (1993) observed that this mu receptor site affinity for methadone molecules resulted in 
the therapeutic medication effect identified as euphoric blockade. Parrino et al. noted that 
when methadone molecules are bound to the mu receptor sites other competing opioid 
molecules are prevented from binding, with resultant reduction or elimination of hedonic 
and other drug effects that would otherwise be experienced through exposure to 
exogenous (presumably illicit) opioids. Thus, there is a marked reduction in the 
classically conditioned effects normally associated with exogenous illicit opioid use. 
Because the methadone maintained individual experiences significantly reduced relapse 
precipitants he or she is much less likely to continue using illicit opioids.  
Steady State 
Methadone medication has a lengthy half-life of up to 36 hours (Preston et al., 
2013), markedly different from the typical four-hour half-life of heroin, hydrocodone, or 
morphine (Batki et al., 2005; Parrino et al., 1993). Daily ingestion of methadone results 
in an adaptive form of allostasis, referenced as steady state, where the methadone blood 
levels have reached reasonably optimal consistency and mu receptor sites in the CNS 
have fully bound with methadone molecules (Batki et al.; Parrino et al.). Batki et al. 
suggested that MAT program patients normally achieve steady state regulation within 
five days. An additional pharmacological property of methadone is that once steady state 





experience continued beneficial drug effects without increasing either tolerance or 
dependence (Batki et al.; Parrino et al.). Thus, individuals participating in MAT programs 
utilizing methadone pharmacotherapy avoid the aversive effects of hedonic homeostatic 
dysregulation as they benefit from the adaptive allostasis afforded by methadone 
medication. 
The benefits of methadone maintenance include alleviation of the signs and 
symptoms of opioid abstinence syndrome, reduction and eventual elimination of illicit 
opioid craving and drug seeking behaviors; and inhibition of euphoria associated with 
illicit opioid abuse (Parrino et al., 1993). 
Kreek (2000) asserted that MAT program participation using methadone 
medication is associated with more adaptive neuronal functioning within the reward 
pathway systems and improved stress response capabilities. Kreek and Koob (2007) 
suggested that because stress exposure has been determined to be a significant relapse 
precursor in opioid dependent individuals, the beneficial stress coping effects of 
methadone medication use are likely to prevent relapse or reduce its severity and 
duration, thereby enhancing well-being and resilience in the patient with opioid use 
disorder. Parrino et al. (1993) asserted that methadone pharmacotherapy within the 
context of the MAT program is safe and effective; the medication is prescribed and 
administered by licensed medical personnel extensively trained in the treatment of 





pharmacotherapy reduces or eliminates illicit opioid use in most patients, associated risks 
to physiological and psychological health are correspondingly reduced. 
Risks Associated with Methadone Medication Use 
As with any medication, there are risks associated with the use of methadone. 
Within the context of its use at MAT programs, these risks are usually minimal. 
Methadone acts as a central nervous system depressant and can cause sedative effects 
including drowsiness, respiratory depression, coma, and death (Batki et al., 2005; Parrino 
et al., 1993). Although there has been a marked increase in methadone associated 
mortality (Fingerhut, 2008), these problems have been predominately associated with 
private physician pain treatment administration, whereas MAT program use of 
methadone continues to be safe and effective (SAMHSA, 2020). Consistent with using 
any drug with potentially sedating effects, methadone-maintained patients must use 
caution when operating motor vehicles or dangerous machinery. Parrino et al. suggested 
that in some cases methadone medication increases sedative effects of other medications 
exerting sedative effects, such as benzodiazepines. Batki et al. advised that methadone 
could increase the sedative effects of alcohol, advising against concurrent ingestion. The 
Food and Drug Administration (FDA; 2007) warned that ingestion of even a single 
methadone dose may be lethal for a person not physically dependent on opioids. In 
keeping with this proscription, the SAMHSA (2020) recommended a very low 






Side Effects of Methadone Medication 
All medications have side effects that need to be considered when use is 
indicated. Methadone acts as a central nervous system depressant and can cause sedative 
effects including drowsiness, respiratory depression, coma, and death (Batki et al., 2005; 
Parrino et al., 1993). The FDA (2007) and Parrino et al. (1993) asserted that common 
side effects of methadone medication include mild constipation (typical with most 
opioids), sweating, changes in libido, and lethargy. 
Parrino et al. (1993) posited that severity of these side effects recedes over time. 
The MAT program physician plays a key role in assisting the patient with managing these 
side effects. The FDA (2007) asserted that individuals maintained on methadone 
medication will experience the condition of physiological opioid dependence, thus abrupt 
discontinuance of the medication results in rapid onset of opioid abstinence syndrome 
with resultant physiological discomfort, psychological distress, and elevated relapse risk. 
Benefits of Treatment in MAT Programs 
Participation in MAT using methadone is associated with significant reductions in 
criminal activity (Parrino et al.), illicit opioid use, alcohol misuse, and other drug use 
(Batki et al., 2005). After stabilization on methadone medication, the properly maintained 
methadone patient is fully functional (Batki et al.). Positive behavioral changes are 
learned or reacquired as treatment continues. The patient gains insight through 
participation in ongoing supportive counseling largely based on therapeutic approaches 





Rogers, 1957; 1961; 1979; 1980), and through development of the therapeutic alliance 
with his or her counselor (McCann et al., 1994). These functional improvements result in 
learning or reacquisition of adaptive lifestyle changes. The MAT program patient thence 
benefits from substantial improvements in intrapersonal and interpersonal functioning. 
MAT treatment is associated with significant reductions in societal costs 
associated with opioid use disorder. Overutilization of public health systems associated 
with drug misuse, active drug craving, and seeking are lessened, and interaction with the 
legal system is significantly reduced, thereby lessening associated costs (Parrino et al., 
1993). Reduction in health risks associated with opioid injection use is significantly 
reduced (SAMHSA, 2020). In California, the annual cost for methadone maintenance for 
a single individual is approximately $5,000 annually, minimal in comparison to the 
yearly prison expenses of up to $60,000 annually (Gerstein et al., 1994). Gerstein et al. 
found the cost-benefit ratio for MAT patients maintained on methadone was $1.00/$7.00. 
These data suggest multiple societal benefits exist for maintaining individuals with opioid 
use disorder in MAT programs. 
Clinical Effectiveness of Methadone Medication 
Research over the past several decades suggests that participation in MAT 
programs using methadone pharmacotherapy is a highly effective treatment approach for 
individuals with opioid use disorder (Ball & Ross, 1991; California Society of Addiction 
Medicine, 2008; Leshner, 1999; 2001; Rothbard et al., 1999). The combination of daily 





for MAT program participants effectively mediates the neurobiological substrates 
implicated in the condition of opioid use disorder (Childress et al., 2008; Dennis & Scott, 
2007; Kosten & George, 2002). In addition, MAT programs are cost-effective forms of 
treatment (Barnett, 1999; Doran et al., 2003). Despite the effectiveness of this 
comprehensive treatment approach, relapse risk remains as high as 69 percent for a 
significant number of MAT program participants (Rosencrantz et al., 2007); particularly 
those who have not yet stabilized in treatment or are exposed to severe environmental 
stressors (Kreek, 2002; 2007). This suggests that any additional treatment interventional 
approach readily accessible to a majority of MAT program patients that effectively 
reduces relapse frequency and severity is likely a clinically useful treatment adjunct. This 
proposal evaluated one such treatment adjunct: MBRP (Bowen et al., 2011). 
Conceptual Framework 
In this section historical antecedents of mindfulness-based practices are explored. 
The theoretical and interventional elements of various clinical approaches based on 
mindfulness practices will be examined. Given that mindfulness practices reflect a unique 
and specific approach to attentional mediation the psychological and neurobiological 
factors of attentional regulation are evaluated. Following this, research evaluating the 
neurobiological substrates of mindfulness practices is examined, and the implications of 
this research for addressing the neurobiological dysfunction associated with the condition 






Historical Antecedents of Mindfulness Practices 
Mindfulness-based practices arose from Vipassana, a term used to connote breathing 
or insight meditation (Jain et al., 2007). Vipassana denotes a contemplative approach 
utilizing awareness of breathing as a means of focusing attention. Present-day 
mindfulness practices evolved from Buddhist teachings originating some 2,500 years ago. 
These early philosophical and contemplative learnings were preserved as an oral 
tradition, eventually being documented in written form in two disquisitions: the 
Anapanasati Sutra and the Satipatha Sutra (Goldstein, 2013; Kabat-Zinn, 1982; 
Rosenberg, 1999). Gunaratana (2002) and Kabat-Zinn (1982) observed that individuals 
studying mindfulness practices are taught to approach their learning with skepticism and 
curiosity. 
Mindfulness practices reflect use of a critical, investigative mindset where 
experiential phenomena are evaluated with each mindfulness practitioner’s perceptions, 
attitudes, and attentional mediation capabilities forming the basis for his or her 
experiential evaluation. Empirical investigations of mindfulness approaches for treating 
illness were initially conducted to evaluate mindfulness-based stress reduction (MBSR; 
Kabat-Zinn, 2003) as a treatment for chronic pain secondary to cancer, and to address 
other physical conditions such as dermatitis. Subsequently, multiple mindfulness-based 








Mindfulness practices are predominantly focused on regulating attention. A 
background in attentional regulation and its implications for mindfulness and substance 
use is explored in the following. 
Cowan (1988) said selective attention is composed of an executive regulation 
function, attentional orienting function, perceptual filtering capability, and habituation. 
Pessoa and Ungerleider (2005) said these functions are limited by maximal processing 
capacity, or cognitive loading effects, and by processing motives, where the individual 
attends to data based on its salience and valence properties. They further noted that 
unattended processing attenuates. These perspectives suggest that humans are capable of 
attending volitionally to data in the internal and external environments, and yet retain the 
capability for responding automatically to some data percepts, and concurrently 
assimilating and responding to new data as well (Yiend et al., 2005). Mirams et al. (2012) 
observed that attention data sources subject to selective regulation include interoceptive, 
referencing internal somatic sensations, proprioceptive, referencing positional and spatial 
sensory data, and exteroceptive, referencing within the external environment detected by 
any of the senses. 
Mindfulness-based approaches to attentional regulation offer a comprehensive 
awareness of these same attentional functions (Kabat-Zinn, 2002; 2009; Stahl & 
Goldstein, 2010), achieved through cultivation of metacognitive awareness (Teasdale, 





features. This suggests that individuals tend to respond to perceived negative stimuli 
through attributing negative valence, associated with aversion characteristics in 
mindfulness nomenclature, whereas they tend to respond to perceived positive stimuli 
through attributing positive valence, associated with mindful acceptance.  
Cowan (1997) asserted that novel stimuli likely attract attention involuntarily due 
to their inherent elevated threat potential. Siegel (2012) asserted that the brain is 
structured to be highly sensitive toward novel stimuli, in part because previously 
unencountered experience poses potentially greater survival risk. Hanson (2009, 2013) 
and Kiken and Shook (2011) observed that the brain tends toward a negative bias, using 
this protective sensitivity to over broadly interpret even innocuous stimuli as threatening. 
Emotional associations evoked through phenomenological exposure thus direct volitional 
attentional processing. In the cases of opioid use urges and cravings, opioid withdrawal, 
elevated environmental stressor exposure, and functional cognitive deficits, the person 
with opioid use disorder will likely benefit from improved attentional regulation skills 
that mediate adverse of effects of negative biasing. Taken together, these assertions 
suggest potential for more effective regulation of involuntary attentional phenomena as 
the mindfulness practitioner learns to experience novel data as transient phenomena that 
can be processed acceptantly and nonjudgmentally, rather than fearfully or anxiously.  
Stahl and Goldstein (2010) and Hanson (2009, 2013) asserted that mindfulness-
based approaches offer a more balanced means of voluntary attentional regulation, 





environmental stimuli. Ortinski and Meador (2004) posited that through conscious 
awareness the individual attends to environmental stimuli and exerts a volitional 
behavioral response. This resonates with mindfulness-based attentional regulation 
approaches where all elements of internal and external stimuli are apprehended and 
processed in accord with the individual’s pre-established intentionality. 
Mindfulness and Attentional Regulation 
Ives-Deliperi et al. (2011) said downregulation of midline cortical activity during 
states of mindfulness meditation, specifically involving the AI, left ventral ACC, right 
PFC, and bilateral precuneus. In a controlled MRI investigation, Leung et al. (2013) 
found that loving-kindness focused mindfulness meditators had significantly greater gray 
matter volume in the right angular and posterior parahippocampal gyri and left temporal 
lobe, brain areas implicated in affect regulation and empathy. In a controlled study using 
comparative MRI evaluations, Hölzel et al. (2011) found significant increases in brain 
gray matter post-MBSR intervention in previously naïve meditators, with marked 
increases in structural density found in brain areas associated with improved functioning 
of contextual memory, emotional and affective regulation, self-awareness, and situational 
and social perceptual and cognitive functioning. Tang (2013) asserted that mindfulness 
meditators experience functional connectivity changes within the default mode network 
associated with enhanced present-moment awareness and reduced emotional reactivity. 
Using MRI neuroimaging, Zeidan et al. (2011) found that mindfulness meditation 





in the ACC and AI, consistent with the findings of Tops et al. (2014), and pain aversive 
effects associated with activation of the orbitofrontal cortex. The Zeidan et al. study is 
limited by small number of participants (n = 15). Tang and Posner (2013) noted that 
whereas neurobiological imaging is beginning to reveal brain structure and functioning 
implicated in mindfulness practices, improved study controls and participant 
randomization are needed in order to more clearly identify specific factors of mindfulness 
associated with neurobiological substrates.   
The neurobiological functioning implicated in mindfulness practices appears to 
mediate much of the aforementioned attentional neural functioning. In the treatment of 
anxiety and depression, mindfulness practices appear to be effective in promoting 
adaptive neurobiological reregulation that supports associated improvements in 
psychosocial functioning. In their meta-analysis, Chiesa and Serriti (2010) found that 
EEG readings of mindfulness meditators evidenced a connection between predominant 
frontal alpha and theta brainwave activity, linking them to the relaxed but attentive 
condition typically found in mindfulness meditation practitioners. Theta burst brainwave 
activity was more predominant in experienced meditators, suggesting an association 
between ongoing meditative practice and the ability to achieve deep relaxed meditative 
states of awareness, e.g., bare attention (Epstein, 1995). Moreover, Chiesa and Serriti 
observed that some studies suggested that MBSR and MBCT treatment effects produced 
increased alpha wave activity in the left-sided anterior region associated with positive 





in ameliorating the psychological discomfort associated with depressive and anxious 
symptoms. Chiesa and Serriti cautioned that many of these studies lack sufficient controls 
and participant randomization, thereby limiting their generalizability. 
Enhanced Attentional Mediation Capabilities 
Lutz et al. (2008) said focused meditation practice, as found in mindfulness 
approaches, fosters increased capability for sustaining selective attentional focus and 
redirecting attention when distraction occurs. In their comparative evaluation between 
mindfulness meditators and arithmetic calculators, Hölzel et al. (2007) said states of 
mindfulness meditation were associated with stronger activations in the bilateral rostral 
anterior cingulate cortex and dorsal medial prefrontal cortex. This condition is associated 
with enhanced attentional control over distractors (Hölzel et al., 2007). Increased 
activation of the medial prefrontal cortex, right anterior insula, and right hippocampus is 
thought to be associated with enhanced attention and interoceptive awareness, as well as 
more adaptive emotional processing (Chiesa & Serriti, 2010; Hölzel et al., 2007). In their 
cross-sectional controlled study of mindfulness meditators vs. non-meditators van den 
Hurk et al. (2010) found that attentional orienting, efficiency, and executive functioning 
processes were significantly more effective in meditators than in controls. In another 
controlled study evaluating the neural correlates of executive performance monitoring, 
Teper and Inzlicht (2013) similarly found that mindfulness meditators made fewer 
cognitive errors and exhibited greater error-related negativity of briefer duration with 





beneficial effects of reduced negative emotional reactivity and enhanced performance 
monitoring capabilities were instrumental in achieving these executive regulatory 
improvements.  
Limitations of Hölzel et al. (2007) include small effect size due to limited 
participant sample size (n = 40). There were no controls for extraneous participant 
variables such as substance use, duration of meditation experience, or contemplative 
methods used. In addition, Hölzel et al. used correlational analyses, leaving open the 
possibility that increased amounts of grey brain matter may attract meditators, rather than 
result from meditative experience. Limitations of the Teper and Inzlicht (2013) study 
include possible extraneous variable confounding from multiple meditative practices 
utilized by the experimental group participants, and the lack of an empirical measure for 
participant emotional reactivity. Limitations of van den Hurk et al. (2010) include cross-
sectional design, limited effect size due to small number of participants (n = 40), and 
extraneous within experimental group variability through use of two meditational 
approaches: Vipassana and concentration. 
Mindfulness as Adaptive Attentional Regulation 
Garland et al. (2010) said exposure to mindfulness training significantly reduced 
the implicit responses of participants with alcohol use disorder to alcohol-associated 
environmental cues, supporting the contention that increased mindfulness facilitates 
adaptive regulation of autonomic responding to substance use cues. This finding is 





regulation is associated with meditative practices. Garland et al. found that implicit 
attentional biases orienting and alerting toward alcohol use significantly decreased 
through mindfulness practice, suggesting that implicit maladaptive memory and 
attentional processes are effectively mediated through regular mindfulness practice. 
Further findings included significant reductions in perceived stress levels and marked 
reductions in thought suppression associated with more adaptive mediation of alcohol use 
cravings. Generalizability from the findings of Garland et al. is limited due to small 
participant sample size and lack of a control group. 
Chiesa and Serriti (2010) said mindfulness meditation is associated with increased 
bilateral activation of the dorsal medial prefrontal cortex and rostral anterior cingulate 
cortex, both areas of the brain that mediate attentional regulation. Both Chiesa and 
Serreti, and Dakwar and Levin (2009) observed that these adaptive attentional changes 
associated with mindfulness meditation reduced cortical atrophy and aging-associated 
attentional deficits in long-term practitioners. Davis and Hayes (2011) suggested that 
mindfulness practices lead to attenuation of fear responses, more objective appraisal of 
experiential phenomena, enhanced coping skills and motivation, and reductions in 
maladaptive behavioral responses.  
Mindfulness and Neurobiological Regulation Relevant to Substance Use Disorders 
Hölzel et al. (2011a) said exposure to 8 weeks of MBSR mindfulness training 
facilitated adaptive changes in memory integration, emotional regulation, and regulation 





executive functioning, this suggests that exposure to mindfulness practices improves 
aspects of executive functioning essential for managing substance use effectively.  
Blume and Marlatt (2009) asserted that improvement in executive functions 
including attentional regulation and concentration is associated with reductions in 
harmful substance use.  In their fMRI investigation of naïve meditators Westbrook et al. 
(2013) found that exposure to mindfulness practices significantly reduced craving in 
participants with nicotine use disorder to cigarette smoking cue exposure. Witkiewitz et 
al. (2012) asserted that through improved connectivity and functioning of the anterior 
cingulate cortex, dorsal lateral prefrontal cortex, insula, and hippocampus associated with 
mindfulness practices, enhanced top-down regulation of limbic and basal brain functions 
results in improved emotional regulation and inhibition of substance use cravings.  
Chiesa and Serriti (2010) asserted a number of studies have suggested that mindfulness 
meditation facilitates adaptive attentional control, although they advise caution in 
interpreting these data because of extant methodological problems in much of the 
research. Generalizability of these studies’ outcomes is limited due to their lack of 
randomized controlled designs. 
These neurobiological correlates of mindfulness suggest that enhanced PFC 
functioning associated with mindfulness practices improves PFC regulation of the limbic 
system, particularly the hypothalamus, hippocampus and amygdala, improving mediation 





practitioner learns to selectively, and more adaptively, attend to interoceptive, 
exteroceptive, and proprioceptive data.  
Attentional and Neurobiological Liabilities for the MAT Program Patient  
The neurobiological substrates associated with the MAT program patient 
maintained on methadone medication include an adaptive allostasis condition supported 
through steady state regulation (receptor occupation for extended period closely 
mirroring endogenous mu receptor functioning) of the mu opioid receptors located 
throughout the CNS. This neurotransmitter function occurs predominantly in the nucleus 
accumbens and locus ceruleus (Koob & Moal, 2006; Kosten & George, 2002; Parrino et 
al., 1999). Nucleus accumbens mu receptor occupation with methadone molecules results 
in upregulation of dopamine in the ventral tegmental area, associated with a perceived 
sense of wellbeing and contentment. However, this optimal state is inherently liable to 
dysregulation associated with exposure to inter- and intra-personal stressors, effects of 
co-occurring conditions including undertreated anxiety, depression, and posttraumatic 
stress disorders, and through variant methadone medication dosing patterns. Given the 
brain’s inherent predisposition toward negativity bias (Hanson, 2013), the MAT program 
patient is thus liable for onset of the neurobiological concomitants and downward 
emotional spiraling effects of OAS onset described by Koob and Moal (1997; 2006), 
resulting in anxious and depressive affect that foster continued opioid use to avoid 
associated mental disturbances. In their meta- analysis, Hofmann et al. (2010) concluded 





depression. Taken together, these findings suggest that mindfulness practices can 
effectively address the emotional dysregulation found in depressive and anxiety 
disorders. 
Mindfulness Effects on Opioid Use Craving and Seeking 
Neurobiological substrates associated with opioid craving and seeking behaviors 
include nonconscious activation of amygdalal and hypothalamic brain circuits, and 
concurrent downregulation of prefrontal cortex mediation of these functions (Moal & 
Koob, 2007). Further, selective attentional regulation processes regulated by the brain’s 
negativity biasing circuitry (Hanson, 2013) suggest that the MAT program patient 
experiencing any destabilizing internal or external environmental stressors will tend to 
orient his or her attentional focus toward the distressing phenomena, thereby exacerbating 
the downward spiraling of maladaptive allostasis and resultant relapse behaviors. Given 
that mindfulness practices are associated with upregulation of the prefrontal cortex and 
more effective medication of the limbic system circuits (Chiesa & Serriti, 2010; Hölzel et 
al., 2007) it is likely that mindfulness practice can enhance adaptive prefrontal mediation 
of conscious and nonconscious opioid craving and seeking neurotransmission signals 
from the limbic system. The cognitive deficits outlined by Kosten and George (2002) 
suggesting that this prefrontal cortex mediation capability is grossly impaired in opioid 
dependent persons underscores the potential utility of mindfulness -based approaches that 
strengthen PFC functioning. These theoretical perspectives are supported in general by 





mindfulness practice and reductions in implicit reactivity, and more specifically in Hayes 
et al. (2004) where Acceptance and Commitment Therapy (ACT) based approaches to 
mindfulness practices were utilized with a MAT patient population and were associated 
with significant reductions in illicit opioid use and treatment dropout.    
Having examined the theoretical perspectives on attentional processes and their 
relevance to mindfulness practices as evidenced by neurobiological substrates of 
attentional regulation and effects of mindfulness practices on attentional regulation, this 
proposal now turns to explication of contemporary theoretical and practice models 
associated with mindfulness and relevant aspects of mindful attentional regulation 
associated with these bodies of theory and clinical practice.   
Literature Review of Key Variables and Concepts 
Use of Mindfulness Practices for Treatment of Substance Use Disorders 
Having considered the historical, philosophical, theoretical, and neurobiological 
aspects of mindfulness, this proposal now examines contemporary clinical applications of 
mindfulness-based practices and their effectiveness in treatment of substance use 
disorders. Primary focus is given to MBRP as it was developed specifically for 
intervention with persons having substance use disorders. MBRP is the treatment 
approach evaluated in this study. 
Mindfulness Based Stress Reduction 
MBSR is a therapeutic approach combining mindfulness mediation and hatha 





an 8- to 10-week participant group-meeting schedule consisting of 2.5 hours of integrated 
didactic instruction and mindfulness practice. Participants are further required to practice 
individually on a daily basis. MBSR is the first developed and most widely researched 
clinical approach to mindfulness practice in the U.S. MBSR has been found effective in 
treating fibromyalgia, cancer, multiple sclerosis, eating disorders, chronic pain (Kabat-
Zinn, 1982; 2002; 2003; 2009), and anxiety (Miller et al., 1995; Vøllestad et al., 2011). 
Shapiro et al. (2008) found that MBSR practice increased mindfulness, reduced 
depression and anxiety symptoms, increased positive affect, and reduced negative 
ruminations contributing to anger. Ivanovski and Malhi (2007) found that MBSR training 
improved emotional regulation and immune system functions. Majumdar et al. (2002) 
found MBSR practice significantly reduced psychological distress and increased 
perceptions of well-being and quality of life. Jensen et al. (2011) found that MBSR 
interventions reduced perceived and physiological stress in participants, and significantly 
improved their selective attentional capacity, perceptual threshold, and visual working 
memory capacity. Smith et al. (2008) in their study comparing MBSR effects with 
cognitive behavioral stress reduction (CBSR) found that MBSR was significantly more 
effective than CBSR at increasing mindfulness and reducing adverse effects of stress and 
pain. Using fMRI evaluative data, Kilpatrick et al. (2011) found that in comparison to 
controls MBSR participants showed changes in brain areas implicated in visual, 
attentional, and self-referential processes. Kilpatrick et al. observed that these changes 





studies suggest the effectiveness of MBSR in reducing stress and symptomatic severity 
associated with multiple medical and psychological conditions. To date MBSR has not 
been studied for use with persons having opioid use disorder or persons participating in 
MAT programs. 
Mindfulness Based Cognitive Therapy 
MBCT represents an amalgamation of mindfulness-based and CT treatment 
approaches. Building upon existing CT therapies (Beck, 1967; Beck, 1979; Beck, 1995; 
Beck et al., 1979; Beck et al., 1993; Butler & Beck, 1995; Clark et al., 1999; Clark et al., 
2004), Teasdale, Segal, and Williams (2000) combined elements of MBSR with CT to 
treat refractory depression. Lau and McMain (2005) asserted that the MBCT-based 
approach recognizes the chronic, relapsing nature of depressive disorders and is intended 
to reduce frequency and severity of depressive relapse episodes. Sherer-Dickson (2004) 
asserted that MBCT approaches use interventions intended to foster enhanced 
metacognitive awareness, such that the participant attends to emerging cognitions using 
an enhanced knowledge base, a non-evaluative processing style, and acquired attentional 
monitoring and regulating skills. Lau and McMain (2005) posited that increased 
metacognitive awareness reduces depressive relapse through fostering decentering from 
maladaptive cognitions. Zoysa (2011) and Williams and Kuyken (2012) found an 
approach integrating mindfulness and CBT was effective in treating depressive disorder. 
Williams et al. (2012) evaluated MBCT effectiveness for depressive relapse 





compared to controls using cognitive psychological education (CPE) and TAU alone. The 
Williams et al. (2012) study limitations include that the TAU approach was non-
standardized, thus potentially introducing extraneous variable effects and unmeasured 
between-group effects associated with sociocultural variables. Evans et al. (2008) found 
that MBCT treatment significantly reduced anxiety and depressive symptoms in patients 
with generalized anxiety disorder (GAD) as measured by pre- and posttest reductions in 
clinician-administered Beck Anxiety Inventory (BDI; Beck & Steer,1990), Penn State 
Worry Questionnaire (PSWQ; Meyer, et al., 1990), Profile of Mood States (POMS; 
McNair et al., 1971), and Beck Depression Inventory-II (BDI-II; Beck et al., 1996). The 
Evans et al. (2008) study limitations include small participant size (n = 11), thereby 
limiting statistical power and generalizability, use of a cross-sectional design without 
randomization or controls, and potential extraneous variables associated with unique 
participant demographic characteristics (self-selected and highly educated). King et al. 
(2013) found significant reductions in PTSD symptoms for the MBCT treatment group 
versus the TAU group especially in the avoidance and dissociative symptom clusters. 
King et al. (2013) study limitations included lack of randomization, small participant 
sample size (n = 37) thereby limiting statistical power and generalizability of results, and 
potential confounds from between-group distinctions in treatment duration. 
In their meta-analysis of MBCT effectiveness Coelho et al. (2013) found MBCT 
as an adjunct to TAU effective for participants with three or more depressive episodes, 





observed that the evaluated study designs were either non-randomized or failed to 
describe their randomization methods, and did not evaluate MBCT as a single treatment, 
thereby suggesting potential extraneous variable effects across all studies from the 
combined MBCT-TAU modality. Coelho et al. (2013) study limitations include basing 
evaluations on study reports rather than original data, and conclusions based on 
comparison of studies with inconsistent methodologies. 
Investigation of the literature to date did not uncover any studies of MBCT 
applied to individuals with opioid use disorder, or as an adjunctive treatment for those 
participating in MAT programs. It should be noted that several elements of MBCT, 
particularly those focused on facilitating adaptive cognitive restructuring, are utilized in 
MBRP (Witkiewitz et al., 2013b). 
Mindfulness Based Rational Emotive Behavior Therapy  
REBT involves enhancing development of self-acceptance and high frustration 
tolerance through fostering formulation of adaptive belief systems, introspective, values-
driven and reality-based evaluation of cognition, affect, and behavior, and integration of 
intrapersonal, interpersonal, and environmental phenomenal acceptance (Ellis et al., 
1998; Ellis & Dryden, 1997; Ellis & MacLaren, 2005). In a seminal paper comparing 
REBT to MBSR Ellis (2006) noted many similarities between the two clinical 
approaches, including cultivation of non-judgmental attitude, patience, beginner’s mind 
(openness to experience), intentionality, awareness of and commitment to values and 





aspects of MBSR, including trust, especially blind trust in one’s intuition, which could 
lead to erroneous inferences and associated behaviors, and thence emotional disturbance, 
and further disagreed with the MBSR approach to non-striving, asserting that even 
participation in mindfulness suggests a desire to strive toward some perceived or needed 
change. In a proposal for case-specific treatment approaches integrating elements of 
MBCT and REBT Whitfield (2006) proposed an integrated MBREBT approach utilizing 
three interventions. The first consisted of using awareness of interoceptive and 
metacognitive processes to experientially reinforce apprehension of the associations 
between beliefs and consequences. The second consisted of using awareness of 
interoceptive processes and acceptance to counter low frustration tolerance. The third 
intervention consisted of using awareness of intentions and cultivation of nonjudgmental 
attitude to examine and thence counter harmful irrational beliefs.  
A search of available literature failed to uncover any empirical research 
evaluating the effectiveness of MBREBT-based treatment approaches, and no research 
evaluating MBREBT as a treatment for opioid use disorder or as a treatment adjunct for 
MAT program participants was found. 
Acceptance and Commitment Therapy 
Hayes et al. (2012) suggested that Acceptance and Commitment Therapy (ACT) is 
based on the perspective that cognition, affect, and behavior are derived within an 
interrelated experiential and environmental context. Hayes (2002) asserted that humans 





lived experience using language. Hayes described this predominant tendency as the 
capacity to create relational frames. Hayes and Smith (2005) asserted these relational 
frames often limit flexibility and adaptive responding to evolving life situations, thereby 
resulting in use of maladaptive coping strategies that increase human suffering. 
Relational framing often fuses an experience with an evaluative thought about that 
experience, resulting in harmful implicit associations that thence regulate cognitive and 
affective processes for other similar experiences.  Through this cognitive fusion of 
relational frames, individuals developed automatized, often maladaptive responding to 
their experience.  Hayes and Smith further asserted that fused thoughts exacerbate 
experiential pain and intrapersonal dysfunction through: (a) evaluation, the recollection 
of painful events and their associated attributions; and (b) self-conceptualization, the 
integration of maladaptive cognitive fusion processes into one’s perception of and 
valuing of the self. Hayes et al. (2002) identified several relational frames commonly 
used by most individuals, including temporal and comparative phenomenal associations. 
Hayes et al. (2012) described ACT interventions as facilitating multiple aspects of 
cognitive functioning including awareness and acceptance of unfolding experience from 
moment to moment, cultivating a contextual self-perspective using decentered 
observational approach, commitment to behaving in accord with chosen values, 
acceptant, and nonjudgmental appraisal of unfolding experience. Hayes et al. further 





where behavioral and cognitive therapeutic interventions are used to decenter from 
maladaptive cognitions, affective states, and associated behaviors.  
ACT has been found effective in treatment of multiple conditions including 
seizure disorders, chronic pain, diabetes, depression, anxiety, and posttraumatic stress 
disorder (Bach & Hayes, 2002; Gregg et al., 2007; Hayes, & Smith, 2005; McKay et al., 
2012; Varra et al., 2008; Walser & Westrup, 2007). Gratz (2007) found that ACT 
interventions effectively enhanced participant awareness and acceptance of emotional 
states, reduced impulsive behaviors, facilitated engagement in adaptive emotional 
regulation strategies, and reduced frequency of engagement in self-harm. In their 
randomized, controlled between-groups comparison study Forman et al. (2007) found 
that ACT-based treatments were effectively equivalent to traditional cognitive therapy 
interventions in reducing anxiety and depressive symptoms. Bach and Hayes (2002), in 
their randomized controlled trial of 80 psychiatric inpatient participants found that 
administration of four ACT-based therapy sessions resulted in significantly higher 
symptom reporting, significantly lower symptom reification, and a 50% reduction in 
participant rehospitalization rates. In his meta-analysis of ACT treatment efficacy Öst 
(2014) asserted ACT interventions used for psychiatric, somatic, and distress conditions 
exhibited a small mean effect size (d = 0.42) and in comparison to behavioral, CT, and 
CBT treatments showed a nonsignificant difference.  In their meta-analysis of ACT 





were significantly more effective than controls and placebos but were no more effective 
than existing traditional treatments such as CT and CBT. 
ACT-based treatments are effective in terms of reducing the negative social 
stigma and internalized shame often experienced by individuals with substance use 
disorders (Luoma et al., 2008; Luoma et al., 2012). Gonzaléz-Menéndez et al. (2013) said 
ACT was significantly more effective than CBT at 18-month follow-up in reducing 
substance use relapse (ACT 85.7% abstinence at 18 months; CBT 50% abstinent at 18 
months).  
In a single study, ACT-based treatment approaches were utilized with MAT 
program patients (Hayes et al., 2004), where they were combined as an adjunct to TAU 
and outcomes compared to a TAU-alone control group and an Intensive Twelve-Step 
Facilitation (ITSF) group also combined adjunctively with TAU. The group trials were 
run sequentially, using nonduplicated participants who participated in structured 
manualized versions of ACT and ITSF individual and group therapies in addition to 
TAU, or in TAU alone. Individual and group therapists were of at least Master’s degree 
level and had a minimum of 2 years’ experience in substance use disorder treatment. All 
therapists were trained prior to implementation of their respective ACT or ITSF models, 
whereas TAU utilized the MAT program counselors. ACT and ITSF sessions were 
videotaped and evaluated to assure adherence to their respective treatment models. 
Effects on drug use were measured by random monthly UDS results obtained pre- and 





Hayes et al. found no significant differences (p < .05) between the groups for 
illicit opioid use at pre- or posttest, although a significant difference was found at six-
month follow-up where 42% of the ACT adjunct participants had illicit opioid free UDS 
results versus 15% of the MAT-only participants using Pearson x2(1, N = 43) = 7.51, p = 
.006. Hayes et al. also found that ACT treatment adjunct group participants were retained 
in the MAT program for significantly longer periods than their TAU counterparts were. 
Limitations of the Hayes et al. study included a high participant dropout rate (34%), and 
potential confounds due to participant funding distinctions. It is unclear why the posttest 
UDS results were not significantly different between the groups, as were the six-month 
follow-up results. The reasons for the high participant dropout rate are also unknown. 
These outcomes suggest that ACT combined with TAU for MAT program patients may 
be more effective than TAU alone, but further evaluation is needed using methods that 
reduce the impact of participant dropout and evaluate for the posttest effectiveness. No 
further studies evaluating ACT as an adjunctive treatment for individuals participating in 
MAT programs or those having opioid use disorder were found.  
This literature review now focuses on mindfulness-based treatments intended for 
reducing and eliminating the harmful effects of substance use conditions. 
Mindfulness Oriented Recovery Enhancement  
In a randomized controlled pilot study using volunteer participants (n = 53) living 
in a therapeutic community, Garland et al. (2010) evaluated the effectiveness of the ten-





intervention. The control group received standard evidence-based weekly alcohol group 
support based on the Matrix model (Rawson & McCann, 2006) of manualized treatment. 
Treatment for both groups was provided by Master’s level social worker. Participant 
mindfulness was measured using the Five Factor Mindfulness Questionnaire (FFMQ; 
Baer et al., 2006). Other measures used by Garland et al. included the Penn Alcohol 
Craving Scale measure (PACS; Flannery et al., 1999) for measuring participant alcohol 
craving, the Brief Symptom Inventory (BSI; Derogatis & Melisaratos, 1983) for 
measuring participant psychological distress, the Impaired Alcohol Response Inhibition 
Scale (Guardia et al., 2007), the Perceived Stress Scale (PSS; Cohen et al., 1983) 
measuring participant stress levels, and the White Bear Suppression Inventory (WBSI; 
Wegner & Zanakos, 1994), measuring participant tendencies toward thought suppression. 
Garland et al. measured Alcohol-associated cue reactivity using electrocardiogram 
readings taken during participant exposure to visual alcohol associated cues, and 
participant alcohol attentional bias was measured using a computerized dot probe task 
containing randomized exposure to alcohol associated visual cues. 
Using bivariate correlation and repeated measures ANOVA (among other tests), 
Garland et al. (2010) found that for the MORE participants, reductions in thought 
suppression were significantly correlated with changes in ECG response (r = .49, p = 
.042), increased impaired alcohol response inhibition (r = .48, p = .045), and reductions 
in post-intervention heart rate variability (HRV) recovery, (r = .49, p = .045). The 





reduced the implicit responses of participants with alcohol use disorder to alcohol-
associated environmental cues, supporting the contention that increased mindfulness 
facilitates adaptive regulation of autonomic responding to substance use cues. Garland et 
al. found that implicit attentional biases orienting and alerting toward alcohol use 
significantly decreased through mindfulness practice, suggesting that implicit 
maladaptive memory and attentional processes are effectively mediated through regular 
mindfulness practice.  Further findings included significant reductions in perceived stress 
levels and marked reductions in thought suppression associated with more adaptive 
mediation of alcohol use cravings. Generalizability from the findings of Garland et al. is 
limited due to small participant sample size and lack of a control group. Another 
limitation is use of the Matrix (Rawson & McCann, 2006) treatment intervention for 
participants with alcohol use disorder, a use for which it has not been normed or 
validated. Although suggesting important implications for attentional regulation of 
substance use this study did not examine MBRP effects and did not evaluate for 
mindfulness effects on attentional regulation of participants with opioid use disorder. 
Yoga Nidra 
Yoga Nidra references a specific approach toward breathing, originally developed 
several thousand years ago in India. It involves mindful focus on the breath where the 
rhythm and duration of in- and out-breaths are intentionally manipulated to achieve a 
deep level of relaxation (Miller, 2010). Practitioners sit or lie in specific postures, guided 





example of this unique breathing approach is internally counting to four for the inbreath 
and to eight for the duration of the outbreath, over periods of several minutes to an hour 
or more (Miller). 
 Stankovic (2011) reported in a feasibility clinical trial that daily Yoga Nidra 
practice for a duration of eight weeks effectively reduced PTSD symptom severity in a 
cohort of male war veterans, and that the participants reported increased sense of calm 
and self-efficacy. This trial is limited by small participant size (n =16) and lack of a 
control group. Temme et al. (2012) found that Yoga Nidra significantly reduced relapse 
precursor symptoms and further resulted in improved mood for individuals with 
substance use disorders enrolled in residential treatment. Limitations in Temme at al. 
included potential variability from reported inconsistent participant understanding of test 
measure response items, possible participant expectation bias, and relatively few female 
participants. Taken together, these early research efforts suggest that the Yoga Nidra 
contemplative approach potentially offers benefit to MAT program patients, particularly 
those with trauma exposure history or co-occurring posttraumatic stress disorder, but 
further evaluation is needed. Thompson et al. (2011) asserted that mindfulness practices 
are effective for persons with traumatic exposure. Further empirical research will more 
comprehensively evaluate these preliminary findings. At time of this writing available 
research is extremely limited, thus further empirical validation of this mindfulness-based 
approach is necessary. No published research to date has evaluated Yoga Nidra as an 





Mindfulness Based Relapse Prevention 
The treatment adjunct to be evaluated in this study, MBRP, is a recently 
developed manualized treatment approach for substance use disorders that utilizes relapse 
prevention strategies integrated with mindfulness meditation (Bowen et al., 2011; Marlatt 
& Chawla, 2007). It is based on an amalgamation of CBT approaches and mindfulness 
traditions. Bowen et al. (2011) described several core constructs of MBRP. The first is 
cultivation of a present-moment focus, wherein the individual with substance use 
problems learns to apprehend and accept experience as it unfolds, thereby reducing 
preoccupation with substance use as a means of coping with past or future concerns. The 
second is development of acceptant, nonjudgmental attitude toward unfolding experience, 
where the person learns to skillfully experience and cope with physical and emotional 
discomforts rather than attempting to avoid them through substance use. The third is  
developing increased understanding of the nature of evolving experience, whereby the 
person apprehends the thoughts and cravings for substance use as phenomena whose 
frequency and intensity will lessen over time. The fourth is cultivation of metacognitive 
awareness, such that the individual perceives his or her substance use in a larger context, 
as a conditioned response that can be attenuated or discontinued in accord with personal 
values and volition. The fifth is reduction in negative emotional states associated with 
stigmatization of substance use, where the individual experiences more effective 
regulation of automatized negative self-referents such as guilt, shame, and reduced sense 





Focus on Experiential Inquiry 
Bowen et al. (2011) emphasized that MBRP focuses on supporting participants’ 
inquiry into the nature of their present moment experience rather than interpreting, 
analyzing, or finding solutions for the participants’ unfolding thoughts, emotions, images, 
and sensations. Bowen et al. noted that such inquiry eventually results in increased 
capability for differentiation between direct experience and reactive responding to that 
experience, thereby facilitating increased awareness of internal processes and reducing 
reactivity. Further, they asserted that these inquiry processes result in enhanced 
awareness of shared experiences, fostering universality, a sense of compassion for self 
and others, and a correspondingly reduced sense of the individualized nature of problems 
and suffering. 
MBRP Program Structure 
MBRP treatment is structured as an eight-week course where participants meet 
once weekly in a private group setting for two hours with the group facilitator, conduct 
daily individual guided meditation practice exercises, and complete daily CBT-oriented 
homework assignments (Bowen et al., 2011). The first session consists of an introduction 
to the course requirements and two mindfulness meditation exercises (Bowen et al.). 
Each subsequent session includes a review of the homework assigned to participants 
during the previous session, discussion of participants’ mindfulness meditation practice 
experience during the prior week, interactive discussion of mindfulness and relapse 





and discussion of the following weeks’ homework assignments, and closing remarks (see 
Appendix A).  
MBRP Urge Surfing Intervention 
Urge surfing is a mindfulness practice designed to decondition the individual’s 
identification with substance-associated thoughts, cravings, and urges. The practitioner 
envisions the craving or urge as an ocean wave that is cyclical, rising and falling in its 
intensity, and ultimately subsiding. Through continued practice, the individual develops 
the capability to tolerate the presence of substance-associated cravings and urges without 
carrying out the substance seeking and using behaviors, thereby resulting in a classical 
deconditioning effect that reduces the frequency and intensity of substance-associated 
cravings and urges (Marlatt & Chawla, 2007; Ostafin & Marlatt, 2008). The effectiveness 
of the urge surfing intervention has been empirically established with persons dependent 
on or abusing a variety of substances including alcohol, opioids, and stimulants (Bowen 
et al., 2006; Brewer et al., 2010; Marlatt & Chawla; Ostafin & Marlatt, 2008; Witkiewitz 
et al., 2005). 
MBRP Sober Breathing Space Intervention 
This mindfulness-based approach to relapse prevention utilizes mindful attending to 
the breath and to the individual’s unfolding experience to facilitate adaptive responding 
in situations where relapse risk is potentially high. The at-risk person learns the acronym, 





• S – Stop, taking a moment to mindfully pause, before proceeding with automatic 
reactivity; 
• O – Observe, taking note of emerging thoughts, feelings, sensations, and images; 
asking. what is unfolding in awareness at this moment; 
• B – Breathe, focusing attention on the breath; taking a minimum of three to six, or 
even more, mindful breaths; 
• E – Expand, fully expanding one’s awareness; examining the thoughts, feelings, 
sensations, and images emerging within this augmented awareness of the 
situation. Attempting to further explore with openness, acceptance, curiosity, 
without judgment; and  
• R – Respond, using the enhanced depth of awareness achieved within the 
unfolding moment, responding mindfully, with intentionality, and compassion 
(Bowen et al., 2011). 
MBRP Perspectives on Substance Use 
From an MBRP-based perspective, substance use is a form of experiential 
avoidance that is frequently and largely nonconsiously activated in response to 
encountering aversive situations, negative thoughts, disturbing emotions, overly intense 
affect, physiological pain, and discomfort (Bowen et al., 2012). Bowen et al. asserted that 
individuals, when examining their coping behaviors associated with encountering 
aversive situations tend to respond reactively, with automatized, usually maladaptive 





sensations associated with substance use disorders assists the MBRP practitioner in 
uncovering the nature of this automatic responding. Bowen et al. posited that as the 
individual explores his or her relationship to the substance of misuse and its effects, 
acceptantly, without judgmental distortions, it is likely that more comprehensive 
understanding of substance-related thoughts, feelings, cravings, urges, and associated 
behaviors is possible. The practitioner thence more objectively evaluates his or her 
experience associated with use of substances, earning to cope more adaptively with them 
while concurrently reducing and thence eliminating tendencies toward automatized 
responding associated with substance use, such as those evoked by environmental cue 
reactivity. 
This perspective suggests that attempting avoidance generally strengthens the 
individual’s identification with the object of the avoidance behavior, whereas mindfully 
accepting all aspects of experience with the object fosters disidentification, thereby 
reducing its conditioned power. This further suggests that mindfulness practices offer a 
means of adaptively changing the individual’s relationship with substance dependence 
and other forms of addiction (Smith, 2010). 
Evaluation of MBRP Research 
Witkiewitz et al. (2005) conducted a preliminary investigation of the effectiveness 
of Vipassana meditation, one of the therapeutic elements integral to MBRP, using an 
incarcerated population (n = 306) of individuals with alcohol and other substance use 





TAU, consisting of self-help group (Alcoholics Anonymous) participation, 
psychoeducation, and social skills training offered at the prison facility. Using ASI 
Alcohol/Drugs subscale measures, Witkiewitz et al. found that at three-month follow-up 
the Vipassana group reported 29.3% reduction in cutoff alcohol use frequency (defined as 
4 drinks per week), a significant difference (p = .08), whereas the TAU group reported a 
13.9% reduction. They further found that at three-month follow-up the Vipassana group 
reported a 18.1% reduction in cutoff daily alcohol use frequency (defined as seven or 
more drinks per day), a trend difference (p = .08) whereas the TAU group reported a 
0.2% increase. Witkiewitz et al. reported that limitations of this study included a very 
high participant dropout, with 218 participants not completing the study. Further 
limitations include lack of randomized participant assignment and possible participant 
selection bias stemming from self-selection of groups, and absence of clearly defined 
participant control group intervention effects. 
Witkiewitz et al. (2013b) conducted a randomized controlled trial of MBRP using 
volunteer participants with alcohol use disorder and a mixture of other substance use 
disorders (45.2% alcohol, 49.9% stimulants, 7.1% opioids, 5.4% cannabis, 1.9% 
undetermined) enrolled at an outpatient Washington treatment facility. They found that 
MBRP was significantly more effective at reducing participant alcohol use cravings than 
the TAU group receiving psychoeducational, 12-Step (self-help), and relapse prevention 
group interventions. MBRP manualized treatment providers were experienced therapists 





licensed substance use counselors with varying levels of education and experience 
(Witkiewitz et al.). Therapist adherence to the MBRP manualized treatment was 
evaluated using the Mindfulness-Based Relapse Prevention Adherence and Competence 
Scale (Chawla et al., 2010). Study measures used at pre-, posttest, and at two- and four-
month follow-up included the PACS (Flannery et al., 1999), used to measure alcohol and 
other drug use cravings; the FFMQ (Baer et al., 2006), used to measure acting with 
awareness and nonjudgmental elements of mindfulness; and the Acceptance and Action 
Questionnaire (AAQ; Hayes et al., 2004), used to measure participant acceptance (also an 
element of mindfulness). Witkiewitz et al. noted that random group participant 
assignment was achieved through use of random number sequencing.  Participants were 
provided with gift card incentives upon completion of study measures. Witkiewitz et al. 
(2013b) found that MBRP participants had significantly lower alcohol use craving scores 
measured at midtreatment: t (125) = 2.43, p = 0.02); and posttreatment: t (101) = 2.37, p 
= 0.02), whereas at two-month and four-month post-treatment follow-up the MBRP 
participants no longer experienced significant differences from their TAU counterparts in 
alcohol use cravings. It is important to note that no evidence suggests these findings are 
predictive for use of MBRP in the treatment of opioid use disorder. 
The Witkiewitz et al. (2013b) study was limited in that no objective measures of 
substance use, such as UDS results, were utilized, leading to overreliance on self-
administered participant report measures. Further limitations included lack of an 





normed or validated for substances other than alcohol use, use of mindfulness measures 
that did not specifically target design factors used in MBRP, the lack of a waitlist 
comparison or control group, and the between-group distinctions in therapist education 
and training. Additionally, the causal association between substance use craving and 
actual relapse behavior remains unclear.  
 In a randomized trial of participants (n = 168) with multiple substance use 
disorders (45.2% alcohol, 49.9% stimulants, 7.1% opioids, 5.4% cannabis, 1.9% 
undetermined) Witkiewitz and Bowen (2010) evaluated for effectiveness of MBRP in 
reducing substance use and cravings associated with depression. This study utilized 
therapists with graduate degrees who were trained in MBRP, whereas TAU services 
providers were licensed substance use counselors with varying levels of education and 
experience (Witkiewitz & Bowen). MBRP sessions were audio recorded and assessed for 
fidelity with MBRP criteria using the Mindfulness-Based Relapse Prevention Adherence 
and Competence Scale (Chawla et al., 2010). Measures used by Witkiewitz and Bowen 
for this study included the PACS (Flannery et al., 1999) for substance use cravings, the 
Timeline Followback (TLFB; Sobell & Sobell, 1992) a calendar-based daily log for 
substance use reporting, and the BDI-II (Beck et al., 1996) for depression. Measures were 
administered at pre- and posttest intervals, and at two- and four-month follow-up. 
Witkiewitz and Bowen found that the MBRP group showed significantly reduced 
depression-associated substance use cravings compared to TAU during the MBRP 





.05). Witkiewitz and Bowen noted these effects were maintained at four-month follow-up 
(η2 = .02, p < .05) only for those participants that continued their MBRP meditative 
exercises. Those continuing participants showed a remarkable zero percent relapse rate at 
four-month follow-up.  
Limitations of the Witkiewitz and Bowen (2010) study included a relatively short 
duration of follow-up measurement and undetermined potential extraneous variable 
effects arising from reliance on participant self-report, unmeasured differences in 
therapist skill level, and high participant attrition rates (27%). Further limitations include 
that multiple participants (62.7% of TAU group, 52.8% of MBRP group) were court 
mandated to participate in treatment and to abstain from illicit substance use, a possible 
confounding variable. Finally, no objective data confirming participant substance use was 
obtained.  
Hsu, Collins, and Marlatt (2013) evaluated effectiveness of MBRP manualized 
treatment moderation effects on distress tolerance for participants (n = 168) with 
substance use disorders including alcohol, cocaine, methamphetamine, opioids, cannabis, 
and undefined other substance use who were enrolled in outpatient treatment for their 
substance use conditions. Participants were randomly assigned to the MBRP or TAU 
group, with TAU consisting of 12-step group participation, psychosocial education, and 
process-based intervention. Measures used included the Distress Tolerance Scale (DTS; 
Simons & Gaher, 2005) to evaluate participant capacity for adaptive responding to 





and other drug use. Mindfulness was measured using the FFMQ (Baer et al., 2004) and 
convergent validity between the DTS and FFMQ was assessed. 
Hsu et al. found that MBRP participant DTS results showed a significant positive 
correlation with all five FFMQ subscales (r =. 28; r =.41; r =.4; r =.41; r=.47; p = .001), 
suggesting strong convergent validity of the measures and an association between higher 
distress tolerance and mindfulness. They further found a significant positive association 
between MBRP intervention and reduction of substance use at posttest and two-month 
intervals, Wald χ2 (13, N =162) = 3595.33, p =.001. Hsu et al. found that MBRP 
participants with lower distress tolerance who received MBRP showed significant 
reductions in alcohol and other drug use over time compared to their TAU counterparts 
with lower distress tolerance through two-month follow-up. 
Limitations of the Hsu et al. (2013) study include lack of objective substance use 
data collection, resulting in overreliance on participant retrospective self-reporting of 
substance use, a brief follow-up period, potential between-group variability arising from 
distinctions in MBRP and TAU group content and procedures, lack of waitlist control 
group, distinctions in education, training, and clinical approach between the MBRP 
therapists and the program counselors, and uncontrolled participant demographic 
variables.  
Bowen and Kurz (2011) evaluated post-MBRP intervention moderating effects on 
therapeutic alliance and between-session meditative practice on mindfulness in a 





substance use disorders (45.2% alcohol, 49.9% stimulants, 7.1% opioids, 5.4% cannabis, 
1.9% undetermined). Their study utilized therapists with graduate degrees who were 
trained in MBRP (Bowen & Kurz). MBRP sessions were audio recorded and assessed for 
fidelity with MBRP criteria using the Mindfulness-Based Relapse Prevention Adherence 
and Competence Scale (Chawla et al., 2010). Bowen and Kurz found that participation in 
MBRP was significantly associated with increases in mindfulness at post-intervention. 
Bowen and Kurz noted that paired sample t-testing revealed a significant increase in 
levels of mindfulness between baseline and posttest, t(33) = - 2.43, p = 5.02, and through 
four-month follow-up t(33) = -2.57, p = 5.014. Using regression analysis, Bowen and 
Kurz found that increased levels of participant mindfulness were significantly associated 
with an effective therapeutic alliance as measured by the Working Alliance Inventory-
Short Form (WAI-S; Tracey & Kokotovic, 1989) post-treatment and at two-month 
follow-up, β =.479, t(31) = 3.51, p = .001 although results were not significant at four-
month follow-up. Their results suggested that the strength of the therapeutic alliance is 
associated with increased levels of participant mindfulness and may be enhanced through 
MBSR practice. Implications include that an effective therapeutic alliance, enhanced 
through MBSR participation, may foster improved treatment outcomes for substance 
users, although this association was not studied.  
The Bowen and Kurz (2011) study limitations include a reliance on participant 
self-report measures and correspondent lack of objective participant substance use data, 





practice, lack of a control group, and high participant attrition rates (57%) that reduced 
statistical power and generalizability. 
Lee et al. (2011) conducted a randomized controlled trial evaluating MBRP 
effectiveness for an incarcerated Taiwan population of individuals with currently 
asymptomatic substance use disorders for “cannabis, amphetamine, cocaine, MDMA, 
heroin, Ketamine, glue, and LSD” (p.479) use. The MBRP intervention was provided by 
licensed psychologists trained for two years in mindfulness meditation and relapse 
prevention. TAU consisted of substance use education. Measures used by Lee et al. 
include drug use Identification Disorders Test-Extended (DUDIT; Berman et al., 2007) to 
measure positive and negative perspectives on and frequency of illicit substance use, the 
Drugs Avoidance Self-Efficacy Scale (DASE; Martin et al., 1995) to evaluate for self-
efficacy of substance refusal skills, and the BDI-II (Beck et al., 1996) to measure 
depressive affect. Participants (n = 24) were randomly assigned to either the MBRP or 
TAU groups, and Lee et al. used MANOVA to evaluate between group differences and 
repeated measures ANOVA to evaluate for MBRP within group changes over the 10-
week duration of the study. Lee et al. found that MBRP participants experienced 
significantly higher negative perspectives toward drug use (t = 2.46, p < 0.05), 
significantly higher negative expectancies toward potential substance use (t = −5.22, p < 
0.01), and significantly less depressive affect (F (1, 9) = 110.40, p < 0.05) than their TAU 
counterparts. The findings of Lee et al. suggest a significant association between 





and expectancies toward substance use. These results are consistent with Hendershot et 
al. (2011), whose review findings asserted the importance of enhanced self-efficacy and 
adaptive outcome expectancies resultant from MBRP participation. 
Limitations of the Lee et al. (2011) study include use of male-only participant 
selection, lack of measurement for depressive affect in the TAU group, lack of objective 
and subjective substance use measures, no long-term follow-up, and small participant 
size (n = 24), thereby reducing statistical power and generalizability. 
Bowen et al. (2014) conducted a randomized clinical trial comparing the effects 
of MBRP, RP, and TAU as an aftercare treatment for a population (n = 286) of volunteer 
participants who had previously completed either a 28 day or 90-day inpatient 
rehabilitative treatment for alcohol, stimulants, opioids, cannabis, and other undetermined 
substance use disorders. TAU consisted of eight weeks of process-oriented support 
groups based on 12-Step principles. RP consisted of an eight-week intervention focused 
on relapse risk assessment, improving cognitive and behavioral skills, increasing self-
efficacy, establishing goals, and using social support systems. The eight-week MBRP 
intervention was used in place of TAU, rather than as an adjunctive treatment. TAU 
therapists were certified counselors, whereas the RP and MBRP therapists were graduate 
students at the Master’s degree level or higher and were extensively trained in either RP 
or MBRP administration. Study measures included the TLFB (Sobell & Sobell, 1992) for 





participants, and monitoring of recorded intervention sessions to evaluate for adherence 
to manualized treatment guidelines.  
Bowen et al. (2014) used Cox proportional hazards regression models to estimate 
hazard ratios for number of days prior to participant relapse into alcohol or drug use. 
They found that MBRP and RP groups showed a 54% decreased risk of relapse to drug 
use (β = −0.77, HR = .06, p = .05) and a 59% decreased risk of relapse (β = −0.89, HR = 
.41, p = .05) to heavy drinking in comparison to the TAU group, and the MBRP group 
showed a 21% increase in relapse risk to first drug use (β = .19, p = .05) compared to RP. 
Using negative binomial hurdle statistical models to determine incidence rate ratio (IRR), 
at six-month follow-up Bowen et al. found no significant differences between RP and 
MBRP effects on drug or alcohol use, whereas RP and MBRP participants reported a 
significant  31% fewer days of alcohol use than their TAU counterparts (β = 0.33, IRR = 
.69, p < .05). Finally, Bowen et al. noted that at twelve-month follow-up there was 
significant difference between MBRP and RP in drug use (β = −0.37, IRR = 0.69, p < .05) 
and in likelihood of participant alcohol use using odds ratio (OR) measure for likelihood 
of drinking (β = 0.43, OR = 1.51, p < .05). These results suggest that both RP and MBRP 
are significantly more effective interventions for alcohol and drug use than TAU up 
through 12 months posttreatment, with MBRP exerting stronger inhibiting effects on 
substance use. 
Limitations of Bowen et al. (2014) included inconsistent objective data collection 





distinctions in levels of therapist training and education, subjective evaluation of therapist 
adherence to RP and MBRP models, and large differences between TAU group and the 
RP/MBRP groups in participant therapeutic assignment and intervention time 
requirements.    
In general, limitations of MBRP research include a small number of randomized, 
controlled study designs (Bowen et al., 2011; Bowen et al., 2014). An additional concern 
raised by Levin, Dalrymple and Zimmerman (2014) in their randomized, controlled study 
comparing mindfulness factors between persons with substance use disorders and an 
abstinent control group is that capabilities for fostering states of mindfulness are limited 
in persons with SUD history. Hendershot et al. (2011) noted that further research 
evaluating the theoretical constructs and clinical applications of MBRP are needed, 
especially those incorporating study designs using randomized controlled trials.  
An important consideration here is that many of the preceding MBRP studies 
(Bowen & Kurz, 2011; Hsu et al. 2013; Witkiewitz & Bowen, 2010; Witkiewitz et al., 
2013b) were conducted using the same participant population. This suggests the 
possibility that unique, albeit unidentified characteristics of that population could exert 
unknown effects on these multiple study outcomes. Other concerning limitations of the 
preceding studies include the lack of objective measures for participant substance use 
data and that the participants were predominantly individuals with alcohol use disorder, 
as only 7.1% reported opioid use. Although Bowen et al. (2014) collected objective 





consistently from all participants. A further consideration here is that these studies mostly 
focused on MBRP’s subjective effects on substance use cravings rather than objectively 
measuring substance use behaviors. Two other MBRP studies (Witkiewitz et al., 2005; 
Lee et al., 2011) were conducted using incarcerated populations, suggesting an important 
limitation on generalizability of results, and the majority of these participants were 
presenting with alcohol use disorder histories. Of even greater importance, none of the 
preceding studies used MAT program patient populations to evaluate the effectiveness of 
MBRP for opioid use disordered populations. 
Bowen et al. (2017) conducted a study of 15 participants with OUD that were 
enrolled in a MAT program, maintained on methadone medication, and exposed to the 
eight-week MBRP group manualized treatment protocol. Bowen et al. found a significant 
reduction in opioid cravings at p£ .05 for participants at study conclusion. They further 
noted significant changes in reduction of depression and trauma symptoms reported by 
the seven participants completing the MBRP group. Limitations of this study included the 
small sample size (n=15) thereby limiting statistical power, insufficient attendance at the 
MBRP group (59% over the course of the study), and a marked reduction in number of 
participants enrolled at study completion compared to initial enrollment (from n=15 to 
n=7). An important limitation was that this study design did not include a control group 
or randomized participant assignment. A further limitation included the use of the 
Acceptance and Action Questionnaire (AAQ; Hayes et al., 2004), an instrument that 





psychological flexibility, but does not specifically evaluate for more direct aspects of 
mindfulness including curiosity and decentering as evaluated for in the TMS (Lau et al., 
2006). Overall the Bowen et al. study represents an important initial feasibility evaluation 
for use of MBRP with methadone-maintained patients.      
Lyons et al. (2019) undertook a randomized controlled study of incarcerated 
males with varied substance use disorders. Lyons et al. utilized a randomized cohort 
assignment design including an MBRP participant cohort and a control cohort using a 
six-week version of the Mapping-Enhanced Counseling Manuals for Adaptive Treatment 
(MECMAT; Joe et al., 2012). Lyons et al. used a revised version of the MBRP protocol 
that reduced the eight-week group period to six weeks through elimination of the 
mountain meditation exercise and amendment of other exercises integral to the original 
MBRP manualized treatment protocol. The potential effects of this revision remain 
unknown as Lyon’s et al. did not undertake a comparative analysis between the original 
and revised versions. Lyons et al. found that drug  cravings were significantly reduced 
(p=.05) for the MBRP intervention group at completion of an abbreviated (six-week) 
MBRP intervention in comparison to the MECMAT participant control group. To 
evaluate for levels of participant mindfulness they used multiple measures including the 
Five Factor Mindfulness Questionnaire (FFMQ; Bohlmeijer et al., 2011) and the Freiburg 
Mindfulness Inventory (FMI; Walach et al., 2006). Lyons et al. observed a significant 
increase (p=.05) in participant mindfulness for the experimental condition as measured by 





mindfulness in the control group. Limitations of the Lyons et al. study include the 
undetermined empirical efficacy of their abbreviated MBRP protocol and any resultant 
potential covariability, a participant attrition rate of 31% with its attendant reduction in 
statistical power, and potential, albeit unmeasured, covariability between the MBRP 
exposure experimental condition and extant jail therapeutic community effects.  
Imani et al. (2015) in their randomized , controlled study evaluated effectiveness 
of MBRP as a treatment adjunct for 30 participants enrolled in an opioid treatment 
program (OTP) and maintained on either methadone or buprenorphine medication. Both 
the experimental and control groups included maintenance treatment as usual (TAU). 
Randomized participant assignment was used to determine group selection. Imani et al. 
used the ASI Alcohol/Drugs subscale (Leonhard et al., 2000; McLellan et al., 1985) to 
measure participant opioid use and the FFMQ (Bohlmeijer et al., 2011) to measure 
participant mindfulness. Imani et al. observed a reduction in opioid use as measured by 
ASI Alcohol/Drugs subscale outcomes and concurrent increase in mindfulness as 
measured by FFMQ outcomes but neither of these findings proved statistically significant 
(p=.05). Limitations of the Imani et al. study included a lack of distinction between 
participants prescribed methadone versus those prescribed buprenorphine, which could 
exert unmeasured covariability into the MANCOVA statistical analysis they used. 
Another limitation was a potential, albeit undetermined MBRP manual fidelity problem 
resultant from its translation into Farsi to facilitate communicating in the participants’ 





additional limitation was the small number of enrolled participants (n=30) that limited 
statistical power and generalizability of the results. Notably, participant attrition was 
small, with 29 participants completing the study (Imani et al.).      
In a random controlled study evaluating the effectiveness of MBRP in the 
treatment of individuals with stimulant use disorder Glasner-Edwards et al. (2017) found 
no significant post-treatment difference (p=.05) in stimulant use between the MBRP 
group and the control group. They noted some posttest improvement for MBRP 
participants that reported reductions in stimulant use and reduced symptoms of 
depression and anxiety, but these changes did not rise to the level of significance. The 
control group received eight weeks of health education group meetings run concurrently 
with the experimental group receiving the MBRP manualized treatment (Glasner-
Edwards et al.). The FFMQ (Baer et al., 2004) was used for pretest and posttest 
measurement of participant mindfulness. A twelve-week contingency management 
protocol was run with the initial four weeks preceding the experimental and control 
groups implementation (Glasner-Edwards et al.). A feasibility strength of the study was 
the demonstrated strong MBRP protocol fidelity adherence as measured by MBRP 
Adherence and Competence Scale (Chawla et al., 2010) outcomes. Study limitations 
noted by Glasner-Edwards et al. included a 59% study participant attrition rate, with an 
initial 63 participants reduced to 26 remaining at study conclusion, and the unmeasured 
potential for covariability resultant from combining the experimental and control 





Hayes et al. (2004) evaluated the effectiveness of mindfulness-based approaches 
for MAT program patients, and this study, while demonstrating significant effects of the 
ACT-based intervention, did not evaluate for the effectiveness of MBRP. Whereas ACT 
and MBRP can both be regarded as mindfulness-based treatment approaches, ACT is 
strongly dissimilar to MBRP in its theoretical constructs, treatment approach, and 
interventional design. ACT is conceptually based on the theoretical constructs of 
relational framing (Hayes, 2002) and cognitive fusion (Hayes et al., 2012), with 
interventions focused toward achieving cognitive defusion with maladaptive relational 
frames using mindfulness-based decentering exercises. MBRP, in contrast, is based on 
principles of cognitive therapy, relapse prevention, and mindfulness (Bowen et al., 2011), 
using interventions amalgamated from these disciplines to increase participant 
metacognitive awareness, self-efficacy, and affect regulation, and improve coping skills, 
which together improve participant capabilities for effectively managing substance use 
cravings and reducing harmful behaviors associated with substance use. 
Grant et al. (2017) found in their meta-analysis of MBRP efficacy that MBRP did 
not show significant reductions in substance use relapse prevention, or increased levels of 
mindfulness in comparison to relapse prevention, CBT interventions, or TAU. They 
suggested the need for larger participant sample sizes, and to find methods for reducing 
participant attrition, which appeared to be a common confounding factor across multiple 





differentiate between distinct drugs of abuse, an essential consideration in the present 
study as it focused on persons with OUD enrolled in MAT.   
Considered together, research outcomes suggest the MBRP treatment approach is 
likely an effective treatment for many substance use disorders and that volitional 
attention, when adaptively directed, appears to reduce the compelling nature of the 
association between substance use-associated cognitions and cravings. Despite these 
efforts, important MBRP research gaps remain in that as of the development of this study 
there has been thus far only a single study (Imani et al., 2015) using a random controlled 
participant assignment design to evaluate MBRP effectiveness with individuals that have 
opioid use disorder, are enrolled in a MAT program and are being maintained on 
methadone. This study was limited by a potential fidelity concern due to unevaluated 
translation of the MBRP manualized treatment document and undefined number of 
methadone-maintained participants. The only other study evaluating MBRP effectiveness 
for methadone-maintained individuals with OUD lacked a control group and randomized 
participant assignment, and was limited by a severe participant attrition rate (Bowen et 
al., 2017). 
Rationale for Study Variables 
Two measures for of illicit drug use in MAT program patients have been 
consistently utilized at MAT programs and in the associated substance use disorder 
research: random monthly urine drug screen outcomes and the ASI Alcohol/Drugs 





treatment and investigative methodology, one measurement for DV utilized in this 
proposal to evaluate for frequency of participant illicit opioid use is the ASI 
Alcohol/Drugs subscale (Leonhard et al., 2000; McLellan et al., 1985). Given the strong 
association between opioid use cravings and opioid use behaviors (Batki et al., 2005; 
Parrino et al., 1993; Wasan et al., 2012), an additional DV measurement for this proposal 
was the OCS (McHugh et al., 2014). 
A potential MV was the level of participant mindfulness as measured by 
participant TMS (Lau et al., 2006) outcome scores at pretest, midtest, and posttest 
intervals. Statistical covariance data outcomes were to be used for determining any 
significant mediating association between changes in participant mindfulness and 
changes in dependent variables outcomes. 
MBRP (Bowen et al., 2011; Bowen et al., 2014; Bowen & Enkema, 2014) is a 
manualized treatment specifically researched and designed to address and reduce 
substance use-related thoughts, cravings, and reactive responding to environmental cues 
and stressors exposure (substance use as maladaptive coping).  Given the impaired stress 
response of individuals with opioid use disorder (Kreek, 2000) and its associated elevated 
relapse risk, MBRP likely offers an effective strategy for reducing MAT program patient 
illicit opioid use and the onset of its harmful concomitants. Moreover, MBRP has not yet 
been effectively evaluated as a treatment adjunct for MAT program patients. Thus, the 
MBRP manualized treatment protocol was selected in order to evaluate its effectiveness 





previously described research gap. The independent variable (IV) in the study was 
defined as two treatment levels: level one being administration of the MBRP (Bowen et 
al., 2012) manualized treatment intervention to the experimental group of MAT program 
participants concurrently participating in TAU for the proscribed eight-week period, and 
level two being the control group of MAT program participants participating only in 
TAU for the proscribed eight-week period. 
Review and Synthesis 
The research literature clearly indicates that opioid use disorder is a chronic, 
relapsing condition. Whereas MAT programs offer viable and effective treatment for this 
disorder, relapse for MAT program participants remains a serious concern, occurring in 
up to 20 percent of the treated population at any given time (Kreek, 2007). The risk of 
relapse is strongly associated with stress exposure in persons with opioid use disorder 
(CSAT, 2005; Kreek, 2000; Kreek & Koob, 1998; 2007). The medical, psychological, 
and social risks associated with relapse into illicit opioid use are of great concern 
(CSAT). Individuals experiencing relapse are at high risk for overdose, oversedation 
effects, and death (CSAT; Parrino et al., 1993, SAMHSA, 2020). Overdose death rates 
associated with illicit opioid use have tripled since 1990, and continue to increase (Chalk 
et al., 2013). Other associated risks include initiation or exacerbation of psychological 
conditions including anxiety and depression, alienation from friends and family, loss of 
beneficial functionality such as employment, and mounting legal problems with their 





are accrued mostly through overutilization of public healthcare, social support services, 
and criminal justice and court systems, and are estimated to amount to more than $500 
billion annually (Manchikanti et al., 2012). Moreover, the annual U.S. healthcare costs 
associated with illicit opioid use are estimated to be greater than $ 72.5 billion (Rinaldo 
& Rinaldo, 2013).  Taken together, the preceding considerations strongly suggest that any 
treatment adjunct that can potentially reduce the frequency of illicit opioid use in the 
MAT program patient population is thus of considerable benefit to both MAT program 
patients and society.  
The research evaluating neurobiological substrates of opioid use disorder suggests 
several key functional aspects of brain function that contribute to the condition. The first 
is hedonic homeostatic dysregulation, where activation of the ventral tegmental area 
(VTA), nucleus accumbens (NAc), and locus ceruleus (LC) located within the brain’s 
mesolimbic dopaminergic reward pathway occurs in response to repeated ingestion of 
exogenous (illicit) opioids through reduction in endogenous mu opioid receptor site 
occupation (Koob & Moal, 2006; Moal & Koob, 2007; Kosten and George, 2002). 
Continued hedonic homeostatic dysregulation results in allostasis, the neurobiologically 
conditioned phenomena of increased tolerance of and physiological dependence on illicit 
opioid use (Koob & Moal, 1997; 2006; 2007). The use of exogenous opioids is reinforced 
through classical conditioning hedonic effects that include sensations of well-being and 





increased dopamine levels from the VTA into the NAc and LC (Koob & Moal; Kosten & 
George). 
Neurobiological functioning further contributing to OUD includes the 
phenomenon of opioid abstinence syndrome (OAS), or the state of opioid withdrawal, 
wherein the individual with opioid use disorder experiences a protracted constellation of 
increasingly severe and aversive physiological symptoms in response to discontinuance 
of or marked reduction in exogenous illicit opioid use (Chalk et al., 2013; CSAT, 2005; 
Parrino et al., 1993).  OAS symptoms are precipitated by reduction in mu receptor site 
occupation in the LC, which thence results in upregulation of  noradrenaline levels in the 
endocrine system that cause the marked discomfort of OAS symptoms (CSAT; Koob & 
Moal, 2006; Parrino et al.). Further, reduction of mu receptor site occupation in the VTA 
results in correspondent reduction of dopamine levels in the NAc with attendant 
dysphoric effects (Koob & Moal). Moreover, these aversive symptoms are immediately 
relieved through again ingesting illicit opioids, reducing noradrenaline levels and 
increasing dopamine levels, and thereby further reinforcing and perpetuating continued 
illicit opioid use (Kosten & George, 2002). 
A third contribution factor in OUD is that of cognitive deficits, where the 
neurotransmitter signals from prefrontal cortex (PFC) of the brain, normally implicated in 
sound judgment and planning, are overridden by competing neurotransmission signals 





the impaired decisional and behavioral control leading to continued illicit opioid craving, 
seeking, and use (Kosten & George, 2002). 
Considering MBRP as a MAT Program Adjunct 
The research evaluating neurobiological substrates of mindfulness suggests that 
recurrent use of mindfulness practices results in enhanced PFC regulation of the more 
primitive limbic system functioning, neurobiologically evidenced in measurable increases 
in adaptive PFC functioning and structural mass (Chiesa & Serriti, 2010; Hölzel et al., 
2007; Hölzel et al., 2011b; Sperduti, Martinelli, & Piolino, 2011). Witkiewitz et al. 
(2013b), Kashdan et al. (2011), and Williams (2010) posited that these structural and 
functional effects result in enhanced awareness and attentional control, reduced reactivity 
to stress and environmental cues, and increased acceptance and management of 
discomfort. Witkiewitz et al. asserted the existence of several neurobiological substrates 
implicated in MBRP practice. Improved metacognitive awareness fosters Dorsolateral 
PFC, anterior cingulate cortex (ACC), ventral striatum (VS), insula, and amygdala 
bottom-up processing of substance use-associated stimuli without reactivity. The PFC 
and ACC upregulate adaptive attentional monitoring and control of cognitive, affective, 
and somatic functions associated with substance use cravings. Resultant improved self-
regulation is reflected in adaptive inhibitory control of substance use sustained through 
the medial PFC, orbitofrontal cortex (OFC), and ACC; and tolerance for discomfort 
previously associated with substance use is improved through adaptive functioning of the 





Through these increased structural and adaptive functional capabilities individuals 
are able to more adaptively regulate their conditioned responses to internal mental and 
physiological conditions and to external environmental cues (Farb et al., 2012; Hölzel et 
al., 2011b); stimuli that would otherwise likely result in illicit substance use (Bowen & 
Enkema, 2014; Dickenson et al., 2013; Witkiewitz et al., 2013a; Witkiewitz et al., 
2013b). Thus, the maladaptive neurobiological responses associated with hedonic 
homeostatic dysregulation and allostasis, as well as the neurobiological responses 
associated with OAS, likely could be more effectively mediated through the enhanced 
PFC control capabilities achieved through engagement in mindfulness practices. Zgierska 
and Markus (2010), in their review of the empirical literature, asserted that mindfulness 
practices have been found effective for addressing multiple concomitant conditions 
experienced by persons with substance use disorders that exacerbate relapse risk. Shorey 
et al. (2014) found that reduced levels of participant mindfulness were significantly 
associated with increased illicit substance use. Further, Shorey et al. (2013) found that 
individuals with substance use disorders have significantly reduced levels of mindfulness 
compared to healthy adults, suggesting that interventions increasing mindfulness in 
substance users would likely reduce tendencies toward illicit drug use as a maladaptive 
avoidance or coping strategy. Considered together, the concepts of neurobiological 
functioning, maladaptive functioning of the brain’s reward pathway associated with 





functional regulation of the PFC arising through mindfulness-based practices, underlie 
the research questions and hypotheses central to this pilot study. 
Empirical research strongly suggests that mindfulness practices are effective in 
reducing substance use associated thoughts, cravings, and relapse (Blume & Marlatt, 
2009; Bowen et al., 2006; Bowen et al., 2007; Bowen et al., 2009; Bowen et al., 2011; 
Bowen et al., 2014; Bowen & Enkema, 2014; Brewer et al. 2012; Brewer et al., 2009; 
Zgierska and Markus, 2010); and in reducing harmful effects of stress exposure (Baer, 
Carmody, & Hunsinger, 2012; Kabat-Zinn, 2002; 2003; 2009; Zgierska and Markus). 
Substance use-related cues, thoughts, and cravings are effectively mediated through use 
of mindfulness based attentional regulation (Witkiewitz et al., 2013; Hölzel et al, 2011b), 
suggesting that through engagement in mindfulness practices individuals with opioid use 
disorder likely can reduce their harmful substance use cognitions and behaviors, while 
concurrently improving their capabilities for adaptive stressor response. 
Kabat-Zinn (2002; 2009) asserted that mindfulness approaches include 
intentional, decentered, acceptant attentional regulation of percepts, cognitions, and 
affective phenomena. Use of decentered selective attention is exemplified in MBRP by 
mediating substance use associated thoughts and cravings through multiple cognitive 
strategies. The first is conceptualization of such cognitions as impermanent mental events 
that need not be intrusive or compelling (Bowen et al., 2011). The second is enhancing 
adaptive coping with them via use of the ocean wave meditative exercise and other 





together, strengthen PFC regulation of the more primitive conditioned limbic system 
responses (Bowen et al.). 
Thus, as Witkiewitz et al. observed, MBRP interventions target brain functioning 
that is strongly associated with substance use and relapse. In their controlled study of 
MAT program patients Nejati et al. (2012) found that daily use of methadone medication 
fostered improved selective attentional capabilities through associated reductions in 
automatized illicit opioid use biases and maladaptive responding to environmental 
stressors. This suggests that methadone medication is unlikely to impair the selective 
attentional functions inherent in mindfulness practices. Taken together, these 
considerations suggest MBRP is potentially a viable treatment adjunct for use with 
individuals participating in MAT for opioid use disorder and thus its evaluation as a 
treatment adjunct for MAT program participants is relevant, likely addressing a key gap 
in the research.  
Summary and Conclusion 
A considerable body of research suggests mindfulness-based treatment 
approaches offer effective interventions for a number of conditions including anxiety, 
depression, chronic pain, substance use disorders, and multiple general medical 
conditions. Further, research evaluating mindfulness practices appear to enhance 
neurobiological, cognitive, and affective protective functioning. Mindfulness meditation 





conditions and enhancing adaptive responding, thereby markedly reducing human 
distress and suffering. 
Neurobiological research evaluating mindfulness has found strong correlations 
between use of mindfulness-based practices and adaptive modifications to 
neurobiological structure and functioning. Research shows that impaired connectivity 
between the PFC and limbic system secondary to stress exposure, general medical illness, 
psychiatric illness, and substance use disorders has been implicated in symptomatic 
exacerbation of these conditions. Mindfulness research shows that even in naïve 
meditators, neurobiological changes have been observed including increases in neuronal 
mass within and blood flow from areas of the PFC to the limbic system, suggesting 
improved PFC regulation of more primitive central nervous system functions. An 
important area of investigation into mindfulness practices remaining unexplored to date is 
how such adaptive reregulation capacity could affect the neurobiological dysfunction 
associated with psychiatric illness, especially that specific to substance use disorders. 
This pilot study attempted to address this research gap through evaluating the 
effects of a specific mindfulness-based intervention, MBRP, on the illicit opioid use 
behaviors of individuals concurrently participating in MAT. This study continues with 






Chapter 3: Research Methods 
Study Purpose 
Opioid use disorder is a chronic, relapsing condition where post-remission relapse 
is likely (APA, 2006; 2013; Dennis & Scott, 2007; Kosten & George, 2002; Leshner, 
1989; 2001; Parrino et al., 1993; Volkow, 2007a; 2007b). MAT is an effective treatment 
for addressing opioid use disorder (Kosten & George, 2002; Parrino et al., 1993; Volkow, 
2007b). Nevertheless, given the chronic and relapsing nature of this condition,  MAT 
program participants remain at risk for illicit opioid use relapse and are thus likely to 
benefit from adjunctive treatment interventions that reduce this risk (Logan & Marlatt, 
2010; Parrino et al., 1993). 
MBRP treatment interventions are effective in terms of treating substance use 
disorders and their associated craving behaviors, have not yet been investigated for their 
effectiveness as a MAT program treatment adjunct. This study involves addressing this 
gap in the research through evaluating the effects of illicit opioid use among MAT 
program participants. 
Overview of This Chapter 
 This chapter includes an outline of the research design and its rationale, including 
research questions addressed by the study,  study design, types of variables , time 
constraints imposed by the design, how the design addressed existing gaps in the 
research, and the rationale for the study intervention. Characteristics of the target 





for participant recruitment and data collection are identified and described. The rationale 
for conducting this pilot study is explicated. The MBRP manualized treatment 
intervention is described, and associated procedures for implementation are discussed. 
Measures used to evaluate DV outcomes are discussed, as well as their relevance for use 
in this study and reliability and validity characteristics. Study variables are operationally 
defined, and measurement, scoring, and interpretational methodologies are discussed. 
The data analysis plan is outlined, including software, research questions and hypotheses, 
explanation of statistical tests, evaluative methods for inclusion of covariates and 
controlling for confounding variables, and interpretational factors including confidence 
intervals. Validity threats are evaluated, including external and internal factors, as well as 
construct and statistical validity concerns. Ethical considerations are identified and 
discussed, including procedures used to assure consistency with Walden University IRB 
and APA ethical standards for participant research, institutional permissions, adherence 
to MAT program ethical standards, ethical treatment for all study participants regardless 
of nature or duration of their participation, and  concerns regarding potential conflicts of 
interest. This chapter concludes with a summary of the experimental design and method 
of inquiry in this study.  
Research Design and Rationale 
This pilot study was intended to evaluate the effects of administration of a MAT 
program intended to develop and enhance mindfulness skills in participants concurrently 





pharmacotherapy. Mindfulness-based interventions are associated with significant 
reductions in frequency and severity of substance use behaviors and cravings associated 
with substance use relapse (Bowen et al., 2006; Brewer et al., 2010; Ostafin & Marlatt, 
2008; Marlatt & Chawla, 2007; Witkiewitz et al., 2005). These outcomes suggest that a 
mindfulness-based treatment intervention administered to participants concurrently 
enrolled in MAT programs using methadone pharmacotherapy may result in reductions in 
terms of frequency of illicit opioid use behaviors and severity of opioid cravings. This 
provides a context for evaluating the potential utility of conducting subsequent larger 
studies involving MBRP groups at multiple MAT programs, thereby evaluating MBRP 
manualized treatment effects in terms of statistical power associated with larger groups of 
study participants. 
Research Questions and Hypotheses 
RQ1: Is exposure to MBRP manualized treatment associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H01: Exposure to MBRP manualized treatment is not associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Ha1: Exposure to MBRP manualized treatment is associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 





RQ2: Is exposure to MBRP manualized treatment associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H02: Exposure to MBRP manualized treatment is not associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Ha2: Exposure to MBRP manualized treatment is associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Study Variables 
The study was a quantitative design utilizing mixed within-between subjects 
design with time as the within-subjects factor and groups as the between-subjects factor. 
MANCOVA was to be used to evaluate relationships between the dependent and 
independent variables over time (Cohen et al., 2003, p. 608).  
The DVs in the study were: (a) participant illicit opioid use during the eight- week 
study period as measured by the ASI Alcohol/Drugs subscale (McLellan et al., 1985) 
outcomes positive for illicit opioids and participant illicit opioid craving severity as 
measured by the OCS (McHugh et al., 2014).   
The IV consisted of two levels: the first being provision of the MBRP (Bowen et 





group of MAT program participants for eight-weeks, and the second consisting of TAU 
in the control group of MAT program participants for the concurrent eight-week period. 
A potential MV was level of participant mindfulness as measured by the TMS 
(Lau et al., 2006) outcome scores. Investigation to determine the significance of this MV 
was not included in the study design, although it was the subject of limited commentary. 
The TMS was administered at pretest, midtest, and posttest intervals. Statistical 
covariance data outcomes would likely reveal any significant mediating association 
between changes in participant mindfulness and changes in dependent variables 
outcomes. A positive significant scoring difference at posttest would suggest that the 
participant increased his or her level of mindfulness in association with MBRP exposure, 
whereas the absence of a significant difference in pre- and posttest scores would suggest 
that there was not a change in participant mindfulness resultant from MBRP exposure. A 
negative significant scoring difference would suggest that the participant decreased his or 
her level of mindfulness in association with MBRP exposure. 
The first research question for this study asked if participant exposure to the 
MBRP manualized treatment is associated with reductions in percentage of illicit opioid 
use for individuals concurrently participating in MAT for their opioid use disorder. The 
research design addressed this research question through its measurement of this DV 
associated with two levels of IV administration throughout the eight-week study period.  
The second research question for this study asked if participant exposure to the 





craving for individuals concurrently participating in MAT for their opioid use disorder. 
The research design addressed this research question through its measurement of this DV 
associated with two levels of IV administration throughout the eight-week study period.  
The study duration was 14 weeks, including phases for study participant 
enrollment, pre-treatment data collection, administration of the MBRP manualized 
treatment, posttreatment data collection, and participant debriefing. Participant 
enrollment procedures were to begin at the MAT program site three weeks prior to 
beginning the study. 
Research regarding effects of mindfulness-based adjunctive interventions for 
MAT program participants maintained on methadone pharmacotherapy is severely 
limited, and thus far has not consistently included randomized, controlled designs. This 
study addressed these concerns through its empirical methodology utilizing a minimal 
number of group participants and relatively brief study period to minimize potential 
adverse effects on study integrity such as time and fiscal constraints.  
Study Population Characteristics  
The target population was individuals in the U.S. with opioid use disorder who 
are enrolled in MAT programs and who are maintained on methadone pharmacotherapy. 
At the inception of study design, there were an estimated 270,000 patients serviced by 
some 1,200 MAT program located throughout the US (SAMHSA, 2011). At the 
conclusion of study implementation there were an estimated 350,000 methadone-





U.S. healthcare rules and associated increases in multiple states reflecting support for 
treatment of opioid use disorder, the number of individuals enrolled in MAT programs 
for treatment of opioid use disorder will likely continue to increase.   
Sampling Procedures 
Larger sample sizes reduce standard error and larger effect sizes increase 
statistical power (Gravetter & Wallnau, 2007). Gravetter and Wallnau observed that a 
type I error, where a treatment effect is falsely reported, can be reduced by decreasing 
alpha level, whereas a type II error, where an extant treatment effect is not detected, can 
be addressed through increasing effect size. They further noted that reducing standard 
deviation reduces variance, thereby reducing standard error and increasing power and 
effect size. A sufficient sample size thus must address these considerations.  
Julious (2005) asserted that criteria for pilot study sample size include 
considerations about feasibility, precision of mean and variance, and regulatory 
requirements, where applicable. Julious observed that whereas larger studies have 
specific recommendations in the literature to assure optimal levels of standard error and 
statistical power at the chosen significance level, such standards have not been 
consistently applied to pilot studies. 
Mean and variance precision characteristics include consideration that whereas 
increased sample size is associated with reduced standard error, sample size increases 
beyond 12 participants are likely to yield decreasing reductions in standard error given 





of 30 participants per group (n = 60) was likely to minimize standard error of the mean at 
significance p ≤ 0.05. To assure optimal variance precision characteristics in a pilot study 
Julious asserted that the sample size contain sufficient degrees of freedom such that a 
future study would have sufficient statistical power at chosen significance (p ≤ 0.05) if  
based on the prior pilot study. As recommended by Julious, a sample size assuring 20 
degrees of freedom is sufficiently large to assure 50% statistical power given p ≤ 0.05. At 
n = 45, this study would have assured greater than 20 degrees of freedom. This study 
design reflected the preceding recommendations, thereby assuring equivalence between 
the control group and experimental group. To account for possible participant dropout, 
which could not be predicted, this study design was planned for number of participants n 
= 60, including group n TAU = 30 and MBRP = 30. 
Participant Inclusion and Exclusion Criteria 
Study participants were individuals aged 18 years or more who are concurrently 
enrolled in a medication assisted treatment (MAT) program located in California. Each 
participant had a primary DSM-5 diagnosis of 304.00 opioid use disorder, severe, on 
maintenance therapy (American Psychiatric Association, 2013). Federal guidelines 
(SAMHSA, 2015) and California State regulations (Title 9, Section 4, Part 4) require that 
patients meet these primary diagnostic criteria as a condition of MAT program 
admission, unless an infrequently utilized regulatory exception process is initiated by the 
program and approved by state and federal authorities. MAT program policies and 





unless they are minimally 18 years of age and able to provide informed consent to opioid 
treatment. No participants were excluded provided they completed study informed 
consent, maintained study participation, and maintained their concurrent MAT program 
participation at the study site for the duration of the study. Study enrollment will not be 
limited by sex, age (above adult status), ethnicity, race, educational level, or the presence 
(or absence) of any co-occurring psychiatric or medical conditions. 
A private room at the MAT program site was used for implementing study 
interventions and data collection. Study materials were provided and study procedures 
conducted in a manner sensitive to the strengths, needs, abilities, limitations, and 
preferences of the participants (Commission on Accreditation of Rehabilitation Facilities 
[CARF], 2012).  
 Study participation was voluntary, and post enrollment, participants were able to 
withdraw at any time. Participants that did not complete the requisite informed consent 
process were excluded from study participation.  
Continued MAT program enrollment was required in order for an individual to 
receive program services, including the MBRP group services (BAART Programs, 2015). 
Thus, participants were required to maintain enrollment in the MAT program throughout 
the duration of the study. In cases where a participant discontinued MAT program 






Each participant was required to maintain adherence with MAT program 
participation standards for the duration of the study implementation period. For study 
purposes, such adherence was defined in accordance with MAT program policy 
requirements requiring that patients attend individual counseling sessions in accord with 
the schedule identified on their respective individualized treatment plan, typically once 
weekly for 50 minutes, and that patients ingest their methadone medication on a daily 
basis as ordered by the program physician (BAART Programs, 2015). MAT program 
requirements may additionally include patient participation in group therapy services, 
including but not limited to MBRP, relapse prevention, and groups for support of 
individuals experiencing he effects of trauma, grief, and loss (BAART Programs). Any 
participant that demonstrated substantial MAT program requirement nonadherence 
during the course of the study was discontinued from study participation and debriefed. 
Examples of such nonadherence would include missing more than one scheduled 
individual or group counseling session or more than two scheduled dosing appointments 
during the eight-week MBRP intervention period. The principal investigator was 
provided access to OTP program computer data systems to verify participant adherence 
with MAT program requirements. 
Participant Recruitment  
Participant recruitment occurred at the MAT program site selected for study 
implementation. For a three-week period prior to implementation phase of the study, an 





program front desk staff persons as they check in to the program for TAU services. This 
flyer described the study purpose and procedures, outlined participatory requirements, 
and provided principal investigator phone contact information to address any additional 
questions or concerns participants may have prior to participant enrollment and study 
implementation. The principal investigator was available at the program site during 
normal operation hours to answer questions and implement study enrollment process for 
interested MAT program patients. Participants were informed that a $ 25.00 debit card 
would be provided to all those completing the study as required. Participants were 
informed that discontinuing study participation prior to completion would result in 
ineligibility for this compensation. A private room at the MAT program site was used for 
study enrollment. 
Participant Informed Consent Procedures 
The study principal investigator facilitated the provision of informed consent for 
each participant, though review, discussion, and signing of the study informed consent 
document provided to each participant (See Appendix C). Participants were informed of 
the study purpose, treatment methods to be used, how they will be provided with relevant 
study outcome data, their right to discontinue the study at any time, and study personnel 
identifying information, qualifications, and contact information. The meetings with 
participants for purposes of effecting informed consent took place in a private office 





three weeks period prior to implementation of the eight-week MBRP manualized 
treatment study phase.     
Informed consent procedures were carried out in a manner consistent with all 
Walden University IRB requirements and institutional approval letter stipulations. 
Additionally, this study was conducted such that all state and federal laws regulating 
MAT program patient privacy (HIPAA rule) and confidentiality (42CFR rule) are fully 
adhered to for all study participants.  
Types and Sources of Information or Data 
Data sources included study participant reporting of the above-described testing 
instrument outcomes. In order to assure privacy and confidentiality of the participants, 
data outcomes for each participant were  associated with a unique four-digit number 
assigned by the principal investigator. Deidentified study participant record information 
collected from the MAT program computerized patient record included participant MAT 
program attendance records to assure participant continued in concurrent treatment for 
the duration of the study. Deidentified participant record information collected from the 
MBRP group services provider (the principal investigator) included dates of participant 
attendance at each MBRP group meeting group session and records of participant weekly 
MBRP homework assignment completion. Deidentified participant record information 
collected by the principal investigator from all participants included pretest, midtest, and 





al., 1985), and OCS (McHugh et al., 2014). Participant report of an adverse event (see 
Appendices E and F), if any, would also have been collected, however there was none. 
Data Collection Procedures 
Participants were randomly assigned to either the treatment group (n = 30) or 
control (TAU) group (n = 30). Random participant (n = 60) assignment to either 
treatment or control group was achieved through use of a randomization table. After 
selection, each participant was assigned a unique four-digit identifier that was associated 
with all study data collected about that participant. A key tying the randomized 
participant assignment identifying numbers to the participant names was securely 
maintained by the principal investigator in an encrypted file format stored on secure 
computer system with the encryption key known only by the principal investigator.  Raw 
test data was retained in secure, private storage using a locked file cabinet by the 
principal investigator for subsequent scoring and recording data outcomes in the study 
database. All study data was retained in a manner that ensures adherence with participant 
privacy and confidentiality rules. Only participant ID numbers were noted on any study 
test materials. No participant names were used on any study data other than the 
aforementioned encrypted key log. The study database consisted of outcomes for all 
measures previously identified in participant recruitment and data collection procedures. 
A private room at the MAT program site was used for implementing study data 





sensitive to the strengths, needs, abilities, limitations, and preferences of the participants 
(Commission on Accreditation of Rehabilitation Facilities [CARF], 2012).  
Pretest Data Collection 
The pretest data collection phase occurred during weeks three and four, prior to 
the first MBRP group meeting. The principal investigator met with each study participant 
(in both study groups) individually in a confidential, private setting at the MAT program 
site, and administered the pretest ASI Alcohol/Drugs subscale (McLellan et al., 1985), 
OCS (McHugh et al., 2014), and TMS (Lau et al., 2006) measures. 
Midtest Data Collection 
For Midtest data collection the principle investigator met with each study 
participant (in both groups) individually in a confidential, private setting at the MAT 
program site, and administered the midtest ASI Alcohol/Drugs subscale (McLellan et al., 
1985), OCS (McHugh et al., 2014), and TMS (Lau et al., 2006) measures.  
The principal investigator met with the MAT program MBRP group participants after the 
fourth group meeting (end of study implementation week 8) to collect data on MBRP 
group participation. This data collection consisted of several elements for each MBRP 
participant, including the dates of participant MBRP group attendance, participant 
completion of weekly MBRP assignments, a review of MAT program adherence data for 
all participants, a review of MBRP group facilitator  adherence with MBRP group 





preceding data was recorded in a computer spreadsheet securely retained by the principal 
investigator for subsequent discussion.    
Posttest Data Collection 
Weeks 13-14 comprised the study posttest data collection phase wherein the 
principle investigator met with each study participant (in both groups) individually in a 
confidential, private setting at the MAT program site, and administered the posttest ASI 
Alcohol/Drugs subscale (McLellan et al., 1985), OCS (McHugh et al., 2014), and TMS 
(Lau et al., 2006) measures. 
This data collection for each MBRP participant included the dates of participant 
MBRP group attendance, tracking the completion of weekly MBRP assignments, review 
of MAT program dosing and counseling requirements adherence, review of MBRP group 
facilitator adherence with MBRP group administration manualized procedures; and 
review of any participant adverse event reporting.  
Management of Potential Adverse Effects 
The principal investigator was responsible for meeting with study participants 
reporting adverse events.  Adverse event data would have been immediately reported to 
the Walden IRB, however, no adverse events were reported. Documentation of adverse 
event data would be securely retained in a locking file cabinet accessible only to the 
principal investigator. Participants were informed that should they experience such events 





excused from further MBRP group participation until the concerns can be satisfactorily 
resolved, if possible, or their study participation discontinued.    
Although any adverse effects from study participation were considered unlikely, 
during the course of the study all participants reporting any unanticipated adverse effects 
would be assessed and appropriately referred by the principal investigator. Such 
assessment proved unnecessary, as no such adverse events were reported.  This 
assessment would have included the following elements: (a) eliciting participant 
reporting of adverse effects thought to be associated with study participation; (b) 
documentation of reported adverse effects; (c) discussion of and documentation of 
participant consent to disclose in accord with provisions and restrictions of Federal 
Confidentiality Rule for Alcohol and Drug Treatment programs (42CFR); (d) report of 
adverse effects and referral to the MAT program physician for further evaluation and 
development of recommended course of treatment, if any; (e) an explanation to 
participant that given the reported adverse effect he or she may discontinue study 
participation immediately; (f) an explanation to participant that his or her MAT program 
enrollment status will not be affected by any reporting of adverse effects; and (g) 
reporting of the adverse event and its outcome to the Walden IRB. Because no adverse 
events were reported, implications of adverse event data were not analyzed by the me. 
Participant Post-Study Debriefing 
All active participants were debriefed at the conclusion of the study 





were required of study participants, and at the debriefing meeting each participant 
completing the study received the participation compensation as explained during the 
study informed consent process. Participants that discontinued the study prior to 
completion of all data collection phases were offered debriefing services by the principal 
investigator, regardless of the reason for study discontinuance. Upon completion of the 
study data analyses all participants were offered a summary of the study outcomes and 
findings without charge. Participants in the control group were offered MBRP 
manualized treatment adjunct services after the conclusion of study debriefing.   
Summary of Study Procedures 




Outline of Study Procedures 
________________________________________________________________________ 
 
Study Phase and Description    Period 
_______________________________________________________________________ 
 
Study information provided to potential participants                    Weeks 1 and 2 (before MBRP starts) 
Informed consent obtained from participants                                 Weeks 1-3 (before MBRP starts) 
Pre–test data collection       Weeks 3-4 (before MBRP starts) 
MAT Program staff provides MBRP to participants                         Weeks 5-12 (MBRP administered)  










Nature of MBRP Manualized Treatment Intervention  
The MBRP manualized treatment is an eight-week structured clinical intervention 
course where participants meet once weekly in a private setting at the MAT program site 
for up to two hours (as needed to complete proscribed MBRP treatment activities) with a 
MAT program staff person designated by the MAT program, who will function as group 
facilitator; conducting daily individual guided meditation practice exercises, participating 
in conceptual discussion of relevant manualized treatment topics, and reviewing and 
completing CBT-oriented treatment assignments (Bowen et al., 2011). The first session 
consists of an introduction to the course requirements and two mindfulness meditation 
exercises (Bowen et al.). Each subsequent session includes a review of the homework 
assigned to study participants during the previous session, discussion of participants’ 
mindfulness meditation practice experience during the prior week, interactive discussion 
of mindfulness and relapse prevention practices and approaches, guided mindfulness 
meditation exercises, review and discussion of the following weeks’ homework 
assignments, and closing remarks. The MBRP manualized treatment (Bowen et al.) 
structure is described in detail in Chapter 2 and Appendix A of this proposal.  
Study Instrumentation and Construct Operationalization 
This experimental design attempted to evaluate whether there is an association 
between participant exposure to the MBRP manualized treatment adjunct and percentage 
of participant illicit opioid use. This was achieved through between groups comparison of 





outcomes evaluation using repeated measures MANCOVA were planned to be conducted 
at significance (p < .05). 
The ASI Alcohol/Drugs subscale (McLellan et al., 1985) was administered at 
pretest, midtest, and posttest intervals by the principal investigator. ASI Alcohol/Drugs 
subscale scoring outcomes were reviewed by the principal investigator to assure data 
collection and interpretive accuracy. The OCS (McHugh et al., 2014) was administered at 
pretest, midtest, and posttest intervals by the principal investigator. OCS scoring 
outcomes were reviewed by the principal investigator to assure data collection and 
interpretive accuracy. The TMS (Lau et al., 2006) was administered at pretest, midtest, 
and posttest intervals by the principal investigator. TMS scoring outcomes were 
evaluated for possible mediating effects on ASI and OCS outcomes. TMS scoring 
outcomes were reviewed by the principal investigator to assure data collection and 
interpretive accuracy. 
 Quantitative analysis of the multiple independent and dependent study variables 
was planned using MANCOVA. If an inverse covariability were to be found between 
experimental group participant exposure to MBRP and illicit opioid substance use as 
predicted by the first alternative hypothesis, then the first null hypothesis would be 
rejected in favor of the first alternative hypothesis. This outcome would suggest that 
administration of MBRP manualized treatment to concurrently enrolled MAT program 
patients is associated with significant reductions in illicit opioid use. If an inverse 





MBRP and illicit opioid craving as predicted by the second alternative hypothesis, then 
the second null hypothesis would be rejected in favor of the second alternative 
hypothesis. This outcome would suggest that administration of MBRP to concurrently 
enrolled MAT program patients manualized treatment is associated with significant 
reductions in illicit opioid craving.  
Materials required for the administration of all test measures included printed 
versions of each measure, pens for indicating line item responses, and a comfortable 
private setting where the participants can be interviewed. These were readily available at 
the MAT program site. Substance use scoring outcomes were reviewed by the principal 
investigator to assure data collection and scoring accuracy. Finally, the strength of this 
study’s quantitative methodology was enhanced through minimization of extraneous 
variable effects achieved by conducting the experiment in the MAT program 
environment known to the study participants. 
Addiction Severity Index 
The fifth edition of the ASI (McLellan et al., 1985) evaluates for examinee 
functioning across multiple domains, asking lifetime problem frequency for a total 
number of years, where the problem was evidenced at least once during any year, and 
problem frequency within past 30 days, where the problem was evidenced at least once. 
Using a Likert scale design the examinee indicates problem severity and need for 





Using a Likert scale design from 0 to 4, the examiner then indicates three 
evaluative items for each ASI functional domain: Problem severity ratings; The 
examinee’s ability to understand the test questions; and the examinee’s ability to answer 
test items honestly and accurately (McLellan et al., 1985). 
The ASI demonstrates strong concurrent reliability (α = .89) and consistent 
validity and reliability scores for widely diverse substance use disordered populations 
(Leonhard et al., 2000; McLellan et al., 1985). Butler et al. (2001) found that one-month 
test-retest reliability of the ASI drug use domain index is strong (α = .77), as is criterion 
reliability for the drug use domain index (r = .67).  
 Mäkelä (2004) found inconsistent reliability in non-English version ASI 
interviewer severity ratings and composite scoring, attributed to insufficient interviewer 
training and combined composite scoring methodologies that may artificially reduce 
index score levels. McLellan, Cacciola, and Alterman (2004) asserted the ASI is in 
revision with the intention of improving reliability. The standard English version of the 
ASI will be used in this study, and will be administered by the principal investigator, who 
has extensive experience in ASI administration and interpretation.  
 This study used the ASI Alcohol/Drugs subscale data pertaining to illicit opioid 
use. This ASI subscale is scored through weighted summing of individual item results 
within each subscale. Index composite score ranges from no problem severity (0.00) to 
very high problem severity 1.00 (Cacciola et al., 1997). Scoring methodology includes 





and dividing by the total number of test items (McGahan et al. 1986). The final two test 
items asking for examinee reporting of problem disturbance level and desire for treatment 
are divided by 4, then by 13 (McGahan et al.). A composite subscale score for the drug 
use domain at or near 1.00 thus indicates severe substance use. The ASI Alcohol/Drugs 
subscale is in the public domain. 
Opioid Craving Scale 
 This study used the OCS to measure severity of participant cravings for illicit 
opioids. The OCS consists of three visual analogue scale items measured in 0 (no desire 
for opioids) to 10 (strong desire for opioids) for item one, and in severity from 0 (no 
severity) to 10 (extremely strong severity) for the remaining two items. The first scale 
asks the participant to evaluate the strength of desire to use opioids during the past 24 
hours. The second scale asks the participant to rate how strong desire to use opioids has 
been during the past week when exposed to an environmental cue associated with opioid 
use. The third scale asks the participant to recall the most recent environment and time of 
day where he or she used opioids and rate the likelihood of opioid use if the participant 
were in that environment at that time today (McHugh et al., 2014). The scoring 
methodology for this scale consists of averaging the three individual scale outcomes 
together for a composite craving severity score (McHugh et al.).  
 The OCS appears to demonstrate strong reliability and validity. Using Spearman’s 
rho, Mann-Whitney U, and Kruskal-Wallis testing, McHugh et al. (2014) found that the 





strong concurrent and predictive validity for illicit opioid use (OR = 1.17, 95% CI = 1.11, 
1.22 , p < .54). For the OCS, a composite score close to 0 would suggest little to no 
craving, whereas a composite score close to 10 would suggest severe craving likely 
predictive of illicit opioid use. The OCS is in the public domain. 
Toroto Mindfulness Scale 
The TMS  measures two factors considered essential components of mindfulness: 
curiosity and decentering. In psychometric evaluations by Lau et al. (2006), the TMS 
evinced high internal consistency (α = .95), with statistically significant factor loadings 
for curiosity (α = .56) and decentering (α = .82), and internal consistency of the two 
scales were (α = .86) and (α = .87). Lau et al. noted that composite reliability scores were 
robust for curiosity (CR = .93) and decentering (CR = .93). Criterion validity is supported 
by significantly higher scores evidenced on both factors for post versus pre MBSR 
training groups, as well as for mindfulness meditators with greater than one-year 
experience versus those with less than one year of meditation experience (Lau et al.).  
Lau et al. (2006) described how the measure consists of 13 questions associated 
with factors contributing to mindfulness, requiring approximately three minutes for 
administration. The examinee indicates level of agreement with the test item statement 
using the Likert scale design: 0 - not at all, 1 - a little,  2 – moderately, 3 - quite a bit, or 4 
- very much.  
 Curiosity index scores are derived from individual test item scores for 3, 5, 6, 10, 





2, 4, 7, 8, 9, and 11 (Lau et al., 2006). Higher scores indicate increased clinical evidence 
of mindfulness effects in the test subject (Lau et al.). The TMS appears psychometrically 
sound and will require little administration time. The TMS is in the public domain. 
Operationalization of DVs and IVs 
Only data collected during the study implementation period was used. This period 
was defined as two weeks prior to start of MBRP group services to participants, 
concluding two weeks after conclusion of same. No archival data was used. For the first 
research question, the DV was frequency of illicit opioid use as measured by ASI 
Alcohol/Drugs subscale scoring outcomes. For the second research question, the DV was 
participant OCS scoring outcomes.  
Each ASI Alcohol/Drugs subscale outcome score greater than zero for opioids 
indicates the participant used illicit opioids for one or more days during the past month 
and will be considered as an illicit opioid positive result. An example of an ASI 
Alcohol/Drugs subscale result positive for illicit opioids is where any illicit opioid use is 
reported for five of the past 30 days.  Each Opioid Craving Scale composite scale score 
of five (moderately severe craving) or greater is considered as representative of 
participant illicit opioid craving.  
The IV consisted of two treatment levels: provision of the MBRP (Bowen et al., 
2011) manualized treatment intervention to the experimental group of MAT program 
participants (in addition to TAU) for the proscribed eight-week period, and the control 





Any experimental group participant not attending at least six of the eight MBRP 
group sessions while consistently participating in TAU at the MAT program was 
considered as not meeting the IV requirement, identified as a study dropout, and this 
outcome so noted in the study data analysis. Where possible, dropout participants were 
debriefed and their data was not used for the quantitative analysis of the study.  
The control group experienced TAU as it is consistently practiced within the 
context of the MAT program, excluding MBRP group participation. For the control group 
any participant not consistently participating in TAU for the eight-week study period was 
considered as not meeting this IV requirement, identified as a study dropout, and this 
outcome so noted. Study dropout participant data was not be utilized for purposes of 
study quantitative data analysis. The only between groups variable was administration of 
the MBRP manualized treatment. 
Data Analysis Plan 
Statistical Software and Data Validation 
Software planned for use in data analysis in this study was the Statistical Package 
for the Social Science (SPSS; International Business Machines, 2009), with the alpha 
value set at .05 for all statistical procedures used. All outcomes data were planned to be 
uploaded into a computer running SPSS software and results that will be calculated by 
the SPSS program. Each participant data entry record was to be reviewed against the 
original documentation provided by the study site coordinator to assure data entry 





variables using the SPSS program, thereby crosschecking to assure that data outliers or 
entry errors are not significantly skewing data outcomes. Finally, the SPSS Data 
Validation procedure was to be run to assure that missing or erroneous data entries are 
not influencing data analyses outcomes. The principal investigator was responsible to 
assure that all outcomes data were accurately transcribed, that appropriate statistical tests 
were run, and that inferences made from these results would be interpreted accurately in 
accord with the statistical model used (MANCOVA) and experimental design utilized. 
 Despite the data analysis plan described above the principal investigator was 
unable to carry out as planned due to unforeseen high levels of participant dropout. This 
confound led to an insufficient number of participants remaining in the MBRP group 
(n=3), thereby invalidating data analysis due to inability to achieve sufficient statistical 
power. 
Research Questions and Hypotheses 
RQ1: Is exposure to MBRP manualized treatment associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H01: Exposure to MBRP manualized treatment is not associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 





Ha1: Exposure to MBRP manualized treatment is associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program. 
RQ2: Is exposure to MBRP manualized treatment associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H02: Exposure to MBRP manualized treatment is not associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Ha2: Exposure to MBRP manualized treatment is associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Data Analysis Methods 
This study planned for use of a quantitative, randomized, controlled design 
utilizing repeated measures of dependent variables and a single measure of a between 
groups independent variable.  It reflected a mixed within-between subjects design with 
time as the within-subjects factor and groups as the between-subjects factor. 
Quantitative Methodologies 
Cohen et al. (2003) said MANCOVA is used for statistical evaluation research 
designs where there are multiple DVs and IVs. This supports a study design and 





IVs and DVs over time. Cohen et al. further suggested that requisite properties for the 
MANCOVA test include utility when examining non-nominal multivariate factors, 
calculating partial variance, determining multivariate significance, and calculating 
“measures of association, parameter estimation, hypothesis testing, and statistical 
analysis” (p. 609) within a unified conceptual statistical approach. Given the complexity 
of multivariate data gathered over distinct periods in this study, MANCOVA testing was 
considered the most effective method of statistical analysis.    
Gravetter and Wallnau (2007) and Cohen et al. (2003) suggested that when an 
experiment consists of three or more treatment conditions use of t-tests would result in 
accumulation of type I errors from each test, collectively known as the experiment-wise 
alpha level. A single MANCOVA test can simultaneously test all means using one alpha 
level, thereby avoiding the inflated alpha error effect. Real world participant sampling 
suggests the possibility that unequal sample sizes must be compared due to unanticipated 
phenomena such as participant drop out. MANCOVA provides a valid test with sufficient 
sample size where groups are sufficiently large: n ≥ 12 for pilot studies (Julious, 2005), 
and sample size differences are not too great. 
 The preceding MANCOVA methodology assumed that a minimum of number of 
participants (n ≥ 12) would complete the entire study, would consistently attend study 
MBRP group meetings, and would participate in and complete study measures as 
scheduled for the pretest, midtest, and posttest measure administration. The most direct 





number of participants such that even with participant dropout the minim number of 
participants would remain. 
Threats to Validity 
External Validity Threats 
An important consideration here is that of extraneous variables caused by TAU 
effects. Generally, TAU for the MAT program patient includes daily methadone 
pharmacotherapy administered by a program nurse, weekly individual counseling 
sessions, and appointments with program medical staff where indicated (Batki et al., 
2005). Inconsistencies in TAU services frequency or quality may exert unknown effects 
on participants, possibly influencing substance use behavior, study participation, or test 
item response data. This study was designed to control for these potential extraneous 
variables through use of random participant assignment and a control group. 
Other validity threats could arise through distinctions in MAT program 
counseling styles and therapeutic approaches used, or from differences in counselor 
education, training, and experience. Batki et al. (2005) and McCann et al. (1994) asserted 
there is considerable variability in therapeutic approaches and counselor education and 
training at MAT programs. At the MAT program site used for the study clinical 
approaches attempts were made to support consistency in clinical approach through use 
of mandatory organizational training and work implementation standards based on 
implementation of standardized policy and procedure (BAART Programs, 2013). All 





genuineness, and unconditional positive regard (Miller et al., 1999; Rogers, 1961; 1980), 
and in use of motivational interviewing practices (Miller & Rollnick, 2002). Whereas the 
preceding TAU variables argue for caution in interpretation of experimental results, the 
inclusion of randomized participant assignment and a control group was intended to 
protect study outcomes from these potential validity threats. 
Distinctions in participant lived experience, personality, and behavior may have 
exerted unknown confounding effects. Extraneous variability could arise from varied 
levels of participant knowledge and skill level relevant to mindfulness practices, or from 
naïve participant mindfulness states and traits. These distinctions could result in 
differences in participant conceptual and experiential levels of mindfulness, thereby 
exerting effects on individual participant meditation practice and efficacy of mindfulness 
practices integration. Random participant assignment and use of a control group in this 
study design were planned to reduce such potential effects.  
Lau and McMain (2004) asserted that key to effective mindfulness research is the 
use of research personnel experienced in mindfulness practices prior to teaching others. 
This study addressed this potential source of variability through use of the principal 
investigator, who held the requisite training and experience in use of the MBRP 
manualized treatment; as the MBRP group facilitator.  
Internal Validity Threats 
Nastasi and Schensul (2005) observed that confirmation bias may occur in 





that extraneous, relevant data is overlooked and illusory correlations are formulated. 
Johnson and Onwuegbuzie (2004) cited multiple internal validity threats, including 
foreclosure effects, where relevant data is erroneously ruled out, and discounting error, 
where an expected association is found and other potentially relevant associations are not 
considered. The study attempted to address confirmation bias potential through use of 
randomized participant assignment, use of a control group, use of data crosschecking 
methods, and critical exploration of study limitations. 
In this study selection, bias could arise through reliance on voluntary participant 
enrollment, where individuals with certain, potentially confounding characteristics seek 
study participation. Participants could be predisposed toward an interest in mindfulness 
practices or have historical experience with such practices that confounds study 
outcomes. These potential participant-biasing effects were controlled through pretest, 
midtest, and posttest measures administration, and through use of a control group. 
Quantitative investigational approaches may be limited in that their 
operationalization methods fail to accurately or sufficiently reflect participant 
understandings of the treatments and measures offered during the course of the study 
(Johnson & Onwuegbuzie, 2004). This issue was addressed through use of clearly 
established quantitative interventional and evaluative methods and procedures 
implemented within the experiential context of the MAT program familiar to study 
participants, thereby likely facilitating participant comprehension of and accurate 





Regression and correlation analyses must be interpreted with caution. Linear 
correlations cannot be used to determine causal relationships or the reason for them 
(Gravetter & Wallnau, 2007). Correlational evaluations are vulnerable to limitations 
posed through unintended effects of data range limitations, outliers, regression toward the 
mean, and insufficient sample size. In this study, correlations between measured pretest, 
midtest, and posttest outcomes were intended for use in asserting a causal relationship 
exists between MBRP manualized treatment effects and any observed correspondent 
reduction in illicit opioid use. 
Ethical Procedures 
Agreement for Participant and Data Access 
 This study was conducted at a MAT program site located in the California 
Bay Area. The agency that operates the MAT program at this site is BAART Programs, 
Inc. This study was implemented in accordance with specific permissions allowing MAT 
program site and patient access and use of patient data as delineated by the BAART 
Programs (See Appendix D).  All such access and use was conditional upon strict 
adherence by all study investigative personnel to regulatory standards regarding MAT 
program patient privacy and confidentiality restrictions and provisions and delineated in 
the Health Insurance Portability and Accountability Act (HIPAA; U.S. Department of 
Health and Human Services, 2003); the confidentiality regulations for drug and alcohol 
patient treatment programs (Confidentiality of Alcohol and Drug Abuse Patient Records 





Research (2008); and existing BAART Programs policy and procures pertaining to 
research conducted at a program site delineated in the BAART Programs Policy and 
Procedures Manual (2015). Individual participant data gathered during the course of this 
study was private and confidential, and was not shared with the MAT program personnel. 
Institutional Permissions 
Ethical considerations for this study included assuring advance Walden 
Institutional Review Board approval and obtaining consent of the sponsoring program’s 
senior management team and board of directors (APA, 2010). Institutional permission for 
participant and data access and usage were obtained from BAART and BayMark 
Programs (See Appendices D, H). Walden University IRB Approval was obtained and 
the approval number was 05-11-18-0067220. 
The study participants were informed of the study purpose, methods to be used, 
and data outcomes and conclusions. Participants were informed of their right to 
discontinue the study at any time and were provided needed qualifications and contact 
information for study personnel. All participants were debriefed after study intervention 
and data collection was ended. Although not anticipated, unintended effects on 
participants, including any identified adverse effects, would have been evaluated by the 
principal investigator and referrals made if indicated. All participants were to receive a 
copy of the final research report without charge. The study was conducted in accord with 
established research guidelines (NIH Office of Extramural Research, 2008) and MAT 





(Confidentiality of Alcohol and Drug Abuse Patient Records Rule, 1987; NIH Office of 
Extramural Research; U.S. Department of Health and Human Services, 2003).  
Considerations in Participant Recruitment 
Assurance of participant confidentiality and privacy is essential to protect 
participants from unauthorized disclosure, to ensure requisite trust for complete and 
accurate participant data reporting, to assure adherence to American Psychological 
Association ethical standards (APA, 2010), and to protect study personnel and the MAT 
program organization from undesirable legal consequences (Creswell, 2003; 
Confidentiality of Alcohol and Drug Abuse Patient Records Rule, 1987; U.S. Department 
of Health and Human Services, 2003). All participants in this study were recruited based 
on provision of informed consent, and all discussion pertaining to the informed consent 
process was carried out in a confidential, private setting at the MAT program site.  
Participants were provided with principal investigator contact information in order to 
facilitate timely responses to any emerging participant questions or concerns. All such 
queries were to be responded to as soon as possible, at the most within seven calendar 
days, although no adverse events were reported. 
Intervention Considerations 
To the fullest extent possible, the principal investigator assured that biases were 
not allowed to affect the study, and the research plan included fully discussing any bias-
based limitations in the research report (APA, 2010; Creswell, 2003; NIH Office of 





mindfulness-based practices and research are beneficial to participants, and have not 
resulted in any harm (Brantley, 2007; Brewer et al., 2010; Chang et al., 2004; Davidson 
et al., 2003; Farb, Anderson, and Segal, 2012; Jain et al., 2007; Kabat-Zinn, 2002; 2009; 
Modinos et al., 2010; Shapiro & Schwartz, 2000; Witkiewitz et al., 2005; Zeidan et al., 
2013). Multiple studies using the MBRP manualized treatment have been implemented 
and concluded without any observed or reported harm to participants (Bowen et. al., 
2006; Bowen et al., 2009; Bowen et al., 2011; Marlatt, 2006; Marlatt & Chawla, 2007; 
Witkiewitz et al., 2005). In their systematic review of multiple meditation studies Arias et 
al. (2006) found some case reports of practitioners participating in extended mindfulness 
retreats experiencing the onset of recurrent dissociative effects. They found other case 
reports where practitioners experienced a sense of detachment or affective flattening, or 
of increased awareness of uncomfortable personal or life situations. However, overall 
Arias et al. found that most mindfulness practice participants perceived overall benefit 
from their meditative experiences. Considered altogether, these studies suggest that the 
risk to mindfulness practice participants is minimal. Given that the MBRP group services 
were provided by the principal investigator, and that this study evaluated data collected 
concurrently from both TAU without the group and including the group, risk to study 
participants was considered minimal. In the unlikely event that an adverse condition had 
arisen from participation in this study, clinical evaluation and referral would have been 






Data Collection, Use, and Storage 
 The principal investigator was responsible for assuring privacy and security of all 
participant test documentation in accord with confidentiality and privacy rules pertaining 
to MAT programs. All documentation of participant informed consent, and study raw 
data and outcomes was stored in a private, locking file cabinet accessible only to the 
study principal investigator. All study data relevant to each participant was associated 
with a unique participant ID number assigned by the principal investigator. A data key 
was securely retained in a separate password protected computer file retained by the 
principal investigator that linked participant names to their unique ID numbers. Aside 
from this procedure, no participant names, birthdates, social security numbers, addresses, 
phone numbers, email addresses, or other information that could potentially be used by 
unauthorized persons to identify any participant was collected, stored, or used as part of 
the study implementation procedures. Study outcome data was planned to be summarized 
and made available without charge to interested study participants and to the BAART 
Programs administrative staff with oversight responsibility for the study. Study materials, 
including all testing data and outcome measures and SPSS database information were, 
and will continue to be, securely retained for a period of five years as required by Walden 








Assuring Participant Privacy and Confidentiality 
Information in the MAT program patient record is referred to as Protected Health 
Information (PHI), and conditions for collection and use of PHI are set forth in the body 
of federal rules known as the Health Insurance Portability and Accountability Act 
(HIPAA; U.S. Department of Health and Human Services, 2003). MAT program patients 
have specific rights pertaining to how their PHI is used by the program and disclosed to 
others. PHI encompasses any health record information that is under the control of the 
program, and any personal information known about the patient that could be used to 
identify the patient. Generally, MAT programs use PHI to assist them in providing 
treatment services, sharing patient information with other agencies or individuals given 
that a written consent to disclose is in effect, and for disclosure to the patient.  
PHI data is subject to the minimum disclosure necessary principle, suggesting that 
only the minimum information required for achieving the authorized disclosure may be 
communicated, and to the need to know principle, meaning that only individuals with a 
need to know in order to carry out indicated patient services are informed of PHI (U.S. 
Department of Health and Human Services, 2003; BAART Programs).  All patients must 
receive a notice about how the program will use and disclose their PHI (U.S. Department 
of Health and Human Services).  
The federal rules also provide for unique MAT program patient confidentiality 
protections under the body of rules commonly identified as 42 CFR (Confidentiality of 





programs are prohibited from disclosure of any patient information without the written 
consent of the patient, and any further or subsequent disclosure of such authorized 
information is prohibited without additional specific written consent. The 42 CFR 
delineates the specific elements required for a patient’s consent to disclose and describes 
circumstances and procedures for legal proceedings where such disclosure may be 
requested with and without patient consent. Through utilization of unique participant 
identifying numbers throughout data collection and analyses the research procedures used 
in this study did not involve collection or disclosure of any patient identifying data, and 
thus did not violate any privacy or confidentiality rules. 
The NIH Office of Extramural Research specifies a number of conditions that 
human participant research must satisfy, including protections against participant harm, 
right to participant discontinuance at any time, and assurance of informed consent 
processes for each participant (NIH Office of Extramural Research, 2008). This study 
rigorously adhered to all such NIH research requirements.    
Additional Ethical Considerations 
The principal investigator had oversight of all aspects of participant study 
involvement. The principal investigator is trained, experienced in, and responsible for 
evaluating administration of the MBRP treatment protocol (Bowen et al., 2006; Bowen et 
al., 2009; Bowen et al., 2011) to study participants during the eight-week study period.  
Upon completion of the study, participants who remained in the study for the full 





efforts. This was intended to foster consistency in study participation throughout the 
implementation period.  
Summary of Study Design and Methodology 
This was a quantitative randomized controlled single-site pilot study design using 
repeated measures of DVs and IVs. It reflected a mixed within-between subjects design 
with time as the within-subjects factor and groups as the between-subjects factor. 
MANCOVA was planned for use to statistically evaluate relationships between multiple, 
distinct IVs and  DVs over time (Cohen et al., 2003). 
The study principal investigator provided the MBRP manualized treatment 
adjunct. Study participants met individually with the principal investigator in a private 
setting at the study site for pretest, midtest, and posttest administration of the TMS to the 
experimental and control groups.  
All treatment groups participated in TAU correspondence with that of the typical 
MAT program participant, which included planned daily program attendance, daily 
administration of the medication(s) prescribed by the MAT program physician, and once 
weekly individual counseling sessions of 50 minutes duration.  
The IV for the quantitative methodology used in this study consisted of two 
adjunctive treatment levels: the first being administration of the MBRP manualized 
treatment intervention to the experimental group of MAT program participants for the 
proscribed eight-week period; and the second consisting of the control group of MAT 





Alcohol/Drugs subscale outcomes collected at pretest, midtest, and posttest intervals and 
OCS outcomes collected at pretest, midtest, and posttest intervals. 
Testing for existence of a significant experimental effect was planned through use 
of quantitative analyses of within- and between-groups effects on pretest, midtest, and 
posttest outcome scores of the ASI Alcohol/Drugs subscale (McLellan et al., 1985) and 
the OCS (McHugh et al., 2014). Comparative data evaluation using repeated measures 
MANCOVA was planned to be conducted (p < .05), although as previously mentioned 
could not be carried out due to very high participant dropout rate. 
Temporal association of MBRP manualized treatment participation with 
significant reductions in illicit opioid use would have suggested that the first null 
hypothesis was not supported and the first alternative hypothesis was supported. 
Temporal association of MBRP manualized treatment participation with significant 
reductions in illicit opioid cravings would have suggested that the second null hypothesis 
was not supported and the second alternative hypothesis was supported. No significant 
increases in mindfulness within the experimental group over time as measured by TMS 
(Lau et al., 2006) outcomes would have suggested the absence of mindfulness effects as a 
MV. In general, the presence of a significant negative (inverse) correlation between 
increased levels of mindfulness and decreased frequency of illicit opioid use and/or 
cravings would have suggested that mindful states are a factor influencing participant 





This study documentation now proceeds to Chapter 4 wherein data outcomes, 






Chapter 4: Results 
Introduction 
In  Chapter 4, data collection outcomes are reported, including a discussion of 
implementation discrepancies in the study design resulting from feasibility impediments. 
Statistical analyses considerations are offered, and implications of study implementation 
and data collection results and findings are discussed.  
Summary of Study Design and Methodology 
This study involved using a quantitative randomized controlled single-site pilot 
study design with repeated measures of dependent and independent variables. I used a 
mixed within-between subjects design with time as the within-subjects factor and groups 
as the between-subjects factor. MANCOVA was used to statistically evaluate 
relationships between multiple distinct IVs and DVs over time. 
Research regarding the effects of mindfulness-based adjunctive interventions on 
MAT program participants is severely limited, and thus far has not involved randomized 
controlled designs. The study involved using a minimal number (n=54) of group 
participants and a brief study period minimizing potential adverse effects on study 
integrity involving time and fiscal constraints.  
Research Questions and Hypotheses 
RQ1: Is exposure to MBRP manualized treatment associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 





H01: Exposure to MBRP manualized treatment is not associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Ha1: Exposure to MBRP manualized treatment is associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program. 
RQ2: Is exposure to MBRP manualized treatment associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H02: Exposure to MBRP manualized treatment is not associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Ha2: Exposure to MBRP manualized treatment is associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Study Variables 
The study involved use of a quantitative mixed within-between subjects design 
with time as the within-subjects factor and groups as the between-subjects factor. 
MANCOVA was used to evaluate relationships between DVs and IVs over time.  
The DVs in the study were participant illicit opioid use during the 8-week study 





Alcohol/Drugs subscale (McLellan et al., 1985) and participant illicit opioid craving 
severity as measured by the OCS (McHugh et al., 2014).  
The IV in the study consisted of two levels: the first being the MBRP manualized 
treatment intervention as an adjunct to TAU for the experimental group of MAT program 
participants for the requisite eight week period, and the second being TAU in the control 
group of MAT program participants for the concurrent eight week period. 
A potential MV in the study was the prestudy level of participant mindfulness as 
measured using the TMS (Lau et al., 2006). Positive significant differences between 
pretest and midtest or posttest scores would suggest that the participants’ level of 
mindfulness as measured by the TMS increased in association with MBRP exposure, 
whereas the absence of significant differences in pretest, midtest, and posttest scores 
would suggest no significant changes in terms of participant mindfulness were associated 
with engagement in MBRP treatment. A negative significant scoring difference would 
suggest that participant level of mindfulness as measured by the TMS was inversely 
associated with MBRP group exposure. Although not the focus of this study, the effects 
of this potential mediating variable were observed through TMS administration during 
the pretest, midtest, and posttests. 
RQ1 was about participant exposure to MBRP manualized treatment and 
associations with reductions in terms of percentage of illicit opioid use for individuals 





this research question by measuring DVs associated with two levels of IV throughout the 
8-week study period.  
RQ2 was about whether participant exposure to MBRP manualized treatment is 
associated with reductions in severity of illicit opioid craving for individuals concurrently 
participating in a MAT program for their opioid use disorder. I addressed this research 
question by measuring this DV associated with two levels of IV throughout the 8-week 
study period.  
Data Collection 
The study included phases for study participant enrollment, pre-treatment data 
collection, administration of the MBRP manualized treatment, posttreatment data 
collection, and participant debriefing. Participant enrollment procedures began at the 
MAT program site three weeks prior to beginning the study. Participant enrollment and 
data collection procedures were conducted by the principal investigator.  
The MBRP manualized treatment adjunct was administered to study participants 
by the principal investigator. The principal investigator provided pretest, midtest, and 
posttest administration to all participants with ASI Alcohol/Drugs subscale (McLellan et 
al., 1985), the OCS (McHugh et al., 2014), and the TMS (Lau et al., 2006). 
All treatment groups participated in TAU as typically provided to MAT program 
participants. This included daily program attendance, daily administration of the 





counseling sessions of 50 minutes duration. Exceptions to TAU participation were noted 
where they occurred. 
The IV for the quantitative methodology used in this study consisted of two 
treatment levels, the first being administration of the MBRP (Bowen et al., 2011) 
manualized treatment adjunct (in addition to TAU) as an intervention to the experimental 
group of MAT program participants for the proscribed eight-week period, and the second 
consisting of the control group of MAT program participants experiencing TAU only for 
the proscribed eight-week period.  
The DVs included the ASI Alcohol/Drugs use subscale (McLellan et al., 1985) 
outcomes collected at pretest, midtest, and posttest intervals and the OCS (McHugh et al., 
2014) outcomes collected at pretest, midtest and posttest intervals. TMS (Lau et al., 
2006) pretest, midtest, and posttest scores were also collected to monitor for any potential 
MV effects, but were not included in the study RQs and hypotheses.  
Study Implementation and Data Collection 
The study duration was planned for 14 weeks, including phases for study 
participant enrollment, pre-treatment data collection, administration of the MBRP 
manualized treatment, posttreatment data collection, and participant debriefing. 












Outline of Study Implementation at MAT Site  
________________________________________________________________________ 
 
Planned Study Phase and Description   Period of Implementation 
________________________________________________________________________ 
 
1. Study information provided to potential participants  Weeks 1 and 2(before MBRP starts) 
2. Informed consent obtained from participants  Weeks 1-3 (before MBRP starts) 
3. Pretest data collection     Weeks 3-5 (before MBRP starts) 
4. MBRP treatment provided to selected participants Weeks 6-9 (MBRP begins) 
5. Midtest data collection     Weeks 10-16 (MBRP concludes) 
6. Posttest data collection and participant debriefing Weeks 17-20 
 
 
After discussion with the MAT clinic director at the program site it was agreed 
that the most effective weekday of study implementation was Wednesday, as this day 
typically had the highest rate of MAT patient attendance. Given the full-time 
employment requirements of the principal investigator, only one day per week could be 
designated for study implementation purposes. Participant recruitment took place over a 
three consecutive week period prior to the implementation of pretest data collection. 
Study information was provided and informed consent obtained during this period. At the 
conclusion of the participant recruitment phase 52 participants were enrolled in the study. 
Random participant group assignment for both participant groups, Treatment as Usual 
(TAU only) and Experimental (TAU plus MBRP), was completed by the principal 






Pretest data collection began in week three and continued through week five. This 
phase took a week longer than planned in study design because of the time required to 
contact individual participants, many of whom no-showed for scheduled pretest 
administration appointments. At the conclusion of this study phase participant dropout 
left 16 participants available (see table four below). These and subsequent participant 
attendance influences on study participation and outcomes are discussed in in further 
detail in the forthcoming section of this chapter evaluating treatment fidelity. 
Phase four of study implementation (weeks 1-4 of MBRP group) began on week 
six of study implementation. The principal investigator administered weeks one through 
four of the MBRP manualized treatment protocol to the selected group participants 
during this period. During this phase marked inconsistency of participant group 
attendance was observed. By the conclusion of this study phase a severe frequency of 
participant dropout for the MBRP group was observed (see table four).  
Implementation of phase five of the study (weeks 5-8 of MBRP group, and 
midtest data collection for all participants) began in week ten, continuing through week 
sixteen. Midtest data collection began during the first week of this period, with all 
measures administered by the principal investigator. The fifth through eighth week of 
MBRP group administration was not completed until the fourteenth week of study 
implementation. Midtest measures were administered to MBRP group participants prior 
to group meetings to reduce potential for confounding between group participation 





The additional weeks of study implementation during phase five were required 
due to only one MBRP group participant presenting on week 13 for the final group 
session, and subsequent no-show of all group participants during week 14 of study 
implementation. Following this, during implementation week 15 the final MBRP group 
was again re-scheduled due to an unexpected staffing crisis occurring at the clinic facility 
overseen by the study principal investigator, that precluded his attendance. Thus, the final 
administration of the MBRP group intervention occurred on week 16 of study 
implementation. Inconsistent participant attendance at this final MBRP group was noted 
by the principal investigator.  
The above described factors influencing inconsistent MBRP group attendance 
during implementation of this study phase are discussed in further detail in the treatment 
fidelity section of this study description. As previously noted during the above 
description of phase four, overlap between measures administration and administration of 
the MBRP group protocol occurred to the competing needs of timely measures data 
collection for both groups and continuance of MBRP treatment group participation. 
Phase six (posttest administration and participant debriefing) began in week 17, 
continuing through week 20 of study implementation. One additional week of measures 
administration was required due to no-show of some participants in both study groups. 
Some participants were unavailable during this study period. Review and scoring of study 
measures, evaluation of study outcomes, and participant debriefings were subsequently 





of this study phase. As previously noted, factors influencing the attendance of study 
participants are discussed in further depth in the following treatment fidelity evaluation 
section. 
Participant Descriptive and Demographic Characteristics 
Study volunteer participants were randomly selected from and thus representative 
of the population of the larger group of individuals participating in MAT programs. The 
study participant characteristics include a current diagnosis of OUD (304.00) (APA, 
2013) participation in the BAART MAT program used for the study, being maintained on 
methadone medication as a treatment for OUD, and exhibiting no signs or symptoms 
contraindicating study participation. All participants were at least 18 years of age.  
 
Analysis of Fidelity in Study Implementation 
Following is an analysis of the preceding factors influencing study 
implementation and outcomes, and thereby impacting fidelity to study design. Their 
ultimate effects led to irregularity of participation in study measures administration, data 
collection, and attendance at scheduled MBRP group meetings. These observed factors 
are described and evaluated in the following discussion.  
Participant dropout and no-show were feasibility factors anticipated to some 
extent in study design. A much higher than anticipated frequency of participant dropout 
was observed throughout study implementation (see table four below). This effect can be 
seen throughout all phases of data collection, notably in the MBRP Group intervention 





in pretest phase, to three in midtest phase, and then two participants remaining in posttest 
phase, a 92% reduction (See table four). More globally, at conclusion of study data 
collection, only nine participants remained from the initial enrollment of 52, representing 
an 83% attrition rate in study participation. These marked reductions in participant 
attendance throughout the study implementation resulted in an insufficient number of 
participants remaining to meet the minimum necessary (n=60) for achieving sufficient 
statistical power. 
Table 4  
 
Participant Dropout Frequency - Both Intervention levels 
________________________________________________________________________ 
 
Study Phase              Group  # Assigned # Remaining  Freq. Difference % Difference  
________________________________________________________________________ 
 
1. Study information NA  0   52*  0             0 
2. Informed consent NA 0  52*  0             0 
3. Pre–test data MBRP 26  7         -19   -73 
collection   TAU 26  9  -17   -65 
4. MBRP treatment ** **  **  **             **  
begins 
5. Midtest data MBRP  26  3  -23   -88 
collection    TAU 26  5  -21   -80 
6. Posttest data MBRP  26  2  -24   -92 
collection  TAU 26  7  -19   -73 
Study conclusion (BOTH) 52  9  -43   -83  
 
*Total participant enrollment. **No participant dropout measured, reported, or observed during this 
phase. Source: Deidentified study participant data. 
 
During phase four (pretest) of study implementation 19 MBRP Group and 17 
TAU participants discontinued study participation (see Table 4). Attempts to contact 
participants to assess reasons for their study discontinuance, and for encouraging possible 





developing a list of participants not presenting as scheduled, and then flagging them in 
the study site computer system. This attempt to control for missed participant 
appointments proved ineffective.     
During phase five of study implementation a total of 23 MBRP Group participants 
dropped out, and a total of 21 Control group participants had dropped out. This 
represented a dropout rate of 88% of MBRP Group participants, and 80% of control 
participants. As noted during the above discussion of phase four, attempts to contact 
participants in order to assess their reasons for study discontinuance were unsuccessful. 
Thus, reasons for study participant dropout remain undetermined. 
During phase six of study implementation a total of 24 MBRP Group participants 
had dropped out, and a total of 19 Control group participants had dropped out. This 
represented a dropout rate of 92% of MBRP Group participants, and 73% of control 
participants (see table 5). As noted during the above discussion of phase five, attempts to 
contact participants in order to assess their reasons for study discontinuance were 
unsuccessful.  
Interventions to facilitate participant attendance were utilized, including 
developing a list for tracking nonadherent participants and flagging them in the study site 
computer system. These attempts to contact participants for study reengagement were 








MBRP Group Participant Attendance 
________________________________________________________________________ 
 
Week Number* No. Scheduled Attendance Freq.        % Attending Freq. Difference % Non-Attending 
________________________________________________________________________ 
 
 1 26  2   07.69  -24  92.31 
 2 26  4   15.38  -22  84.62 
 3 26  6   23.08  -18           69.23 
 4 26  2   07.69  -24  92.31 
 5 26  3   11.54  -23  88.46 
  
 6 26  3   11.54  -23  88.46 
 7 26  3   11.54  -23  88.46 
 8 26  2   07.69  -24  92.32 
  




Note. Excludes weeks where no group was conducted. Source: Deidentified study participant data. 
 
Treatment dropout from MAT programs has been frequently observed by this 
writer in his role as clinic director at two different MAT program sites over the past three 
decades, thus some study participant dropout was unsurprising, albeit not at the frequency 
encountered in this study.  
Although the severity of participant dropout was not anticipated in the study 
design, it is understandable that some dropout would occur as enrolled participants may 
not have been sufficiently motivated to initially or recurrently provide information 
regarding their opioid use, cravings, and level of mindfulness. Further, some of these 
participants may have discontinued due to being inhibited about providing sensitive 





during implementation of informed consent procedures. Assessment of these potential 
contributing causes to participant dropout from the participants’ perspective could not be 
completed due to participant unavailability. Discussion with the clinic director at the 
program site revealed there were multiple potential causes that so many participants 
dropped out. These confounding factors included participant discontinuance of the MAT 
program, participant incarceration, participant no-show on study implementation days,. 
participant transportation impediments, and participant arrival at program outside of time 
periods that study group and data collection procedures were available. 
An additional feasibility factor that may have impacted study data collection was 
the recurrent difficulty several participants had with comprehending some questions 
included in the TMS (Lau et al., 2006). Many participants reported not understanding 
TMS questions. Examples of this included participant commentary during TMS 
administration: (a) “I was curious about what I might learn about myself by taking notice 
of how I react to certain thoughts, feelings, or sensations.” (from TMS test item 3); 
 (b) “I experienced my thoughts more as events in my mind than as a necessarily accurate 
reflection of the way things really are.” (from TMS test item 4); (c) “I was receptive to 
observing unpleasant thoughts and feelings without interfering with them” (from TMS 
test item 7); (d) “I was more invested in just watching my experiences as they arose, than 
in figuring out what they could mean.” (from TMS test item 8); (e) “I was aware of my 





(f) “I was curious about what I might learn about myself by just taking notice of what my 
attention gets drawn to” (from TMS test item 13). In such instances the principal 
investigator attempted to clarify the meaning of the problematic test questions but the 
effects of these efforts on TMS scoring are unknown. This unanticipated problem likely 
interfered with accuracy of TMS scoring, thereby invalidating fidelity to data collection 
implementation of the study. 
In summary, there were multiple unanticipated feasibility confounds that 
impacted study implementation such that efficacy of data collection procedures and 
MBRP group services were invalidated by very high frequency of participant dropout, 
inconsistent participant attendance, MBRP group scheduling inconsistencies, and 
inconsistent participant comprehension of several test items included in the Toronto 
Mindfulness Survey. 
There were no adverse effects on study participants observed by or reported to the 
study principal investigator throughout all phases of study implementation. This 
discussion of study outcomes continues with reporting on the descriptive and 
demographic characteristics of the study participants.   
Study Fidelity Considerations and Impact on Results 
This writer now takes up discussion of the outcome of pretest, midtest, and 
posttest results. Throughout this discussion of study results please refer to tables that 





In comparatively evaluating the MBRP group intervention level outcomes vs. the 
Control level outcomes, data in the tables below suggests that participants in the control 
group tended to have higher severity of substance use than their counterparts in the 
MBRP Group intervention level. On average, the MBRP group participants tended to 
have 0.11 or greater positive scoring difference than those in the Control group 
throughout the study data collection period. Given the comparative elevated participant 
attrition in the MBRP group a statistically significant between-groups comparison cannot 
be made. In general, the data suggest a higher level of drug use in the Control group, but 
attributional etiology regarding this outcome must remain speculative. 
Table 6 
 
MBRP Group Intervention Level Addiction Severity Index Drug Scale Test Results 
________________________________________________________________________ 
 
Pretest Score  Midtest Score  Posttest Score 
________________________________________________________________________ 
 
0.22   0.24   0.23 
0.36   0.21   0.12 
0.20   0.25   * 
0.11   *   * 
0.29   *   * 
0.31   *   * 
0.12   *   * 
 
Average  0.23   0.23   0.18 
             
 
 
Scoring Range: 0.00 – 1.00  Higher Numbers indicate increased substance use severity 





The MBRP experimental group level within-group ASI Alcohol/Drugs subscale 
scores reflected several scoring trends (Refer to Table 6). There was no change in 
average scoring from pretest to midtest. A reduction (-0.05) in average scoring from 
midtest to posttest was observed. These scoring changes suggest a small, likely 
nonsignificant, decrease (-0.50) of MBRP participation on reported opioid use from 
pretest to posttest. There were four less administrations at midtest compared with pretest. 
There were five less administrations at posttest compared with pretest. The variance in 
test administration frequency exerted strong effects on scoring variance such that no 
statistical significance can be determined in these scoring outcomes. 
Table 7 
Control Intervention Level ASI Drug Scale Test Results 
________________________________________________________________________ 
 
  Pretest Score  Midtest Score  Posttest Score 
________________________________________________________________________ 
 
0.54   0.46   0.50 
0.42   0.38   0.46 
0.39   0.39   0.33 
  0.58   0.29   0.25 
  0.27   0.21   0.30 
0.29   *   0.48 
0.38   *   0.23 
0.08   *   *    
 0.08   *   * 
 
Average: 0.34   0.35   0.36 
 
 
Scoring Range: 0.00 – 1.00    Higher Numbers indicate increased substance use severity  *=no test data 





 The TAU control group level within-group ASI Alcohol/Drugs subscale scores 
reflected several scoring trends (Refer to Table 7). There was a slight increase (+0.01) in 
average scoring from pretest to midtest. There was a further slight increase (+0.01) in 
average scoring from midtest to posttest. These scoring changes suggest a small, likely 
nonsignificant, increase (+0.02) in reported opioid use over time from pretest to posttest. 
There were four less administrations at midtest compared with pretest. There were two 
less administrations at posttest compared with pretest. The variance in test administration 
frequency likely exerted strong effects on scoring variance such that no statistical 
significance can be determined for these scoring outcomes.  
Comparative evaluation (Refer to Tables 6 & 7) of the ASI Alcohol/Drugs 
subscale between-group outcomes suggests that participants in the TAU control group 
level tended to have higher severity of substance use than their counterparts in the MBRP 
group experimental level. On average, the MBRP group participants tended to have 0.11 
or greater positive scoring difference than those in the Control group. In general, the data 
suggest a higher level of drug use in the TAU group but this remains a speculative 
observation. The cause for these differences cannot be objectively determined at this 
time, and comparative analysis of these test results is problematic given the disparate 
rates of participant dropout between the groups, as evidenced by two MBRP group 
participants remaining at posttest data collection, as compared to seven control group 
participants. Given the comparative elevated participant attrition in the MBRP group a 







MBRP Group Intervention Level Opioid Craving Scale Test Results 
________________________________________________________________________ 
 
Pretest Score  Midtest Score  Posttest Score 
________________________________________________________________________ 
 
0   3   5 
8   9   12 
8   1   * 
4   *   * 
0   *   *  
13   *   * 
9   *   * 
 
Average: 6   4.33   8.5    
      
 
 
Scoring Range: 0 – 30 Higher Numbers indicate increased craving severity  *= no test data 
collected. Source: Deidentified study participant data. 
The MBRP experimental group level within-group OCS scores reflected several 
scoring trends (Refer to Table 8). There was a slight decrease (-1.67) in average scoring 
from pretest to midtest. There was a marked increase (+4.17) in average scoring from 
midtest to posttest. These scoring changes suggest a marked, likely significant, increase 
(+2.50) in reported opioid cravings over time from pretest to posttest. There were four 
less administrations at midtest compared with pretest. There were five less 
administrations at posttest compared with pretest. The variance in test administration 
frequency likely exerted strong effects on scoring variance such that no statistical 







Control Intervention Level OCS Test Results 
________________________________________________________________________ 
 
Pretest Score  Midtest Score  Posttest Score 
________________________________________________________________________ 
 
4   11   15 
19   15   13 
13   16   10 
0   6   0 
0   20   2 
6   *   15 
10   *   21 
0   *   * 
0   *   * 
0   *   * 
 
Average: 5.2   13.6   10.86    
         
 
Scoring Range: 0 - 30  Higher Numbers indicate increased craving severity 
Source: Deidentified study participant data. 
The TAU control group level within-group OCS scores reflected several scoring 
trends (Refer to Table 9). There was a marked increase (+8.40) in average scoring from 
pretest to midtest. There was a noted decrease (-2.74) in average scoring from midtest to 
posttest. These scoring changes suggest a strong, likely significant, increase (+5.66) in 
reported opioid cravings from pretest to posttest. There were four less administrations at 
midtest compared with pretest. There were five less administrations at posttest compared 
with pretest. The variance in test administration frequency likely exerted strong effects on 







Comparative evaluation (Refer to Tables 8 & 9) of the OCS between-group 
outcomes suggests that the TAU control group participants experienced higher levels of 
opioid craving (10.89) than participants in the MBRP experimental group (8.5). There 
were two MBRP participants remaining at posttest, and seven control group participants 
remaining at posttest. The causes for these differences cannot be objectively determined 
at this time, and comparative analysis of these test results is problematic given the 
disparate rates of participant dropout between the groups. Given the comparative elevated 
participant attrition in the MBRP group a statistically significant between-groups 
comparison cannot be made. 
Table 10 
 
MBRP Group Intervention Level TMS Results 
________________________________________________________________________ 
 
Pretest Score   Midtest Score   Posttest Score 
Curiosity Decentering Curiosity Decentering Curiosity Decentering 
________________________________________________________________________ 
   
14  14  18  14  22  14 
10  13  19  13  15  12 
17  9  9  13  *  * 
24  17  *  *  *  * 
20  10  *  *  *  * 
20  15  *  *  *  * 
14  11  *  *  *  * 
14  12  *  *  *  * 
 
16.63  12.63  15.33  13.33  18.5  13.00 (Avg.) 
          
 
Scoring Ranges: 0 – 24 (Curiosity); 0- 28 (Decentering). Higher Numbers indicate increased level of 





The MBRP experimental group level within-group TMS scores reflected several 
scoring trends (Refer to Table 10). For the Curiosity scale there was a small decrease (-
1.30) in average scoring from pretest to midtest. For the Decentering scale there was a 
very small increase (+0.07) in average scoring from pretest to midtest. For the Curiosity 
scale there was a notable increase (+3.17) in average scoring from midtest to posttest. For 
the Decentering scale there was a very small decrease (+0.33) in average scoring from 
midtest to posttest. For the Curiosity scale there was a notable increase (+1.87) in average 
scoring from pretest to posttest. For the Decentering scale there was a very small increase 
(+0.37) in average scoring from pretest to posttest. There were five less administrations at 
midtest compared with pretest and six less administrations at posttest compared with 
pretest. The variance in test administration frequency likely exerted strong effects on 















Control Intervention Level TMS Results 
________________________________________________________________________ 
 
Pretest Score   Midtest Score   Posttest Score 
Curiosity Decentering Curiosity Decentering Curiosity Decentering 
________________________________________________________________________ 
 
24  12  13  17  22  16   
20  16  11  15  17  11 
17  12  4  3  17  13 
3  4  15  14  14  11 
13  2  9  6  20  18 
18  21  *  *  11  15 
13  12  *  *  24  19 
18  17  *  *  *  * 
9  11  *  *  *  * 
 
15.00  11.89  10.40  11.00  17.86  14.71 (Avg.)  
 
 
Scoring Ranges: 0 – 24 (Curiosity); 0- 28 (Decentering). Higher = increased level of mindfulness *=no data 
collected. Source: Deidentified study participant data. 
The TAU control group level within-group TMS scores reflected several scoring 
trends (Refer to Table 11). For the Curiosity scale there was a notable decrease (-4.60) in 
average scoring from pretest to midtest. For the Decentering scale there was a very small 
decrease (-0.89) in average scoring from pretest to midtest. For the Curiosity scale there 
was a marked increase (+7.46) in average scoring from midtest to posttest. For the 
Decentering scale there was a marked increase (+4.71) in average scoring from midtest to 
posttest. For the Curiosity scale there was a notable increase (+2.86) in average scoring 
from pretest to posttest. For the Decentering scale there was a notable increase (+2.82) in 





compared with pretest, and two less administrations at posttest compared with pretest. 
The variance in test administration frequency likely exerted strong effects on scoring 
variance such that no statistical significance can be determined for these scoring 
outcomes. 
Comparative evaluation of the between-group levels average test scores for the 
TMS (Refer to Tables 10 & 11) measure outcomes suggests that whereas the MBRP 
group scored marginally higher for posttest curiosity subscale (+0.64) the TAU group 
scored somewhat higher for posttest decentering subscale (+1.71). Scoring for both group 
levels was invalidated by the lowered (and diminishing over time) number of MBRP 
Group participants. There were two MBRP group participants remaining at posttest and 
seven TAU control group participants remaining at posttest. These disparate rates of 
participant dropout between the groups limited between-groups analysis. These outcomes 
may suggest that there is a general trend for individuals predisposed toward mindfulness 
to score higher on the TMS than those that are less inclined toward mindfulness, 
regardless of MBRP Group participation. However, given the confound of MBRP patient 
dropout, which is much more severe than that of the control group, this effect could not 
be statistically evaluated. 
As a result of the impact of the multiple feasibility factors described in the 
preceding discussion, an insufficient number of participants remained in the MBRP 
Group at the conclusion of the study, thereby impeding implementation of any valid 





study design could not be carried out. The preceding data strongly suggest that in order to 
objectively determine whether MBRP group participation can reduce opioid craving and 
increase participant mindfulness further evaluative attempts must be made. Such attempts 
must address feasibility factors, in particular, patient dropout effects, and methodologies 
for ameliorating such effects. 
Temporal association of MBRP (Bowen et al., 2011) manualized treatment 
participation with significant reductions in illicit opioid craving and use would suggest 
that the first and second null hypotheses are not supported and the first and second 
alternative hypotheses are supported. Due to participant attrition no significant changes in 
mindfulness as measured by TMS (Lau et al., 2006) outcomes were observed. 
Resultantly, the presence of a significant negative (inverse) correlation between increased 
levels of mindfulness and frequency of illicit opioid use and cravings was not established 
in this study. Given these findings, study outcomes cannot suggest that changes in 
measured levels of mindfulness arising are a MV factor influencing participant illicit 
opioid use and cravings.  
Due to the feasibility confounds posed by high and progressively higher 
participant dropout, testing for existence of a significant experimental effect using 
quantitative analyses could not be accomplished through evaluation of within- and 
between-groups effects on pretest, midtest, and posttest outcomes of the ASI 
Alcohol/Drugs subscale (McLellan et al., 1985) and the OCS (McHugh et al., 2014). 





potential MV effects. Comparative data evaluation using repeated measures MANCOVA 
(p < .05) was not conducted given these experimental confounds.  
As a result of the preceding implementation problems, the first research question 
that asks if exposure to MBRP manualized treatment associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program could not be answered. Further, for the same reasons 
previously described, the second research question that asks is exposure to MBRP 
manualized treatment associated with changes in severity of illicit opioid use cravings for 
individuals with opioid use disorder concurrently participating in a MAT program could 
not be conclusively answered. 
The preceding data strongly suggest that in order to objectively determine 
whether MBRP group participation can reduce opioid craving and opioid use further 
evaluative attempts must be made. Such attempts must address feasibility factors, in 
particular, patient dropout effects, and methodologies for ameliorating such effects. This 
writer recommends that future studies consider methodologies that reduce participant 
dropout in order to foster statistically significant analyses of within and between group 
outcomes.  
Chapter 5 includes interpretations of research findings, study limitations, and 
recommendations for future research. Implications for social change are explored, and 






Chapter 5: Discussion, Recommendations, and Conclusions  
Introduction 
 The purpose of this study was to examine the relationship between participant 
exposure to MBRP manualized treatment protocol as a treatment adjunct and participant 
opioid use and cravings. All participants were diagnosed with OUD, enrolled in the MAT 
program offered at the study site, and maintained methadone medication throughout the 
course of the study. After completing the informed consent process, participants were 
randomly assigned to either the experimental group using MBRP and TAU or the control 
group using TAU only. All measures were completed by me. The MBRP group was 
provided to onsite participants by me over the course of eight weeks. 
The study design included two experimental group levels, one combining MBRP 
exposure with TAU, and the other using only TAU. The study DVs were changes in 
participant opioid use and opioid cravings as measured through pretest, midtest, and 
posttest administrations of the ASI Alcohol/Drug use subscale (McLellan et al., 1985) 
and the OCS (McHugh et al., 2014). The study involved using a quantitative mixed 
within-between subjects design with time as the within-subjects factor and groups as the 
between-subjects factor. Use of MANCOVA (p < .05) was planned to evaluate for 
significant relationships between DVs and the IV. The comparative data evaluation 
involving repeated measures MANCOVA was not conducted due to unexpected 





participant attendance at MBRP group meetings. The study research questions and 
hypotheses were as follows:  
RQ1: Is exposure to MBRP manualized treatment associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H01: Exposure to MBRP manualized treatment is not associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Ha1: Exposure to MBRP manualized treatment is associated with changes in 
frequency of illicit opioid use for individuals with opioid use disorder concurrently 
participating in a MAT program. 
RQ2: Is exposure to MBRP manualized treatment associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program? 
H02: Exposure to MBRP manualized treatment is not associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 
participating in a MAT program. 
Ha2: Exposure to MBRP manualized treatment is associated with changes in 
severity of illicit opioid use cravings for individuals with opioid use disorder concurrently 





 The research gap addressed in this study was identified via an extensive review of 
literature regarding effectiveness of MBRP manualized treatment as an intervention for 
individuals with OUD. The aforementioned research review effort yielded two studies 
that evaluated the effects of MBRP manualized treatment adjunct on individuals with 
OUD who were currently enrolled in a medication MAT program and prescribed 
methadone medication as a treatment for their condition. 
 This study represented a first effort to evaluate and increase understanding of the 
relationship, if any, between participation in MBRP manualized treatment and changes in 
opioid use cravings and using behaviors for methadone-maintained individuals 
participating in a MAT program. 
 If findings in the present study indicated the MBRP treatment adjunct was 
effective in terms of reducing participant opioid use and cravings, individuals with OUD 
would likely benefit from MBRP participation in terms of how to more effectively 
manage their opioid craving and using behaviors, thereby significantly improving their 
quality of life. 
Interpretation of Findings 
 Findings of this study include that the study design, while carefully considered, 
did not account for multiple implementation feasibility factors that served as significant 
confounds in study data collection an analysis. The largest single such factor was 
participant dropout, which by the conclusion of the study was greater than 90% of the 





such a high dropout rate provided difficult because of limited participant contact with the 
primary investigator. The high participant dropout rate resulted in such a small number of 
participants (two posttest MBRP group participants remaining) that statistical analysis of 
participant pretest, midtest, and posttest data using MANCOVA methodology could not 
be conducted with validity at significance p <= 0.05. 
Limitations of the Study 
 This study outcome evidenced the critical importance of fully anticipating 
feasibility factors potentially affecting consistency of participant retention when 
conducting a study at an opioid treatment program site. Limitations included the 
predominant confounding effect of participant dropout on study outcome. The high rate 
of participant dropout experienced in this study severely limited the ability to conduct a 
valid statistical analysis of the testing outcomes because the number of MBRP group 
participants was reduced to two at time of posttest data collection, thereby preventing 
data collection for the minimum number of participants required to complete a valid 
MANCOVA data outcome analysis. In addition, the inability to develop a valid statistical 
analysis of data resulted in being unable to offer associated analyses of theoretical 
research associated with mindfulness, opioid use, and neurobiological functioning. 
Participant Attendance Confounds  
 Participant attendance inconsistencies were repeatedly encountered throughout 
study implementation. These included: (a) no-shows, referencing nonappearance to the 





on study data collection days; (c) discontinuance of the MAT program and thus no longer 
eligible for study participation. (In these cases, the patients never returned to the program 
during the study implementation period, so it was impossible to attempt their 
reengagement in the OTP or the study); (d) incarceration and resultant nonattendance at 
the OTP; (e) hospitalization and resultant nonattendance at the MAT program; (f) transfer 
to another MAT program and thus no longer presenting for services at the study site; (g) 
encountering difficulties obtaining transportation to the MAT program; (h) instances 
where patients arrived too late to receive MAT program services or participate in study 
activities on a given day; (i) reported inability to stay for study participation as scheduled, 
despite receiving MAT program services on such days; (j) reported symptoms of a 
general medical illness that precluded such patients from staying for study activities after 
receiving their MAT medication as scheduled; (k) instances where a participant 
experienced childcare needs that precluded them from participating in study activities; (l) 
instances where participants reported an intention to return for MBRP group services 
after receiving MAT program services but did not do so for undetermined reasons; (m) 
instances of conflicting time schedule between study participation requirements and 
MAT program services, such as cases where a patient was required to participate in a 
counseling session or meet with the program physician. (In such instances, the OTP 
requirements took precedence over the study participation); and (o) instances where a 
study participant had a conflicting responsibility offsite, such as a medical, social 





 The central limitation relative to all the above situations was that the principal 
investigator could only be at the study site once weekly. This meant that study 
participants had only the once weekly opportunity to attend the scheduled study activity. 
Whereas the data collection could be rescheduled for the following week, the group 
meetings proceeded once weekly in accord with the MBRP manualized treatment 
protocol. Ideally, there would have been alternate weekdays for offering MBRP group 
services to address this contingency, but due to time constraints the principal investigator 
could only be at the study site once weekly. Therefore, for example, if a participant 
missed the MBRP group there was no opportunity to reschedule. Additionally, any of the 
above factors, singly or in combination, may have influenced participant dropout.  
Program Operational Confounds 
 Another feasibility confound involved program operational considerations, 
including but not limited to an unanticipated program dispensing nurse staffing crisis that 
interfered with MBRP group administration for one week. The effects of the resultant 
MBRP group meeting schedule change on study outcomes were not measurable but may 
nevertheless have been significant. 
 An unexpected confound arose through the occurrence of errors in flagging 
participant alerts in the MAT program computer system. Although a list for participant 
appointments was provided by the principal investigator to program administrative staff 
the morning of each study implementation day, for unknown reasons some participants 





with MBRP group session attendance. It is also possible that in some instances 
participants simply ignored the study flags and left the MAT program without completing 
their assigned study activities. The effects of this confound on overall study participation 
could not be evaluated and thus remain undetermined. 
 In addition, a potential study design confound was experienced by the principal 
investigator during administration of the TMS (Lau et al., 2006) to study participants. 
Multiple participants in both IV group levels reported a lack of understanding regarding 
some TMS test items, especially those that were more abstractly worded. These test line 
items and related participant reporting are discussed in the following:  
 TMS test item three states:  “I was curious about what I might learn about myself 
by taking notice of how I react to certain thoughts, feelings, or sensations.” (Lau et al., 
2006). For this test item, many participants reported not understanding what it meant to 
learn about themselves through noticing their reactions to the various aspects involved in 
apprehending their life experience. The principal investigator attempted to explain this 
line item through use of verbiage such as “understand yourself more fully through 
becoming aware of your emotions, thoughts, feelings, and sensations in your body.”  
 TMS test item four states: “I experienced my thoughts more as events in my mind 
than as a necessarily accurate reflection of the way things really are” (Lau et al., 2006). 
For this test item, many participants reported not understanding what it meant to 
experience their thoughts as “events in the mind.” The principal investigator attempted to 





understanding what happens around you, or might you be seeing things differently than 
what is actually occurring?” 
 TMS test item seven states: “I was receptive to observing unpleasant thoughts and 
feelings without interfering with them” (Lau et al., 2006). For this test item, many 
participants reported not understanding what it meant to “observe their unpleasant 
thoughts and feelings without interfering.” The principal investigator attempted to 
explain this line item excerpt using verbiage such as “do you think you are really 
understanding what happens around you, or might you be seeing things differently than 
what is actually occurring?” 
 TMS test item eight states: “I was more invested in just watching my experiences 
as they arose, than in figuring out what they could mean.” (Lau et al., 2006). For this test 
item, many participants reported not understanding what was meant by “watching my 
experiences as they arose.” The principal investigator attempted to explain this line item 
excerpt as “are you able to step back from an experience and just allow it to happen, 
rather than getting caught up in what it means for you?” 
 TMS test item eleven states: “I was aware of my thoughts and feelings without 
overidentifying with them” (Lau et al., 2006). For this test item, many participants 
reported not understanding what “overidentifying” with their thoughts and feelings 
meant. The principal investigator attempted to explain this line item excerpt as “getting 





rather than simply as experienced events;” e.g., discerning the difference between “I am 
angry” versus “I am experiencing some anger.” 
 TMS test item thirteen states: “I was curious about what I might learn about 
myself by just taking notice of what my attention gets drawn to” (Lau et al., 2006). For 
this test item, many participants reported not understanding what was meant by “taking 
notice of what my attention gets drawn to.” The principal investigator attempted to 
explain this line item meant to “see what stands out most strongly in a situation or 
experience.”   
As seen in the above described cases the principal investigator was left to 
determine an ad hoc explanation conveying the relevant concepts inherent in the test line 
items to the study participant, but the effects of such an interpretive process were 
impossible to measure, and thus the effects for TMS instrument scoring remain 
undetermined. There was no means of evaluating whether the alternative line item 
explanations offered by the principal investigator were sufficiently consistent with their 
meaning as delineated in the original test instrument. Further, there was no means of 
determining the efficacy of these explanatory alternatives in facilitating participant 
comprehension. At times, several such explanatory attempts using varied descriptive 
language were made in order to better facilitate participant understanding. After each 
explanatory attempt the principal investigator asked the involved participants if they felt 





whether affirmative participant responses to that query in these instances reflected an 
understanding sufficient to support valid line item responses.     
  Anecdotal participant reporting suggested that the majority of study participants 
were educated at a twelfth grade or lower level. Further, the majority of study participants 
were of African American race. These two cultural aspects may have been contributing 
factors associated with the above described difficulties reported by some participants in 
understanding the language used in some TMS line items. These considerations suggest 
the TMS measure may have been developed with limitations posed by inherent cultural 
and educational biases. Further, there may exist some inherent difficulties in participant 
understanding posed by unknown limitations associated with concurrent MAT program 
enrollment. These feasibility confounds likely interfered with accuracy of TMS scoring, 
thereby invalidating fidelity to TMS data collection and scoring procedures. They suggest 
the need for a revised mindfulness measure sensitive to various participant educational, 
cultural, and MAT setting associated needs and limitations that facilitates development of 
test line items readily and consistently understandable to participants in the MAT 
program setting. 
MBRP Group Participation Confounds 
 Group protocol adherence by participants was a feasibility confound observed by 
the principal investigator. In addition to exhibiting markedly inconsistent meeting 
attendance, most participants reported that they either misplaced their meditation practice 





unavailability of a CD player for their use. Another observed feasibility confound was 
that most participants reported that they had either lost their assigned worksheets or 
forgot to bring them to the group meeting for discussion purposes. These feasibility 
problems impaired study validity through exerting unknown but potentially significant 
effects on the efficacy of the MBRP group treatment adjunct.  Chawla et al. (2010) 
developed a fidelity measure for use in implementation of the MBRP manualized 
treatment. They created a scale that evaluates for the adherence and competence factors 
affecting MBRP treatment fidelity. Zgierska et al. (2017) identified multiple elements for 
evaluating fidelity of MBSR group treatment provided to persons with alcohol use 
disorder. Zgierska et al. found that study design best assured fidelity to the MBRP 
manualized treatment when therapists facilitating the MBRP groups were sufficiently 
trained in and had clinical experience with the MBRP treatment. Further identified 
elements supporting MBRP treatment fidelity included  participant adherence with 
weekly MBRP group attendance, assignment completion, and daily meditation practice 
(Zgierska et al.). An additional intervention reported by Zgierska at al. that enhanced 
MBRP treatment fidelity was research staff monitoring of participant adherence with the 
protocol and phoning participants who were not completing assignments, meditations, or 
group attendance as scheduled.  A final identified feasibility element was reported 







MBRP Group Participant Perspectives  
 A critical feasibility factor in this study involved participant perception regarding 
the MBRP treatment adjunct. It is likely that participants would continue for the full 
duration of study implementation if they perceived their participatory experience as 
useful or beneficial for them. In accord with the MBRP protocol administration 
participants in this study, the MBRP group participants were asked to complete a form 
provided to them by the principal investigator that asked for their views on the group 
procedures and how participation affected them. This form, entitled “Reflections on the 
Course Worksheet” (Bowen et al., 2011, p. 170) is outlined below and includes 
deidentified participant responses to the worksheet line items as collected from 
participants by the principal investigator during the final MBRP group session. There are 
three sets of participant responses despite only two group participant attendees in the 
final MBRP session. One nonattending participant turned in his responses at another 
time. The line item responses are delineated here.  
 Line item one asks “What did you find most valuable about this course? What, if 
anything, did you learn?” (Bowen et. al., 2011, p. 170). Participant responses to this line 
item included: (a) “I learned to stop, and observe in my curious mind,”; (b) “Being able 
to be in the moment. Time for self.,”; and (c) “Thinking in a more enlightened way. 
[That] others can learn about meditation.” (From deidentified study participant data). 
 Line item two asks “What, if anything, has changed for you over the past eight 





responses to this line item included: (a) “I have learned to stop and be mindful in tense 
situations, not to be reactionary.”; (b) “Being able to focus better.”; and (c) “Not too 
much, having had prior similar [meditation] experience. Have learned more about self.” 
(From deidentified study participant data). 
 Line item three asks: “Was there anything that got in the way of your learning or 
growth, or that might have improved the course for you?” (Bowen et. al., 2011, p. 170). 
Participant responses to this line item included: (a) “Negative personalities.”; (b) “No”; 
and (c) “Nothing.” (From deidentified study participant data). 
 Line item fours asks: “Other comments?” (Bowen et. al., 2011, p. 170). 
Participant responses to this line item included: (a) “I believe this is a universal group 
that can help people in all aspects of life.”; (b) “None.”; and (c) “Meeting time of group. 
Consider different time for employed [participants]. Evening? Early morning?” (From 
deidentified study participant data). 
 Line item five asks: “On a scale of 1 (not at all) to 10 (very), how important has 
this program been to you?” (Bowen et. al., 2011, p. 170). Participant responses to this 
line item included: (a) “10. It has taught me to stop, think, observe, and respond 
mindfully and calmly.”; (b) “10. Improving coping without drug use overall.”; and (c) “7. 
Gave me something that I enjoyed and liked [the] topic.” (From deidentified study 
participant data). 
 Line item six asks: “On a scale of 1 (not at all) to 10 (very), how likely are you to 





mindful stretching/yoga) after this course?” (Bowen et. al., 2011, p. 170). Participant 
responses to this line item included: (a) “9. It helps strengthen my patience.”; (b) “10. 
Will continue meditation.” And (c) “10. Most definitely.” (From deidentified study 
participant data). 
 Line item seven asks: “On a scale of 1 (not at all) to 10 (very), how likely are you 
to continue engaging in informal mindfulness practice (e.g., SOBER breathing space, 
mindful eating, walking, daily activities) after this course?” (Bowen et. al., 2011, p. 170). 
Participant responses to this line item included: (a) “10. I continually practice informal 
mindfulness daily because of this group.”; (b)  “8. [No rationale for rating provided].” 
(Sooter, 2019). And (c) “9-10. Definitely.” (From deidentified study participant data). 
 Overall, the preceding line item responses suggest that the MBRP group 
participants felt they improved their capabilities for observing their personal experience 
and responding to situations they encountered more effectively. One response to line item 
four (“Other Comments?”) regarding group meeting scheduling suggests that the 
participant saw the need for more scheduling flexibility, likely reflecting an important 
study design consideration. The scaled responses for line item five referencing 
importance of the group suggest that reporting participants valued their MBRP group 
experience highly and gained some meditative and situational coping skills through their 
group participation. The scaled responses for line item six referencing likelihood of 
engaging in continued formal mindfulness practice suggest that reporting participants 





seven referencing likelihood of engaging in continued informal meditation practice 
suggest that reporting participants were highly likely to continue informal meditation. 
Taken together, the responses suggest a generally favorable participant perspective 
toward the MBRP group experience, despite the fact that none of the respondents were 
able to attend every group as scheduled. An important limitation is that despite the 
predominantly positive nature of these responses, they do not represent statistically 
significant findings.   
 Further feasibility factors for this study relevant to participant group attendance 
likely included the knowledge base, facilitative skill, and therapeutic effectiveness 
demonstrated by principal investigator in his role as group facilitator. A broad knowledge 
of mindfulness related concepts including methods of formal and informal meditation 
practice was essential for  effective implementation of the MBRP group manualized 
treatment. Facilitator knowledge of cognitive behavioral therapy and its related 
therapeutic skills were also necessary, as the MBRP group protocol includes elements of 
mindfulness-based meditative practice integrated with CBT based participant exercises 
(Bowen et al., 2011). Facilitative practices deemed essential for this group process must 
include group process informed by evidence-based theory and extensive clinical practice 
(CSAT, 2005). The facilitator must be able to effectively welcome, establish rapport 
with, and sustain therapeutic alliances with the individuals in the group in order to 





 The principal investigator for this study had some 31 years of prior experience in 
provision of clinical services to individuals with Opioid Use Disorder (American 
Psychiatric Association, 2013), including individual and group counseling for patients 
enrolled in the MAT program as well as clinical supervision of program staff. In addition, 
the principal investigator completed a Master’s degree in Psychology along with multiple 
years of participation in the Walden University Clinical Psychology doctoral program. 
Further, the principal investigator completed over 1500 hours of supervised clinical 
practice, providing treatment to patients with substance use, psychiatric, and co-occurring 
disorders. The principal investigator also provided multiple administrations of the MPRP 
manualized treatment to individuals in residential treatment for substance use disorders. 
Finally, the study principal investigator has been a practitioner of mindfulness meditation 
for some 20 years. Taken together, this constellation of clinical and personal experience 
suggests the clinical investigator was well qualified to facilitate the study MBRP group. 
This further suggests that ineffective MBRP group facilitation was likely not a feasibility 
factor adversely affecting implementation of this study.  
MBRP Manualized Treatment Fidelity Considerations 
 As facilitator, the principal investigator was responsible for assuring fidelity to the 
clinical interventions and processes delineated in the MBRP group manual (Bowen et al., 
2011). Given his extensive clinical experience as described above, including that specific 
to facilitation of MBRP group services, it is likely that the MBRP group meetings were 





one exception was the previously described one-week interruption in study 
implementation caused by a temporary nursing staff shortage in the MAT program 
directed by the principal investigator. The resultant adverse feasibility effects on MBRP 
group facilitation were not assessed but may have been significant. Bassett et al. (2016) 
described treatment fidelity as the level of consistency between the intervention provided 
and that specified in the treatment protocol. Clearly, the unanticipated interruption to the 
weekly MBRP group schedule was inconsistent with study design and implementation, 
and resulted in fidelity adherence liabilities that likely impaired effectiveness of the 
MBRP manualized treatment used in this study. Utilizing suitably trained and 
experienced research staff for MBRP group facilitation would likely assure improved 
fidelity with the MBRP manualized treatment in future studies. 
Measures Administration Considerations 
 An additional consideration in study implementation was the effectiveness of the 
principal investigator in administering the measures utilized in the study. These measures 
were the ASI Alcohol/Drugs subscale (McLellan et al., 1985), the OCS (McHugh et al., 
2014) and the TMS (Lau et al., 2006). The principal investigator cultivated a knowledge 
base reflecting the research outcomes and administration recommendations for these 
instruments. Additionally, the principal investigator had several years of experience in 
administering, scoring, and interpreting multiple psychological tests. Given the above, it 






Participant Logistical Considerations 
 A significant factor impeding consistent group attendance was likely that reported 
by one participant in their response to line item four requesting additional comments, 
where the participant observed that group meeting time may have conflicted with 
participant employment schedules. Although not specifically mentioned in the participant 
responses, the recurrent temporal association between no-shows for study group and 
measures administration appointments and competing participant schedule requirements, 
such as medical, legal, childcare, educational, transportation, and other social needs 
suggests these appointments frequently interfered with participant attendance for study 
activities. The most immediate approach to address these conflicting scheduling needs 
would be to offer several groups each week at times participants are most likely to be 
available for group attendance.  The frequency of favorable participant responses to the 
worksheet line items suggests that overall the MBRP group was a positive experience for 
participants, and that the group requirements and procedures as implemented were not a 
negative factor. It nevertheless remains possible that the responding participants did not 
fully or accurately convey elements of the group experience that other participants who 
dropped out may have regarded as reasons for their discontinuance. This again suggests 
the need to rule out the known scheduling conflicts in order to better evaluate for possible 
unknown confounding factors impeding MBRP group attendance. 
 Other studies evaluating the effects of mindfulness on substance use and relapse 





their study evaluating the effects of MBRP group participation on substance use Zgierska 
et al. (2008) noted that out of 19 participants four dropped out prior to completing the 
study. They further noted that out of the remaining 15 participants 89% completed the 
full eight weeks of the MBRP group protocol. 
 In their study of low-income women with substance use disorders in concurrent 
substance use treatment Amaro et al. (2014) observed that 36% of the participants 
completed the MBRP group protocol. They attributed the dropout rate to multiple factors 
including participant relocation, relapse and subsequent treatment program 
discontinuance, and participant nonavailability due to conflicting schedules with legal, 
social services, and medical appointments. 
 Bowen et al. (2009) conducted a pilot study evaluating MBRP effectiveness for 
individuals with multiple substance use disorders. They reported that 65% of study 
participants (n=168) completed all of the MBRP groups sessions, and that 57% 
completed a two-month follow-up while 73% completed a four-month follow-up. They 
noted that 86% of study participants remaining after completion of the MBRP group 
protocol reported continued engagement in mindfulness meditation practices.  
 In his study of a mindfulness-based treatment adapted from MBSR and used to 
treat incarcerated youth with substance use disorders, Himelstein (2011) reported an 80% 
completion rate for study participants (n=60). He observed that the participants not 
completing the study had been transferred out of the incarceration facility and were thus 





Bowen et al. (2017) identified low participant attendance and retention as adverse 
feasibility factors in their study examining effects of the MBRP manualized treatment 
with MAT program patients maintained on methadone. Out of 15 initial participants, 
seven participants completed the study, a dropout rate of 53%. Bowen et al. asserted the 
need for further research that might identify ameliorative strategies for these participatory 
impediments including examination of factors affecting participant motivation and 
otherwise interfering with participant retention.  
In their study evaluating MBRP effectiveness for incarcerated persons with 
substance use disorders Lyons et al. (2019) reported that out of 189 initial participants 
126 completed the study, representing a dropout rate of 34%. While considerably less 
dropout than experienced in the present study, an important distinction in this comparison 
is that due to their incarcerated status the Lyons et al. study participants could be more 
readily accessed and follow-up measures more readily implemented to better support 
MBRP group attendance and overall study participant retention. These findings 
demonstrate commonality with the participant dropout experienced in this study, and 
point to the need for development of design counterstrategies that could reduce this 
confound. Such efforts might include logistical support, including establishing 
transportation support and adaptive scheduling of study MBRP group appointments to 
reduce potential conflicts with participant existential needs. 
 Taken together, the studies discussed above suggest the finding of various 





feasibility concern evidenced in most studies was participant dropout, with relocation of 
participants posing another observed confound. These studies, however, did not 
experience feasibility problems, primarily dropout, of such severity that requisite 
implementation requirements and statistical analyses could not be completed. Thus, 
generalizability of study outcomes could not be determined. This suggests the need for 
further studies examining participant dropout factors and study design methodologies that 
may effectively reduce them. 
Recommendations 
Strategies to Improve Feasibility 
 The preceding discussion of study design and implementation feasibility problems 
suggests the need for consideration of strategies that may effectively reduce or eliminate 
them. As previously mentioned, one limitation that impeded implementation of this study 
was that the entire study was overseen and implemented solely by the primary 
investigator. This meant that there were no additional resources available for participant 
pretest, midtest, and posttest data collection, or for facilitating the MBRP group. The 
principal investigator, due to having full-time job responsibilities elsewhere, could only 
be present at the study site once each week, and had no available qualified personnel 
having the requisite knowledge, experience, and skill set for administration of measures 
used in the study or MBRP group facilitation. 
 This availability limitation resulted in the inability of the principal investigator to 





days and times that might have resulted in improved participant group attendance and 
participant study retention, especially in cases where participants no-showed. A viable 
solution for addressing participant no-shows and scheduling conflicts would be to assure 
that a suitable number of research staff persons is recruited and trained for data collection 
and MBRP group facilitation under the supervision of the principal investigator. This 
substantial research staff could then offer study data collection and MBRP group 
facilitation on differing weekdays and times to best assure participant attendance. 
 Financial resources sufficient for compensating needed research personnel might 
be necessary. As an alternative, research personnel could be recruited from qualified 
college and university students who would likely be willing to engage in study 
implementation for the learning experience alone, rather than requiring financial 
compensation. This student recruitment strategy was utilized to good effect in several 
studies referenced earlier that evidenced significantly higher participant retention and 
MBRP group attendance rates (Amaro et al., 2014; Bowen et al., 2009: Bowen et al., 
2017; Himelstein, 2011; & Zgierska et al., 2008) then that experienced during the course 
of this study. Given the above distinctions in participant retention between this study and 
the others, it is likely that availability of more research personnel is essential for effective 
study implementation and should be an included element in study design. 
 An additional feasibility confound encountered in this study involved the 
previously discussed difficulty participants reported in understanding several of the TMS 





investigator in this study was likely ineffective as it introduced several potential line item 
administration validity confounds in addition to potential inconsistencies in and 
inaccuracy of participant responses. Further, the effects of these confounds could not be 
measured, and remain unknown.  
 To prevent further similar validity concerns for measures evaluating aspects of 
participant mindfulness an alternative evaluative measure should be considered. One such 
instrument is the FFMQ (Baer et al., 2008) utilized in the Bowen et al. (2009) study. The 
FFMQ measure includes 39 line items wherein respondents use Likert scale response 
ratings that assess for the presence of five factors thought to be representative of various 
aspects of mindfulness: observing; describing; acting with awareness; nonjudging of 
inner experience; and nonreactivity to inner experience (Baer et al., 2008). Alpha 
coefficients for the five factors of FFMQ range from .67 to .92, suggesting good internal 
consistency (Baer et al.). Bowen et al. (2008) reported no difficulties in participant 
understanding and successful completion of the FFMQ. These considerations suggest the 
FFMQ would likely be an effective alternative measure of participant mindfulness in 
studies with design similar to this one. 
 Inconsistent participant attendance was a feasibility factor that adversely affected 
outcomes of this study in both the TAU and MBRP IV levels. It was likely strongly 
associated with the marked participant dropout observed during study implementation. In 
most situations where a study participant no-showed she or he also no-showed for the 





services prior to their study implementation activities, and left the study site without 
participating as scheduled. The no-show behavior common to both situations reduced 
participant engagement with the study, a problem exacerbated by further no-shows with 
resultant additional loss of study engagement. Further, in such instances the affected 
MBRP group participants were unable to participate and thereby benefit from the group 
processes, which likely fostered a correspondent reduction in perceived benefits from 
group participation that would further reinforce the no-show behavior. In addition, no-
shows for the MAT program services tended to destabilize the patient in treatment, 
thereby further reducing the likelihood of study participation.  
    Molfenter (2013) described several methods found to more effectively address 
patient no-shows in MAT programs. These included providing appointment reminder 
phone calls, creating a welcoming program environment through inclusion of behaviors 
such as offering warm patient greetings from program staff, reducing wait times for 
receiving program treatment services, utilizing contingency management interventions 
and motivational interviewing practices, and creating more supportive relationships with 
outside persons and agencies, such as social and legal services. Bowen et al. (2017) 
reported similar findings reflecting the effectiveness of study staff engagement with 
MAT program staff. Molfenter further found that the most effective of these strategies 
was assuring a reduction in wait times for program services. The correspondence between 
MAT program no-shows and participant no-shows observed in this study suggests that 





will likely reduce the frequency of participant no-shows for MBRP group meetings and 
study measures administration appointments.  
 Additional procedures for reducing participant no-shows could include assuring 
frequent and consistent communication between study research staff and MAT program 
staff that would facilitate effective participant attendance monitoring and supportive 
intervention where indicated. MAT program counselor staff should be informed of the 
requirements for study participation so that they can assist in scheduling MAT program 
and outside agency appointments such that they do not conflict with scheduled study 
participant appointments. MAT program counselors could further facilitate participant 
attendance by assisting them in addressing any relevant situational factors that increase 
likelihood of no-shows, such as finding consistent and adequate transportation and 
childcare, where applicable.  
 The effectiveness of the $ 25.00 gift card as participant compensation for study 
completion was not evaluated during study implementation. Only three participants 
completed the study, and none assigned to the MBRP group attended all eight meetings. 
Parkinson, Meacock, Sutton, Fichera, Mills, Shorter, Treweek, Harman, Brown, Gillies, 
and Bower (2019) identified three elements of incentive rewards: reimbursement for 
participant expenses, reimbursement for participant time spent in study activities, and 
additional incentive rewards for study participation and completion as required; the latter 
being the reward strategy used in this study. Parkinson et al. (2019) found that providing 





than providing incentives at designated times throughout study implementation. 
Parkinson et al. (2019) further found that incentives were significantly more effective at 
motivating participation when structured in manner reflective of the context in which the 
study occurs, such as assuring the reward is sufficient to be meaningful to the 
participants. These findings suggest that rewards could be more effective in facilitating 
participant adherence if offered periodically throughout the study and tied to completion 
of interim study phases, e.g., pretest, midtest, and posttest in the case of this study. The 
value of incentive awards should be carefully considered to assure participants will find 
their awards sufficient given the time spent in study activities, and such compensation 
should be weighed relative to assessed participant valuing of the reward amount.    
 In summary, the preceding study design and implementation discussion suggests 
that having a sufficient number of well-trained research staff available at the study site is 
essential. Additionally, use of a mindfulness measure that is culturally sensitive toward 
and readily understandable by all study participants will increase validity in this 
evaluative area. Efforts by MAT program staff to more effectively engage and retain 
patients and provide more efficient services will likely foster correspondent 
improvements in participant attendance for study activities implementation. MAT 
program counselor support in resolving study participant problems that contribute to no-
shows, such as finding consistent transportation and childcare where needed, should be 





at suitable intervals over the duration of study implementation, with care taken to assure 
such compensation is sufficient to meet participant valuing of the reward amount.  
Additional Recommendations for Future Research 
 This writer suggests that focus for future research include full consideration of 
study design elements that may be adversely impacted by the feasibility confounds 
experienced during implementation of this study. Participant no-show for MAT program 
services was not evaluated  in this study although no-shows appeared to exert a strong 
adverse effect on study participation, in that participants who no-showed for MAT 
program services also no-showed for study activities scheduled for that day. Future study 
designs should consider inclusion of collaborative MAT program and research staff 
strategies that will likely reduce participant no-shows. These would include reducing wait 
times for receiving MAT program treatment services, facilitating collaboration between 
MAT program staff and research staff in scheduling and supporting participant study-
related appointments, providing participant appointment reminder phone calls, assuring a 
welcoming program environment, and fostering supportive relationships with outside 
persons and agencies.  
 Other effects of participant no-shows that should be considered in future study 
designs include associated increase of participant opioid craving onset and resultant 
increased relapse potential, which could destabilize the participant in MAT and 
resultantly impede consistency of study participation. Future studies may need to include 





program attendance problems, severity of substance use relapse potential, and further 
include ameliorative strategies to minimize the frequency of these potential 
implementation confounds.   
 A further important consideration in future study design is contingency planning 
for possible MAT program operational concerns that may arise and interfere with study 
implementation. Effective collaboration with MAT program administrative staff is 
essential to study implementation, and should be included as a component of study 
design.  
 Future studies should include measures that readily understandable by study 
participants to assure fidelity of measures administration. An example of such a measure 
could be the FFMQ (Baer et al., 2003) used to measure elements of participant 
mindfulness.  
 Multiple weekly MBRP group meeting times should be utilized to assure 
consistent participant attendance. Additionally, alternate media should be considered for 
distribution of guided mindfulness mediations to participants. At present CDs are used 
less frequently than other media options such as portable computer memory devices, e.g., 
USB (universal serial bus) drives, cell phones, and computer programs that are available 
on the internet. Having MBRP group worksheet assignments and meditation exercises 
distributed via these more modern communication options would likely facilitate more 
consistent participant adherence to these required elements essential to assuring fidelity 





relapse prevention adherence and competence scale developed by Chawla et al. (2010) 
would likely assure more effective monitoring and evaluation for fidelity during 
implementation of the MBRP manualized group treatment.    
 Alternate participant incentive strategies could be considered in order to reduce 
participant no-shows and foster more consistency in participant attendance at scheduled 
study group meetings and measures administration activities. In their literature review 
Stizer and Petry (2006) found that contingency management practices are effective in 
improving patient attendance for medication and therapy sessions in MAT program 
settings. Parkinsen el al. (2019) asserted that monetary incentives are more effective than 
their alternatives, although some findiings suggest that they can in some cases reduce 
intrinsic motivation for participants. Parkinsen at al. observed that timing of incentives is 
critical, that payouts should be temporally associated with completion of key study tasks 
assigned to participants. Further, they recommended parsing out incentive payouts over 
the duration of the study implementation to better sustain participant motivation. 
Considered together, these findings suggest that future studies should utilize incentive 
compensation over time as important participant requirements are met to enhance 
participant motivation, engagement, and retention. Such a strategy would likely more 
effectively support  consistent rates of participant MPRP group attendance and 
attendance for pretest, midtest, and posttest data collection.  
 An additional study approach could include use of a design similar to this one but 





initial participant enrollment and likely sufficient retention of enough participants to 
achieve sufficient power for statistical analysis. Outcomes of the two sites could be 
compared using MANCOVA analysis to determine if significant,  distinct effects are 
found between the two sites. This approach would likely reduce extant confounds arising 
from unique factors affecting study implementation at only one site. The two sites might 
exhibit distinct prevalence of participant demographic, social, medical, or psychiatric 
conditions that facilitate broader generalization characteristics with the total population of 
individuals with opioid use disorder.  
 Qualitative study design approaches may be considered for future studies. Use of 
both structured and unstructured data gathering using naturalistic observation and 
participant interviews (Berkwits & Inui, 1998) would foster awareness of feasibility 
considerations that could then support subsequent quantitative study design better 
structured to avoid those identified feasibility confounds. For example, participant data 
could identify factors interfering with participant attendance gathered through direct 
observation and interview techniques that when categorized result in study design that 
minimizes potential for such quantitative study implementation barriers to occur. 
Additionally, MAT program patient interviews might reveal useful information through 
soliciting patient observations regarding elements of study implementation that would be 
useful for future study design approaches, such as pragmatic factors that influence 





 Future research could consider evaluation of alternative manualized treatment 
approaches. It may be that alternative measures of participant mindfulness such as the 
FFMQ; (Baer et al., 2003) could be utilized to rule out the understandability problems 
encountered with use of the TMS (Lau et al., 2006) measure in this study. Additionally, 
multiple measures of mindfulness could be used to evaluate for differences between the 
TMS and FFMQ outcomes, for example. The OCS (McHugh et al., 2014) measure used 
in this study was readily understood by participants, as was the ASI Alcohol/Drugs 
subscale (McLellan et al., 1985), so it may be that these measures could be retained for 
use in future studies.  
 Future research may need to evaluate for the impact of the covid disease 2019  
(COVID19) epidemic on frequency and severity of OUD-associated relapse and 
overdose. In their study evaluating changes in medical services and treatment outcomes 
for Veterans Administration patients with OUD, Abdel-Sattar et al. (2021) found that the 
availability of OUD treatment services for veterans was adversely impacted due to 
reductions in treatment facility staffing and hours of operation. Abdel-Sattar et al. noted 
that VA patients with OUD reported a 25% increase in relapse rates, a 45% increase in 
overdose rates, and 45% increase in emergency room visits during the study period. 
Abdel-Sattar et al. further noted that multiple patients surveyed expressed a need for 
OUD treatment medication dosage increases and greater availability of psychological and 





 Haley and Saitz (2020) found there were significant increases in opioid misuse 
overdoses and deaths during 2019, primarily associated with illegal fentanyl use and the 
combined use of opioids and methamphetamine during the year period. However, Haley 
and Saitz further found the need for additional studies to confirm these findings. The 
Centers for Disease Control (CDC; 2020) reported an increase from prior years to 81,000 
drug overdose deaths for the period from June 2019 through May 2020, with reports from 
multiple areas across the US revealing a 50% to 98% increase in opioid use related 
deaths, depending on the reporting area, the western area of the US showing the highest 
frequency of opioid deaths. The CDC further found that the synthetic opioid fentanyl was 
the drug most frequently associated with opioid overdose deaths, increasing by more than 
38% over the reporting year ending May 2020.  
 Given the continued presence of the COVID19 epidemic, these findings argue for 
effective treatment solutions that incorporate the additional factors individuals with OUD 
encounter when isolated and experiencing concomitant conditions such as depression, 
anxiety, and trauma associated with the loss of significant others. 
Implications 
Potential Impact for Positive Social Change  
The prevalence of OUD and its associated adverse public health problems, 
including overdose deaths, impaired physical and mental health, impairments to social 
functioning, and societal costs associated with these conditions has been clearly 





from an opioid overdose during the period from 1999 to 2000. The CDC described the 
opioid use epidemic as occurring in three waves. The first wave began with a marked 
increase in opioid prescriptions during the decade beginning in 1990 (CDC). The second 
wave ensued in the year 2010 and was characterized by a significant increase in heroin 
overdose deaths (CDC). The third wave started in the year 2013, continuing to the 
present, and has been characterized by a marked shift to and predominance of synthetic 
opioid deaths (CDC). This more recent trend has worsened in association with the 
COVID19 pandemic, as noted in the CDC (2020) report describing a 38.4% increase in 
opioid overdose deaths for the year period ending in May, 2020. These trends strongly 
suggest that opioid misuse in the U.S. is a severe, pervasive, and worsening problem of 
epidemic proportions.   
 There are multiple socioeconomic costs associated with the opioid 
epidemic. Florence et al. (2021) observed that the aggregate economic costs of opioid use 
in the U.S for the year 2017 were estimated at $1,021 billion dollars, comprised of $471 
billion dollars associated with opioid use disorder costs, and $550 billion dollars for 
opioid overdose. These costs reflect healthcare including hospitalizations and emergency 
room care, opioid use treatment, criminal justice involvement, lost work productivity, and 
reduced quality of life for the individuals experiencing OUD (APA, 2013). Persons with 
OUD experience the preceding costs at an immediate level, experiencing substantial harm 





Although MAT programs offer evidence-based, effective treatment for 
individuals with OUD, relapse remains a significant risk. These severe and pervasive 
problems argue for more extensive research regarding treatments, such as MBRP, that 
may increase effectiveness of methadone-maintained MAT program patients. Research 
evaluating such potential interventions may ultimately result in establishing clinically 
effective treatment options that integrate with existing opioid use disorder treatments, 
enhancing the effectiveness of existing opioid use disorder treatment and thereby 
reducing the public health, behavioral, social, and legal problems as well as the severe 
human suffering concomitant with illicit opioid relapse.  
This research supported positive social change through attempted evaluation of 
the MBRP (Bowen et al., 2011) manualized treatment used as a treatment adjunct that 
can be provided at the MAT program site, with minimal impact on existing MAT 
program operations and staffing. The multiple feasibility problems encountered during 
study implementation determined information about study feasibility confounds that will 
support future research through providing enhanced understanding of study feasibility 
problems to be considered when developing future similar study designs. 
Conclusion 
 This study represented an attempt to evaluate effectiveness of participant 
exposure to MBRP manualized treatment (Bowen et al., 2011) used as an adjunct to 
treatment as usual provided in the context of a MAT program setting. Participants were 





or treatment as usual. The ASI Drug/Alcohol subscale (McLellan et al., 1985), OCS 
McHugh et al., 2014), and TMS (Lau et al., 2006) measures were administered at pretest, 
midtest, and posttest intervals to provide data planned for within and between groups 
MANCOVA analysis. Participant retention and inconsistent MBRP group attendance 
proved to be severely limiting study implementation feasibility factors such that reliable, 
consistent data could not be collected to achieve a valid statistical analysis of study data 
outcomes. Several suggestions for future research that may more effectively address 
feasibility confounds encountered in this study have been offered for consideration. 
 The increasingly severe opioid use epidemic observed in the United States over 
the past decade strongly suggests that future studies evaluating effectiveness of 
adjunctive treatment interventions such as MBRP for individuals with opioid use disorder 
concurrently enrolled in a MAT program are essential. It is critical that treatment 
effectiveness for persons with OUD is enhanced through research that leads to additional 
evidence-based treatments and interventions that will more effectively address the social 
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Week one, consisting of participant orientation to the course requirements (Bowen et 
al., 2011): 
• review of the nature of mindfulness; 
• overview of course structure and approach; 
• clarification of privacy and confidentiality requirements; 
• mindfulness exercise focused on eating a single raisin (similar to that used in 
MBSR); 
• the body scan mindfulness exercise (also similar to that used in MBSR), and 
• psychoeducation regarding association between automatized responding and 
relapse.  
Week two, focused on substance use triggers identification and observation of 
associated phenomena (Bowen et al., 2011): 
• review and discussion of challenges encountered during mindfulness 
meditation sessions and how to cope with them; 
• the nature of aversion, craving and desire, restlessness and agitation, 





• guided exercises including body scan meditation; urge surfing meditation (see 
description below) for addressing substance use cravings; and mountain 
meditation for affective calming; 
• homework assignment involving daily formal and informal meditation 
exercises; 
• completion of CBT worksheet focused on substance use trigger identification 
and indicating associated responses; 
• completion of daily meditation tracking sheet; and 
• brief closing meditation on silence. 
Week three, focused on cultivating a mindful approach to daily living (Bowen et al., 
2011): 
• participant check-in; 
• review of past week’s assignments; 
• guided exercises including awareness of hearing meditation, breath 
meditation, and SOBER breathing space meditation (see description below); 
• review of meditation exercise and practice tracking homework assignments; 
and 
• brief closing meditation on silence. 
Week  four, focused on use of mindfulness to cope with substance use and associated 
risk behaviors (Bowen et al., 2011): 





• review and discussion of prior week’s homework assignments; 
• guided exercises including awareness of seeing meditation, sitting meditation 
on sound, breath, sensation, and thought, and walking meditation; 
• group discussion of relapse risks; 
• use of SOBER breathing space mediation in an elevated risk situation; review 
of homework assignments; and 
• brief closing meditation on silence. 
Week five, focused on balancing acceptance and effective behavioral responding 
(Bowen et al., 2011): 
• participant check-in; 
• review and discussion of prior week’s homework assignments; 
• guided exercises including sitting meditation on sound, breath, sensation, 
thought, and emotion, SOBER breathing space meditation with paired 
participants, and mindful movement meditation exercise; 
• group discussion about use of the SOBER breathing space; 
• review of homework assignments; and 
• brief closing meditation on silence. 
Week six, focused on understanding the nature of thoughts (Bowen et al., 2011): 
• participant check-in; 





• guided exercises including sitting meditation on thoughts and SOBER 
breathing space meditation; 
• group discussion on observing and labeling thoughts; 
• group discussion on association between maladaptive thoughts and substance 
use relapse; 
• psychoeducation and group discussion on the relapse cycle, including 
elements of adaptive mindful responding to substance use triggers and 
maladaptive automatized responding; 
• review of homework assignments; 
• discussion and preparation for end of the course; and 
• brief closing meditation on silence. 
Week seven: focused on establishing and assuring continued well-being (Bowen et 
al., 2011): 
• participant check-in; 
• review and discussion of prior week’s homework assignments; 
• guided exercises including meditation on compassion and SOBER breathing 
space meditation; 
• exercise on creating a daily activities worksheet that compares and contrasts 
practitioner affective experience associated with positive and negative 
situations; 





• exercise on creating individualized relapse prevention strategy reminder cards 
for practitioners to carry with them; 
• review of homework assignments; and 
• brief closing meditation on silence. 
Week eight: focused on developing and maintaining support systems for continued 
mindfulness practice and sustaining recovery from substance use (Bowen et al., 2011): 
• participant check-in; 
• review and discussion of prior week’s homework assignments; 
• guided exercises including body scan meditation and concluding meditation; 
• group discussion of the need for support networks; discussion of participant 
perspectives on the course experience; 
• discussion of participant intentions for continuing mindfulness and recovery 
work; 
• closing circle exercise; and 
















You are invited to take part in a research study for the doctoral dissertation 
of Stephen Sooter, MS, from Walden University that is evaluating the effects 
of Mindfulness Based Relapse Prevention (MBRP) on illicit opioid use for 
patients participating in this Medication Assistant Treatment (MAT) 
program. This study will be used to find out if MBRP participation can help 
MAT patients prevent or reduce relapse to illicit opioid use.  
 
If you participate you will be randomly assigned to either a treatment as 
usual (TAU) study group or to an experimental study group which includes 
TAU and the Mindfulness Based Relapse Prevention (MBRP) weekly group 
meetings offered here at the program. If participating, you will be asked to 
provide answers to two brief surveys at the beginning of the study, in the 
middle, and at the end, and to consent to disclosure of other program 
information including your drug use during the study period and your 
MBRP session attendance. If you satisfactorily complete the 8-week study 
you will be eligible for a $ 25.00 gift card. You may discontinue the study at 
any time without penalty, and your MAT program status will not be affected 
in any way by discontinuing the study.   
 
Your information will be assigned to a random number. No names or other 
private identifying information will be used without your written permission. 







The study is planned to start on Wednesday, August 21, 2016. Please contact 
Stephen Sooter, the principal investigator for the study if you are interested 
in finding out more about this study.  





Appendix C: Informed Consent Form 
INFORMED CONSENT 
 
You are invited to take part in a research study that is evaluating the effects of 
participation in Mindfulness Based Relapse Prevention (MBRP) on illicit opioid use for 
patients participating in this Medication Assistant Treatment (MAT) program. The MBRP 
is designed to find out if mindfulness meditation and other therapeutic practices can 
help persons with opioid use disorders prevent relapse to illicit opioid use.  
 
The researcher is inviting persons who are currently enrolled in MAT program treatment 
using methadone medication to be in the study. This form is part of a process called 
“informed consent” to allow you to understand this study before deciding whether to 
take part. 
 
This study is being conducted by a researcher named Stephen Sooter, who is a doctoral 
student in the clinical psychology program at Walden University. The MBRP group 
facilitation is being offered at the BAART MAT program site and is being conducted by 
the study principal investigator. 
 
Background Information: 
The purpose of this study is to evaluate the effectiveness of the MBRP treatment in 
reducing illicit opioid use for MAT program patients. 
 
Procedures: 
If you agree to be in this study, you will be asked to:  
 
• participate in your MAT program dosing and counseling services  as you 
normally do; 
• Meet individually with the principal investigator to take a short test called 
the Addiction Severity Index Drug/Alcohol Scale at the beginning, middle, 
and end of the study; 
• Meet individually with the principal investigator to take two very short tests 
(15 questions or less) about mindfulness: once at the beginning and again at 
the end of the study; and 
• if you are in the study experimental group: 





b. complete weekly homework assignments that are related to the group 
process, which require very little time and are easy to do; 
c. bring completed homework assignments to the weekly group meetings; 
and 
d. practice guided meditation exercises on your own for a few minutes each 
day; you are provided a CD of the exercises for this purpose, which you 
can keep after the study ends.  
Here are some sample test questions: 
 
Below is a collection of statements about your everyday experience. Using the 1–6 scale 
below, please indicate how frequently or infrequently you currently have each 
experience. Please answer according to what really reflects your experience rather than 
what you think your experience should be. 
 
1 2 3 4 5 6 
Almost 
always 








1. _____It seems I am “running on automatic” without much awareness of what I’m doing. 
2. _____I rush through activities without being really attentive to them.  
3. _____I get so focused on the goal I want to achieve that I lose touch with what I am doing right now 
to get there. 
4. _____I do jobs or tasks automatically, without being aware of what I’m doing.  
5. _____I find myself listening to someone with one ear, doing something else at the same time. 
6. _____I drive places on “automatic pilot” and then wonder why I went there.  
7. _____I find myself preoccupied with the future or the past.  
8. _____I find myself doing things without paying attention.  
9. _____I snack without being aware that I’m eating. 
 
Voluntary Nature of the Study: 
This study is voluntary. Everyone will respect your decision of whether or not you 
choose to be in the study. No one at BAART Programs or at this MAT program site will 
treat you differently if you decide not to be in the study. If you decide to join the study 
now, you can still change your mind later. You may stop at any time. If you stop 






Risks and Benefits of Being in the Study: 
Being in this type of study is unlikely to involve any discomfort above and beyond what 
you might normally encounter or experience in your daily life. Some persons may 
experience a small amount of stress due to the testing and group participation 
requirements explained above, although these are not extensive or overly time 
consuming. Being in this study poses minimal risk to your safety and wellbeing. The 
study includes a reporting and intervention procedure to assist you if you experience 
any adverse effects resulting from your participation.  
Potential benefits of this study include the completion of initial research for the MAT 
program population that may help develop such relapse prevention programs for use in 
MAT programs throughout the BAART system and beyond. Any such relapse prevention 
methods are likely to improve quality of life for the participants and reduce risk of 
relapse and the harm that can follow from it.  
 
Payment: 
Each participant that completes the full two-month study period, participating as 
required, will receive a $ 25.00 gift card in acknowledgement of his or her study 
participation. Should you elect to leave the study before completion, not complete 
requested tests, or not participate in all eight MBSR weekly group meetings (if required 
for you)  you will not receive the gift card. Gift cards will be distributed to all study 
participants within two weeks after the study ends. 
 
Privacy: 
Any information you provide will be kept confidential and private. The researcher will 
not use your personal information for any purposes outside of this research project. 
Also, the researcher will not include your name or anything else that could identify you 
in the study reports. Hardcopy data will be kept secure by being retained in a locking file 
cabinet at the program site. Electronically stored data will be securely retained for a 
period of at least 5 years, as required by Walden University. 
 
Contacts and Questions: 
You may ask any questions you have any now. Or if you have questions later, you may 
contact the researcher via and/or via email at the email address. If you want to talk 
privately about your rights as a participant, you can call Dr. Leilani Endicott. She is the 
Walden University representative who can discuss this with you. Her phone number is 
Insert ONE number depending on location of participant 612-312-1210 (for US based 
participants) OR 001-612-312-1210 (for participants outside the US). Walden 
University’s approval number for this study is [IRB will enter approval number here] and 






The researcher will give you a copy of this form to keep for your records. 
 
Statement of Consent: 
I have read the above information and I feel I understand the study well enough to 
decide about my involvement. By signing below, I understand that I am agreeing to the 
terms described above. 
 
Printed Name of Participant:  ____________________________________________________  
 
Date of consent:    ____________________________________________________ 
 
Participant’s Signature:  ____________________________________________________  
 
Researcher’s Signature:  ____________________________________________________  
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Appendix E: Adverse Event Report 
Participant Report of Adverse Event 
Participant ID Number: ____________ 
Date of Event: ____________ 
Participant Report of Event: 
Description of Adverse Effects: 
□ Participant Consent to Disclose above information to MAT program physician
obtained (see attached).
□ Participant referral to MAT program physician made.
□ Participant informed of right to discontinue study participation immediately.
□ Participant informed that study discontinuance will not in any way affect continued
enrollment in the MAT program.
□ Program physician provided a copy of this adverse event report.
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I, the undersigned Principal Investigator in this study, hereby certify that the above 
documentation is true and accurate, and that all action indicated above has been 
implemented in accord with study procedural requirements.  
Principal Investigator Signature/Date: ____________________________________ 
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AUTHORIZATION FOR USE AND DISCLOSURE OF 
PROTECTED HEALTH INFORMATION 
Name of patient: Date of Birth: 
I hereby authorize the use and disclosure of protected health information about the above patient as 
follows: 
From (Name of person, class of persons, or organization 
authorized to make the requested use or disclosure):   
  (check whichever is applicable) 
Stephen Sooter, MS 
Study Principal Investigator 
To (Name of person, class of persons, or organization 




1124 International Blvd. 
Oakland, CA 994606 
Description of patient’s protected health information to be used or disclosed: 
Study participant report of adverse event experienced during study participation. 
Principal Investigator’s description of adverse events. 
¨ Patient must initial this box if this consent authorizes furnishing HIV test results or other HIV
identifying information. 
Patient’s protected health information is being used or disclosed for the following purpose(s): 
Provide clinically indicated assessment and intervention in response to reported experiencing by study 
participant of adverse event.  
I understand that I have the following rights with respect to this Authorization: 
1. The recipient of the protected health information may not further disclose the information unless
the recipient obtains another authorization from me or unless the disclosure is specifically required
or permitted by law. 
2. I may not be required to sign this Authorization as a condition to obtaining treatment or payment or
my eligibility for benefits. 
3. BAART Programs will provide me with a copy of this Authorization.
4. I may revoke this Authorization at any time by mailing or personally delivering a signed, written
notice of revocation to BAART Programs at the clinic where I am a patient. Such revocation will
be effective upon receipt, except to the extent that the recipient has taken action in reliance on this
Authorization. 
5. I understand that I am entitled to notice if BAART Programs will use or disclose the protected
health information for marketing and receive payment for the use or disclosure of my protected
health information. 
BAART Programs  will þ will not receive compensation for the use or disclosure of my protected 
health information. 
This authorization will expire on/when: within one year of date of signing, unless otherwise 
specified.  
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  Signature of Patient/Personal Representative* Describe Personal relationship to patient 
  Date Address and Telephone number of Patient/Representative:
*The personal representative is any of the following: 
• A conservator of the patient’s person;
• An agent appointed by the patient under a power of attorney for health care if
the patient does not have capacity to sign the authorization;
• Any other individual who has the legal authority to make health care decisions
on the patient’s behalf; or
If the patient is deceased, an executor or administrator of the patient’s estate or, if 
none, a spouse or, if no spouse, any responsible family member. 
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Appendix G: Curriculum Vita 
Stephen Sooter, MS 
Objective To obtain a teaching position as an Addiction Studies Adjunct Instructor 
Experience 1993–2019 Clinic Director, BAART Programs 
Antioch, CA 
• Overall responsibility for all aspects of program operations.
• Ensure program compliance with all applicable federal & state regulations.
• Facilitation of CARF Accreditation, Medi-Cal Certification, and DHCS Licensing.
• Outreach and education to communities, families, and other groups.
• Patient group counseling and assessment policies and procedures development.
• Directed startup of Oakland program operations in fall, 2007.
2012-2016 Psychological Assistant Bay Area, CA 
• Provision of individual, group, and couples psychotherapy services at multiple sites
under supervision of Dr. Ron Perry, PsyD.
• Provision of training, group, and individual supervision to psychological interns.
• Provision of individual psychotherapy to adults with psychiatric and co-occurring
disorders at Healthy Partnerships in Fairfield, Ca.
• Implementation of mindfulness based relapse prevention group services to pregnant
and parenting women at Wollam House residential treatment, Pittsburg, Ca.
• Development and implementation of group psychotherapy services using
Mindfulness Based Stress Reduction therapeutic approaches and interventions.
• Development and implementation of group psychotherapy services using Acceptance
and Commitment Therapy therapeutic approaches and interventions.
• Provision of Mindfulness Based Relapse Prevention group and individual services.
2012- 2013 Psychological Practicum/Internship Walden 
University 
• All services provided under supervision agreement between Walden University and
Dr. Ron Perry, PsyD.
• Provision of individual and group psychotherapy services to pregnant and parenting
women at Wollam House residential treatment facility, Pittsburg, Ca.
• Provision of individual psychotherapy services for adults with substance use
disorders at Chance for Freedom in Concord, Ca., and Pittsburg, Ca.
• Provision of individual, group psychotherapy services for persons with psychiatric
and co-occurring disorders at offices of Drs. Ron Perry, PsyD and Carolyn Schuman,
MD in Berkeley, Ca.
• Development of psychological intern training manual.
297 
2010-2012 Academic Residencies Walden 
University 
• June 16-20, 2010 – orientation in academic residency requirements. Academic
research and writing skills.
• January 7-20, 2011 – introduction to cognitive and personality assessment.
Quantitative, qualitative, and mixed-methods research design and implementation
methodologies. Interviewing and observational strategies.
• July 15-28, 2011 – psychological testing: research, approaches, and administration
for Brief Symptom Inventory, MMPI-2, NEO-PI, Rorschach, WAIS-IV, WISC-IV,
WIAT, Woodcock-Johnson III; cognitive, behavioral, personality, and mental status
assessment.
• August 4-8, 2011 – American Psychological Association ethical principles,
standards, and professional codes of conduct. Evidence-based treatment approaches
and interventions: motivational interviewing practices, integrated group
psychotherapy practices, cognitive behavioral therapy practices, and brief
interpersonal therapy practices.
• January 6-19, 2012 – diagnosis, case conceptualization, and psychological report
writing using American Psychiatric Association DSM criteria. APA dissertation
writing style requirements. Statistical design and data analysis. Research
presentation. Group process: clinical approaches, ethical and legal considerations.
Mindfulness in clinical practice.
1992–1993 Supervising Counselor, BAART Programs
Pittsburg, CA 
• Assist clinic director in managing program operations.
• Conduct quality assurance review of patient records.
• Orientation, training, and administrative/clinical supervision of counseling staff.
• Support of program policies & procedures implementation and adherence
monitoring.
1988–1992 Counselor, BAART Programs Pittsburg, CA 
• Provide individual counseling services for up to 40 clients with substance use
disorders.
• Maintain patient record documentation in accordance with regulations.
• Developed and facilitated pregnant patient support group.
Education 
• Doctor of Philosophy in Clinical Psychology, Walden University, currently in
progress.
• Doctoral dissertation proposal: The Effects of Mindful Attentional Regulation on
Illicit Opioid Use for Individuals Participating in Medication Assisted Treatment: A
Pilot Study
• Master of Science, Psychology, Walden University, February 2010.
• Certification in Chemical Dependence Studies, CSUH, 2005.
• Bachelor of Arts, Music, California State University Hayward, June 1988.
• Honors Citation, CSUH Department of Psychology, December 1986.
• National Dean’s List, 1987.
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• Associate of Arts, with honors, Los Medanos College, June 1984.
Professional 
Affiliations 
• Psychological Assistant (PSB36626) California Board of Psychology
• Affiliate Member, American Psychological Association (APA; 9006-9898)
• Professional Member, National Association for Alcoholism & Drug Abuse Counselors
(NAADAC; 103307)
• Member, Western Psychological Association (WPA; 5887400)
• Certified Addictions Treatment Counselor, CAADE (S0412271058)
• Registered Addiction Specialist certification, Breining Institute (S0412271058)
• Composer Member, American Society of Composers, Authors, & Publishers
(ASCAP)
Personal 
Interests Psychological, philosophical, neurobiological, and physical sciences; 
mindfulness practices; music composition and performance; walking; 
baseball; football. 
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300 
Letter of Cooperation For 
Data Management 
This letter of cooperation describes the components of data collection, procedures to 
be followed, and the roles and responsibilities of the organization known as BAART 
Programs, Inc. ("BAART Programs") in the doctoral dissertation research study being 
conducted by Stephen Sooter, MS as partial fulfillment of his requirements in the 
Walden University Clinical Psychology PhD program. It is understood that BayMark 
Health Services, Inc. ("BayMark") is the parent organization of BAART Programs, and 
that David 
K. White, as the Chief Executive Officer of BayMark, is authorized to review and sign
this Letter of Cooperation as required. 
Stephen Sooter is the Principal Investigator for this study, and is employed by BAART 
Programs and as a Treatment Center Director at the Antioch, California program site. 
BAART Programs has reviewed this study design, documentation, and implementation 
procedures, as presented by Stephen Sooter. BAART Programs has authorized the release 
of certain data to Stephen Sooter pursuant to a Data Use Agreement, for the purpose of 
his dissertation analysis. Walden University oversight of  this study is limited to the final 
dissertation analyses only. 
Part I: Participant Consent: 
Consent from each potential study participant will be obtained prior to enrollment in the study as 
follows: 
• A consent compliant with HIPAA and 42 CFR part 2 to disclose from each participant
authorizing the following:
a. The principal investigator to meet with him or her and review
elements of BAART informed consent and participate in post-data
collection period debriefing;
b. Disclosure to the principal investigator of the pre-test, mid-test, and post-
test measures outcomes data used in the study;
c. Verification of MBRP group participation and homework assignment
completion for the duration of the study by the principal investigator;
d. Verification of each participant's MAT program participation in daily
medication dosing as prescribed by the program physician and individual
counseling services as required by the program;
e. Disclosure by the principal investigator to the on-site BAART Programs
physician of any event or condition associated with study implementation that
exerts adverse effects on the participant; and
f. Provision that each participant has the right to revoke his or her consent to
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disclose at any time without any adverse action from the principal 
investigator, BAART Programs, or BayMark. 
• Informed consent for each participant to participate in the study, which will
authorize the following:
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a. The principal investigator to meet with him or her and review elements of the BAART
Programs' informed consent and participate in post-data collection period debriefing;
b. Random assignment of participants by the principal investigator to either the adjunct MBRP
group participation or the treatment as usual only study group levels;
c. Administration and outcomes data collection, scoring, and analyses by the principal
investigator of the Addiction Severity Index Drug & Alcohol Scale (McClellan et al., 1985) at
pre-, mid-, and post-test intervals;
d. Test administration and outcomes data collection, scoring, and analyses by the principal
investigator of the Opioid Craving Scale (McHugh et al., 2014) at pre-, mid-, and post- test
intervals;
e. Test administration and outcomes data collection, scoring, and analyses by the principal
investigator of the Toronto Mindfulness Scale (Lau et al., 2006) at pre-, mid-, and post- test
intervals;
f. Disclosure to the principal investigator of each adjunct MBRP group-assigned participant's
MBRP group participation and homework assignment completion for the duration of the study;
g. Verification of each participant's continued MAT program participation for the duration of the
study as determined by methadone medication dosing and individual counseling session
participation;
h. Hard copy participant data collection by the principal investigator that is securely stored in a
locking file cabinet retained at the program site where the principal investigator works;
i. Electronic participant data collection that is used and stored by the principal investigator
using methods that assure the privacy and confidentiality of each study participant; 
j. Disclosure of any event or condition associated with study implementation that exerts adverse
effects on the participant to the program physician at the study site; and
k. Each participant's right to discontinue his or her participation in the study without any
adverse action from principal investigator, BAART Programs, or BayMark.
Part II: Provision of the MBRP Group Services: 
• Once all requisite participant consents have been effected, the principal investigator will use a random
number table to assign study participants to either the treatment as usual (TAU) control group or the
TAU plus MBRP group experimental group, resulting at the outset in equal or approximately equal
numbers of participants in each group;
• The MBRP Group services will be provided at the study site by the principal investigator;
• The principal investigator will be responsible for administering test measures and collecting pre- test (prior
to beginning MBRP group), mid-test (after four weeks of MBRP group) and post-test (after final week of
MBRP group) MBRP group participation  and  homework  completion  data. This data consists of
verification of MBRP group attendance (or absence}  and verification of MBRP group homework
assignment completion .
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Part Ill: Pre-Test, Mid-Test, and Post-Test Data Collection Measures: 
The principal investigator is responsible for  administration and data collection  of the following measures at pre-test, mid-test 
(after four weeks of MBRP group services), and post-test  (after  eighth week  of MBRP group services)intervals: 
• The Addiction Severity Index (ASI) Alcohol/Drugs subscale (McClellan et al., 1985);
• The Opioid Craving Scale (OCS; McHugh et al., 2014); and
• The Toronto Mindfulness Scale (TMS; Lau et al., 2006).
Part IV: Pre-test Data Analysis: 
• Given the complexity of multivariate data gathered over distinct periods in this study,
Multivariate Analysis of Covariance (MANCOVA) statistical testing will used.
• Software used for data analysis in  this study implementation phase will be the Statistical Package for the
Social Sciences version 24 (SPSS; International Business Machines, 2018), with the alpha value set at .OS
for all statistical procedures used. All outcomes data will be uploaded into a computer running SPSS
software and results that will be calculated by the SPSS program.
• De-identified statistical data outcomes will used by the principal investigator to create data tables
for further study data analysis and outcome reporting.
• After pre-test computerized data entry is completed, the principal investigator will run a statistical data
analysis comparing the Opioid Craving Scale outcome pre- and mid-test scale scores, and comparing
the ASI Alcohol/Drugs subscale pre- and mid-test scores.
• Each participant data entry record will be crosschecked against the original documentation provided
by the study site coordinator to assure data entry integrity.
• A complete descriptive data analysis procedure will be run on all study variables using the SPSS program,
thereby crosschecking to assure that data outliers or entry errors are not significantly skewing data outcomes.
• Finally, the SPSS Data Validation procedure will be run to assure that missing or erroneous data entries are
not influencing data analyses outcomes.
• The principal investigator will be responsible to assure that all outcomes data are accurately
transcribed, that appropriate statistical tests are run, and that inferences made from these results are
interpreted accurately in accord with the statistical model used (MANCOVA) and experimental
design utilized.
• De-identified statistical data outcomes will used by the principal investigator to create data tables
for further study data analysis and outcome reporting.
Part IV: Mid-Test Data Analysis: 
• Given the complexity of multivariate data gathered over distinct periods in this study,
Multivariate Analysis of Covariance {MANCOVA) statistical testing will used.
• Software used for data analysis in this study implementation phase will be the Statistical Package for the
Social Sciences version 24 (SPSS; International Business Machines, 2018), with
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the alpha value set at .OS for all statistical procedures used. All outcomes data will be uploaded into a 
computer running SPSS software and results that will be calculated by the SPSS program. 
• After mid-test computerized data entry is completed, the principal investigator will run a statistical data
analysis comparing the Opioid Craving Scale outcome pre- and mid-test scale scores, and comparing
the ASI Alcohol/Drugs subscale pre- and mid-test scores.
• Should any significant (p= .05) increases in either the Opioid Craving Scale scores or the ASI
Alcohol/Drugs subscale scores be determined, the principal investigator will proceed with
implementation of data safety measures (see Data Safety Agreement).
• Each participant data entry record will be crosschecked against the original documentation provided
by the study site coordinator to assure data entry integrity.
• A complete descriptive data analysis procedure will be run on all study variables using the SPSS program,
thereby crosschecking to assure that data outliers or entry errors are not significantly skewing data outcomes.
• Finally, the SPSS Data Validation procedure will be run to assure that missing or erroneous data entries are
not influencing data analyses outcomes.
• De-identified statistical data outcomes will used by the principal investigator to create data tables
for further study data analysis and outcome reporting.
• The principal investigator will be responsible to assure that all outcomes data are accurately
transcribed, that appropriate statistical tests are run, and that inferences made from these results are
interpreted accurately in accord with the statistical model used (MANCOVA) and experimental
design utilized.
• De-identified statistical data outcomes will used by the principal investigator to create data tables
for further study data analysis and outcome reporting.
Part V: Post-Test data Analysis: 
• Given the complexity of multivariate data gathered over distinct periods in this study,
Multivariate Analysis of Covariance (MANCOVA) statistical testing will used.
• Software used for  data  analysis in this study implementation phase will be the Statistical Package for the
Social Sciences version 24 (SPSS; International Business Machines, 2018}, with the alpha value set at .OS
for all statistical procedures used. All outcomes data will be uploaded into a computer running SPSS
software and results that will be calculated by the SPSS program.
• After post-test computerized data entry is completed, the principal investigator will run a statistical data
analysis comparing the Opioid Craving Scale outcome pre- and post-test scale scores, and comparing
the ASI Alcohol/Drugs subscale pre- and post-test scores.
• Should any significant (p= .OS} increases in either the Opioid Craving Scale scores or the ASI
Alcohol/Drugs subscale scores be determined, the principal investigator will proceed with
implementation of data safety measures (see Data Safety Agreement).
• Assuming there are no significant post-test increases in participant opioid use or cravings, the principal
investigator will run statistical analyses of the data on the password protected, encrypted computer.
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• A complete descriptive data analysis procedure will be run on all study variables using the SPSS
program, thereby crosschecking to assure that data outliers or entry errors are not significantly
skewing data outcomes.
• Finally, the SPSS Data Validation procedure will be run to assure that missing or erroneous data
entries are not influencing data analyses outcomes.
• De-identified statistical data outcomes will used by the principal investigator to create
data tables for further study data analysis and outcome reporting.
Part VI: Data Retention and Destruction: 
• All hard copies of study test measures will be retained in a secure locking file cabinet located
at the BAART Programs Antioch location, which will be accessible only to the principal
investigator and to BayMark Administrative personnel so authorized by the Chief
Executive Officer of BayMark Health Services.
• All hard copy test measure data will be randomly assigned a participant identification
number that will be used for organizing participant records in the computerized study
database.
• A data key will be securely retained in a separate password protected, encrypted computer file
retained by the principal investigator that links participant names to their unique ID
numbers. Aside from this procedure, no participant names, birthdates, social security numbers,
addresses, phone numbers, email addresses, or other information that could potentially be
used by unauthorized persons to identify any participant will be collected, stored, or used as
part of the study implementation procedures.
• The principal investigator will enter the participant pre-test, mid-test, and post-test data onto
a secure, password protected and data encrypted computer file system stored on a computer
accessible only to the principal investigator.
• Similarly, the principal investigator will enter MBRP group attendance (number of
groups attended) and homework completion (number of homework assignments
completed) data .
• At time of entry, the principal investigator will crosscheck data to assure accuracy of
the computerized data entries.
• After the requisite five-year study data retention period has expired, the principal
investigator will assure secure destruction of all hard-copy and electronic study data
records.
• In the event that the employment relationship between BAART/BayMark and the principal
investigator is terminated, Stephen Sooter will destroy all study data no later than the final
day of his employment, unless otherwise directed by BAART and BayMark..
 
Signature and Date of Pri ncipaI Investigato-r: - - - rI--K-f.-'J-- ---'·--'1';· 4/,f(\.J,,    _  ---'z  +-/_,, ;z'-+/,_7"".'D'-,l "i"'- 
, St ephen s s r .I 
Signature and Date of BAART Programs/BayMark CEO : 
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Notification of Study Approval 
by 
BayMark Pilot Study Research Committee 
The BayMark Pilot Study Research Committee has reviewed and approved the proposed 
study of Stephen Sooter, a graduate student at Walden University enrolled in the Clinical 
Psychology PhD Program, based on his research proposal entitled "The Effects of Mindful 
Attentional Regulation On Illicit Opioid Use For Individuals Participating in Medication 
Assisted Treatment: A Pilot Study." Reviewed and approved constituent elements of the study 
intended for implementation at the designated BAART Programs site include, but are not 
necessarily limited to, the following: 
• Summary of Study Design and Procedures
• Letter of Cooperation for Data Management
• Outline of the Mindfulness Based Relapse Prevention (MBRP) treatment protocol
• Participant Informed Consent
• Study Information for Participants letter
• Participant Report of Adverse Event
The principal investigator, Stephen Sooter, will assure that the BayMark Pilot Study Research 
Committee is fully informed regarding all aspects of study design, implementation, and 
effects on participants throughout the study implementation and data analyses periods. 
The BayMark Pilot Study Research Committee will monitor all aspects of study 
implementation and data outcomes as determined necessary. 
BayMark Pilot Study Research Committee: 
Jason Carmichael, VP Quality and Clinical Compliance 
Patrice Oliver, Director Nursing Education and Compliance 
Frank Bauman, COO 
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